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The Role and Regulation of Argininosuccinate Synthase in Endothelial Function 
Bonnie L. Goodwin 
ABSTRACT 
While cellular levels of arginine greatly exceed the apparent Km for endothelial 
nitric oxide synthase (eNOS), nitric oxide (NO) production is limited by availability 
of arginine. Results from this work have provided a unique understanding of 
endothelial NO production, showing that arginine regeneration, that is the 
recycling of citrulline back to arginine by argininosuccinate synthase (AS) and 
argininosuccinate lyase (AL), defines the essential source of arginine for NO 
production. Using RNA interference analysis, selective reduction of AS 
expression was shown to directly correspond with a diminished capacity of 
endothelial cells to produce NO, despite saturating levels of arginine in the 
medium. In addition, the viability of AS siRNA-treated endothelial cells was 
compromised due to apoptotic cell death.  
 
AS expression was also investigated in response to two major vascular effectors. 
Tumor necrosis factor (TNF)-α, which is known to impair endothelial NO 
production, was shown to provoke a dose-dependent reduction of AS expression 
that corresponded to a decrease in NO production. Furthermore, TNF-α was 
shown to suppress AS expression through a NFκB mediated pathway, which 
 vii 
involves three essential Sp1 elements in the proximal AS gene promoter. On the 
other hand, peroxisome proliferator-activated receptor gamma (PPARγ) agonists, 
troglitazone and ciglitazone, which are known to elicit a vascular protective 
response against TNF-α effects, were shown to coordinately induce NO 
production and AS expression via a PPARγ response element in the distal AS 
gene promoter. Importantly, these PPARγ agonists were shown to restore AS 
expression and NO production following down-regulation by TNF-α, consistent 
with their vascular protective properties. 
 
 
 
1 
 
 
 
INTRODUCTION 
 
Nitric oxide 
Nitric oxide (NO) is an important modulator for a wide range of functions 
including vascular regulation, immune function, angiogenesis, neurotransmission, 
gene regulation and apoptosis (1-3). Moreover, NO has a dual role in cell viability 
depending on the tissue type and concentration. Either very high or very low 
concentrations of NO may induce cell death, while basal concentrations may 
inhibit apoptosis (4-7). Previous work has shown that NO protects against serum-
starvation- (8), H2O2- (9), TNF-α- (10) and oxidized low-density lipoprotein- 
induced apoptosis (11, 12) in endothelial cells.  
 
NO is synthesized by three NO synthase (NOS) isoforms; neuronal NOS 
(nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS). nNOS has been 
localized to the brain, cardiac and skeletal muscle, epithelial cells, pancreatic 
islets and kidney macula densa cells. iNOS expression has been detected in 
macrophages, vascular smooth muscle, hepatocytes, endothelial cells and 
mesangial cells. eNOS is expressed in the endothelium as well as in skeletal and 
cardiac muscles and kidney tubules. iNOS activation is transcriptionally regulated 
by cytokines and endotoxins while both eNOS and nNOS are classically 
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considered to be Ca2+ dependent. Endothelial NO production by eNOS is 
regulated by the association of required cofactors, phosphorylation of the 
enzyme, protein:protein interactions, cellular localization and substrate 
availability (13).  
 
Endothelial NO 
eNOS-derived NO is an important regulator of vascular function and blood 
pressure. NO is produced in the endothelium in response to signaling by 
circulating effectors such as bradykinin. It then diffuses into the smooth muscle 
layer and induces relaxation of the vessel wall. Endothelial dysfunction often 
precedes a diagnosis of atherosclerosis and is defined by an impaired release of 
NO by the endothelium (14). Endothelial NO is a potent vasodilator (15) that also 
maintains endothelial function by inhibiting platelet aggregation (16), modulating 
leukocyte adhesion to blood vessels (17) and protecting against apoptosis (18). 
Decreased NO production in the endothelium can significantly interfere in the 
regulation of vascular tone and result in vascular abnormalities such as smooth 
muscle cell proliferation, leukocyte adhesion to the vascular wall and increased 
vascular permeability.  In fact, loss of endothelium-derived NO is associated with 
the prothrombotic and hyperproliferative states present in hypertensive, diabetic 
and atherosclerotic states.  
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Sources of arginine 
Arginine is a precursor for urea, polyamine, creatine, ornithine, NO and protein 
synthesis (19). Arginine synthesized during the urea cycle in the liver is rapidly 
utilized by arginase in the production of urea and ornithine. Arginine in the blood 
circulation comes from the kidney, where it is produced from the conversion of 
citrulline. Transport of arginine and other cationic amino acids into cells occurs 
via the CAT family of transporters (20). Although the intracellular concentration of 
arginine, which has been estimated to be between 100 and 800 µmol/l (21), 
greatly exceeds the apparent Km for eNOS (5 µmol/l), NO production is limited by 
availability of arginine (22-29). This phenomenon, known as the ‘arginine 
paradox’ suggests that there is an intracellular pool of arginine specifically 
directed to NO production. Thus, the source of arginine required to sustain NO 
production in endothelial cells has been investigated and debated. Part of this 
debate seemed to be resolved when the CAT1 transporter, the major transporter 
for arginine for endothelial cells, was co-localized with eNOS in caveolae (30). 
Nevertheless, other evidence persisted, demonstrating that endothelial NO 
production was limited by the capacity to regenerate arginine from citrulline (22-
28, 31). Recently, DNA microarray analysis of shear stress-induced NO 
production demonstrated that up-regulation of AS was coordinated with an 
increase in NO production (32), supporting an important role for AS in endothelial 
NO production. 
 
 
4 
Argininosuccinate synthase 
Argininosuccinate synthase (AS) was first cloned from human carcinoma cells in 
1981 (33). A rare genetic disorder, known as citrullinemia, occurs when AS is 
deficient in humans (34). AS is a 45 kDa protein that forms a homotetramer 
composed of identical 412 amino acid subunits. The sequence is highly 
conserved between human (35), bovine (36), rat (37) and mouse (38). AS, the 
rate-limiting step (23) in the regeneration of arginine from citrulline, catalyzes the 
conversion of citrulline, ATP and aspartate to argininosuccinate, AMP and 
inorganic pyrophosphate. Argininosuccinate is then cleaved by argininosuccinate 
lyase (AL) to produce L-arginine and fumarate. In liver, where AS expression is 
high, AS and AL function together as components of the urea cycle, ultimately to 
form arginine from citrulline. These enzymes are also expressed in proximal 
tubules of the kidney and in the testis as well as at lower levels in most 
mammalian tissues. It was the discovery of arginine-derived NO, catalyzed by 
nitric oxide synthases (NOSs), that revealed a second role for AS and AL (1-3). 
Together with NOS, they function as part of a citrulline-NO cycle, where AS and 
AL convert citrulline to arginine, which is then oxidized to form NO and citrulline 
by NOS.  
 
PPARγ agonists affect the citrulline-NO cycle 
Peroxisome proliferator-activated receptor (PPAR)γ is a member of the nuclear 
receptor superfamily of ligand-activated transcription factors involved in the 
transcription of genes implicated in lipid metabolism (39-42), differentiation (39, 
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42) and cell growth (43). PPARγ is required for adipose, kidney and placental 
development and knockout results in embryonic lethality (44). PPARγ can be 
activated by a number of naturally occurring fatty acid metabolites including 
oxidized linoleic acid (9- and 13-HODE) and 15-deoxy-∆12,14 – prostaglandin J2 
(15d-PGJ2) (45-47).  
 
Thiazolidinediones (TZDs) are synthetic PPARγ agonists developed as anti-
diabetic agents that enhance insulin-stimulated glucose uptake, lower blood 
glucose, triglyceride levels and blood pressure in insulin-resistant humans and 
animals (48). TZDs are believed to induce insulin sensitization by altering gene 
expression via stimulation of PPARγ. However, in several situations, such as in 
skeletal muscle, TZDs have also been shown to act through PPARγ-independent 
effects (49). For example, PPARγ can indirectly repress transcription by binding 
the transcription factor Sp1 in smooth muscle cells and inhibiting binding of Sp1 
to the thromboxane A2 gene promoter (50). Also, PPARγ-independent regulation 
of the vascular endothelial growth factor receptor 2 (KDR) by 15d-PGJ2 and 
pioglitazone are mediated via interaction with both Sp1 and Sp3 (51). In addition, 
PPARγ-independent effects have been shown to be mediated by 15d-PGJ2 in 
endothelial cells, through the down-regulation of Sp1 (52).  
 
Cardiovascular benefits of TZDs have been described to include improved flow-
mediated vasodilation and decrease vascular smooth muscle cell activation (53). 
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Additional cardioprotective properties described include the reduction of blood 
pressure in mammalian models (54-56) and diabetic patients (57). In addition, 
TZDs reduce lesion formation in animal models of atherosclerosis (58-61). This 
occurs, in part, by stimulating NO production by vascular endothelial cells in a 
process that does not induce eNOS protein expression (62, 63). Troglitazone is a 
TZD that was used as an anti-diabetic compound prior to being removed from the 
market due to liver toxicity. Troglitazone increases NO production in aortic 
endothelial cells through two independent signaling pathways that have been 
proposed for the increase in NO production by PPARγ ligands (62). The first is 
PPARγ-dependent phosphorylation of eNOS at Ser1179. The second pathway is 
described as a PPARγ-independent dephosphorylation of eNOS-Ser116 (64). A 
recent report provides additional evidence regarding an additional mode by which 
PPARγ agonists augment endothelial NO production (65). This was found to 
occur via reduction in superoxide through the suppression of NADPH oxidase 
and induction of superoxide dismutase, resulting in an enhanced bioavailability of 
endothelial NO (65). An additional mechanism by which PPARγ agonists could 
increase endothelial NO production is through the up-regulation of AS expression 
and thus an increase in the regeneration of arginine by AS and AL. Since it has 
been shown in many disease states that arginine availability for NO production 
becomes limiting, the following study examines whether PPARγ agonists may 
promote arginine regeneration and relieve, in part, impairment of NO production. 
In addition, these anti-diabetic compounds are also known to counter the effects 
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of the inflammatory response related to elevated serum levels of tumor necrosis 
factor alpha (TNF-α), which contribute to endothelial dysfunction (66, 67). 
 
TNF-α affects the citrulline-NO cycle  
TNF-α is a multifunctional cytokine involved in the regulation of important 
physiological functions including the development of tissues, the coordinate 
activation of immune responses, and in the onset and progression of pathological 
conditions (68, 69). Treatment of endothelial cells with TNF-α reduces eNOS 
mRNA expression (70) and pre-treatment before shear stress or insulin 
stimulation profoundly decreases NO synthesis (71). This pro-inflammatory 
cytokine has been implicated in the pathogenesis of cardiovascular diseases 
such as congestive heart failure, acute myocardial infarction, myocarditis and 
dilated cardiomyopathy (72, 73). Serum TNF-α levels are elevated in patients 
with congestive heart failure and TNF receptors have been identified in the failing 
human heart (74, 75). TNF-α has been linked to insulin resistance (76) by directly 
inhibiting insulin signaling (77-80) and is known to contribute to endothelial 
dysfunction in type 2 diabetes (81), obesity (82) and heart failure (83, 84). 
Clinical studies have also shown that elevated levels of plasma TNF-α in patients 
with type I diabetes were associated with cardiological risk factors (85). 
Monocyte binding to the endothelium, a factor in the development of 
atherogenesis, is induced by TNFα-dependent decreases in NO synthesis (86). 
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Transfection of eNOS is able to prevent the increase in monocyte binding by 
increasing NO production (86).  
 
Recovery of TNF-α suppression of the ctrulline-NO cycle by PPARγ activators 
Inflammatory cytokines such as TNF-α have been linked to the insulin-resistant 
states associated with obesity and type II diabetes (reviewed in (87)). PPARγ 
activation can inhibit a number of inflammatory responses (88) and block 
inhibition of the insulin pathway by TNF-α (89). There are several examples in 
the literature where PPARγ agonists interrupt TNF-α signaling outside of the 
insulin signaling pathway. For instance, PPARγ activators can actually inhibit 
cardiac expression of TNF-α by targeting NFκB activity (90). 15d-PGJ2 inhibits 
NFκB signaling in a PPARγ-independent manner by modifying IκB-Kinase and 
NFκB subunits (91). In further support of the role of NFκB in TZD signaling, 
troglitazone decreases NFκB expression and DNA binding in human 
mononuclear cells, while increasing the NFκB inhibitor IκBα expression (92). In 
brown adipocytes, rosiglitazone treatment impairs TNF-α-induced activation of 
p38 and p42/44 MAPK, restoring insulin signaling and leading to normalization of 
glucose uptake (93). In addition, troglitazone inhibits TNF-α-induced 
plasminogen activator inhibitor type 1 (PAI-1) production through both ERK- and 
NFκB-dependent pathways (94). While migration of VSMCs toward TNFα is 
MAPK dependent, TZDs can block migration, but cannot attenuate TNF-α-
induced MAPK activation, indicating that the action of the troglitazone lies 
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downstream of MAPK in this system (95). On the other hand, in adipocytes, 
troglitazone does not impair TNF-α-induced NFκB activation, but rather 
antagonizes the transcriptional regulatory activity of NFκB (96). In another 
system, troglitazone and ciglitazone can inhibit VEGF-induced AKT activation 
(phosphorylation) in endothelial cells (97). All of these studies lead to the 
hypothesis that the PPARγ agonists may prevent TNF-α inhibition of the 
citrulline-NO cycle at the level of NFκB, through the MAP Kinase pathway or 
through AKT activation.  
 
Strategies for preventing TNF-α activity include neutralization of the cytokine via 
either anti-TNF-α antibodies, soluble receptors, or receptor fusion proteins; 
suppression of TNF-α synthesis via drugs such as cyclosporine A, 
glucocorticoids, or IL-10; reduction of responsiveness to TNF-α via repeated low 
dose stimulation; and lastly, by inhibition of secondary mediators such as IL-1, IL-
6, or NO (98). Pharmaceutical companies such as Peptech Limited have 
developed different antibodies to TNF-α, some of which inhibit various TNF-α 
functions and others which do not affect protein activity. For instance, Remicade 
(TM) is a chimeric Igk monoclonal anti-TNF-α antibody manufactured 
by Centocor which has been used to treat Crohn's disease, which is a chronic 
inflammatory disease of the intestines (Contocor, 2000). Soluble TNF receptor 
will also neutralize TNF-α before it can bind to its target cell receptor. Another 
drug, Enbrel (TM), developed by Immunex Corporation, is a fusion of two soluble 
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TNF-α receptors and a human immunoglobulin (Immunex Corporation, Nov. 
1999). It has been approved for treatment of rheumatoid arthritis. Additionally, 
Chloroquine inhibits transcription of the protein in macrophage (99). My research 
shows that TZDs can effectively reverse the effects of TNFα on NO production, 
in part, due to the coordinate effects on eNOS and AS expression. 
 
The AS promoter 
Although AS is considered a ubiquitously expressed enzyme, a number of 
hormones, nutrients and cytokines are able to regulate AS expression (100). 
Since the critical role of AS in NO production becomes increasingly apparent, 
there has been a renewed interest in regulation of its expression. However, the 
promoter region for this gene still remains only partially characterized (38, 101, 
102). Three of six identified GC boxes have been shown to synergistically 
activate the promoter through Sp1-DNA binding. Recently, stimulation of Caco-2 
cells with IL-1β was shown to activate expression of AS through NFκB activation 
(103).   
 
Specific aims 
Our work and the work from other laboratories has developed a strong evidential 
case supporting the proposal that substrate availability, governed by arginine-
regeneration as part of the citrulline-nitric oxide cycle, plays a key role in NO 
production thus affecting vascular endothelium function and viability (18, 22, 23, 
25). If AS is essential for endothelial NO production, then even in the presence of 
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excess arginine, depletion of AS should decrease the capacity of endothelial 
cells to produce NO. The first paper in this dissertation tests this hypothesis 
using RNA interference analysis to knock down AS in bovine aortic endothelial 
cells (BAEC). The work demonstrates a significant and dose-dependent 
reduction of AS protein following siRNA transfection. I also show a concomitant 
decrease in enzyme activity corresponding to a decrease in stimulated and 
unstimulated NO production in endothelial cells with reduced AS expression, in 
spite of excess arginine in the media. In addition, I demonstrate that the viability 
of endothelial cells grown in excess arginine and treated with AS siRNA was 
significantly diminished compared to control cells.  
 
Having defined the important role AS plays in both endothelial NO production 
and in endothelial cell viability, the next aim of this dissertation investigates the 
regulation of the enzyme by two major effectors of vascular function. The second 
paper confirms the important elements of the AS promoter and further  
demonstrates that TNF-α, which represses NO production in endothelial cells, 
does so not only by down-regulating eNOS expression, but also by suppressing 
the availability of arginine. Evidence is provided that the mechanism by which 
TNF-α transcriptionally represses eNOS expression is mimicked in the down-
regulation of AS expression through similar transcription factors.  
 
Since it has been shown in many disease states that arginine availability for NO 
production becomes limiting, I examined in the third paper the role that PPARγ 
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agonists may have in promoting arginine regeneration and relieving, in part, 
impairment of NO production. The transcriptional regulation is investigated and 
includes the identification of a PPARγ-response element (PPRE). In addition, the 
use of TZDs to improve vascular function via the reversal of TNF-α effects is also 
implicated. 
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SUMMARY 
While cellular levels of arginine greatly exceed the apparent Km for endothelial 
nitric oxide synthase (eNOS), current evidence suggests that the bulk of this 
arginine may not be available for nitric oxide (NO) production. We propose that 
arginine regeneration, that is the recycling of citrulline back to arginine, defines 
the essential source of arginine for NO production. To support this proposal, RNA 
interference analysis was used to selectively reduce expression of 
argininosuccinate synthase (AS), since the only known metabolic role for AS in 
endothelial cells is in the regeneration of L-arginine from L-citrulline. Western blot 
analysis demonstrated a significant and dose dependent reduction of AS protein 
as a result of AS siRNA treatment, with a corresponding diminished capacity to 
produce basal or stimulated levels of NO, despite saturating levels of arginine in 
the medium. Unanticipated, however, was the finding that the viability of AS 
siRNA-treated endothelial cells was significantly decreased when compared to 
control cells. Trypan blue exclusion analysis suggested that loss of viability was 
not due to necrosis. Two indicators, reduced expression of Bcl-2 and an increase 
in caspase activity, which correlated directly with reduced expression of AS, 
suggested that loss of viability was due to apoptosis. Exposure of cells to an NO 
donor prevented apoptosis associated with reduced AS expression. Overall, 
these results demonstrate the essential role of AS for endothelial NO production 
and cell viability.  
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INTRODUCTION 
Nitric oxide (NO) is an important modulator for a wide range of functions 
including vasodilation of blood vessels, immune system function, angiogenesis, 
inhibition of leukocyte adhesion and platelet aggregation, gene regulation and 
apoptosis (1-3). Moreover, NO has a dual role in cell viability depending on the 
tissue type and concentration. Either very high or very low concentrations of NO 
may induce cell death, while basal concentrations may inhibit apoptosis (4-7). 
Previous work has shown that NO protects against serum-starvation- (8), H2O2- 
(9), TNF-α- (10) and oxidized low-density lipoprotein- induced apoptosis (11, 12) 
in endothelial cells.  
 
Argininosuccinate synthase (AS), the rate-limiting step (13) in the regeneration of 
arginine from citrulline, catalyzes the synthesis of argininosuccinate, AMP and 
inorganic pyrophosphate from citrulline, ATP and aspartate. Argininosuccinate is 
then cleaved by argininosuccinate lyase (AL) to produce L-arginine and 
fumarate. In liver, AS and AL function together as components of the urea cycle, 
ultimately to form arginine from citrulline. While the expression of AS and AL in 
liver is high, both enzymes are found in most mammalian tissues, although at 
significantly lower levels. The discovery of arginine-derived NO, catalyzed by 
nitric oxide synthases (NOSs), revealed a second role for AS and AL (1-3). 
Together with NOS, they function as part of a citrulline-NO cycle, where AS and 
AL convert citrulline to arginine, which is then oxidized to form NO and citrulline 
by NOS.  
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Although both extracellular and intracellular concentrations of arginine are much 
higher than the reported Km of arginine for endothelial nitric oxide synthase 
(eNOS), NO production still appears to be limited by the availability of arginine 
(13-20). Recently, DNA microarray analysis of shear stress-induced NO 
production demonstrated that upregulation of AS was coordinated with an 
increase in NO production (21), supporting an important role for AS in endothelial 
NO production. If AS is essential for endothelial NO production, then even in the 
presence of excess arginine, depletion of AS should decrease the capacity of 
endothelial cells to produce NO. To test this hypothesis, RNA interference 
analysis was carried out using AS-specific RNA duplexes in bovine aortic 
endothelial cells (BAEC). In this report, we demonstrate a significant and dose-
dependent reduction of AS protein following siRNA transfection. We also show a 
concomitant decrease in enzyme activity corresponding to a decrease in 
stimulated and unstimulated NO production in endothelial cells with reduced AS 
expression, in spite of excess arginine in the media. In addition, we demonstrate 
that the viability of endothelial cells grown in excess arginine and treated with AS 
siRNA was significantly diminished compared to control cells.  
 
EXPERIMENTAL PROCEDURES 
Cell Culture: Bovine aortic endothelial cells (BAEC) were propagated in 
Dulbecco’s modified Eagle’s medium (1 g/L glucose, Mediatech) supplemented 
with 10% fetal bovine serum (Hyclone Laboratories), 100 units ml-1 penicillin and 
100 µg ml-1 streptomycin (Mediatech) at 37°C and 5% CO2. Twenty-four hours 
34 
prior to transfection, BAEC were seeded in a 24-well plate at 5 X 104 cells per 
well. Transfection of siRNA was carried out with TransIT-TKO (Mirus) as 
described by the manufacturer. For each well, 0.1-10 nM siRNA duplex was 
combined with 3 µl liposome in serum free DMEM and applied to cells at 50-70% 
confluency. Cells were assayed after 24-48 h transfection. 
 
RNA duplex preparation: Ambion’s SilencerTM siRNA Construction Kit was used 
to synthesize 21-nucleotide RNA duplexes. Target sequences were chosen 
following the guidelines described by Tuschl et al. (22, 23). The siRNA sequence 
specific to AS corresponded to bp 73-93 relative to the first nucleotide of the start 
codon: GGAGCAAGGCUAUGACGUCtt. A control siRNA was designed by 
scrambling the bases of the AS siRNA: UAGAUGGAGAGGCACUCGCtt. Both 
sequences were subjected to BLAST search to rule out homology to known 
proteins.  
 
Cell lysate preparation and immunoblotting: BAEC were trypsinized and then 
washed in ice-cold phosphate-buffered saline (PBS) and resuspended in RIPA 
buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1X protease inhibitors 
in PBS) by vigorous pipetting followed by brief vortexing. The lysate was 
incubated on ice for 30 minutes and the protein concentration was determined by 
BCA assay (Pierce). Equal amounts (5-10 µg) of protein were resolved on 4-15% 
polyacrylamide gels (Bio-Rad) and blotted onto Immobilon-P PVDF membranes. 
Western blotting was performed as previously described (24). Briefly, 
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membranes were blocked for 1 h in 5% non-fat dry milk (NFDM) in TBS-T and 
subsequently washed. Membranes were incubated with primary antibody (1:2500 
anti-AS (BD Transduction Labs), 1:1000 Bcl-2 (Santa Cruz) and 1:7500 anti-actin 
(Sigma)) in 5% NFDM for 1 h. Following washing, membranes were incubated 
with secondary antibody in 5% NFDM for 1 h. Signal was visualized by 
chemiluminescence using ECL reagent (Amersham Biosciences) and exposed to 
film. Band intensities were quantitated using ImageQuant software (Molecular 
Dynamics). 
 
RNA isolation and quantitative RT-PCR: Total RNA was isolated from 
transfected BAEC using a commercially available kit according to the 
manufacturer’s protocol (Ambion). RNA was treated with DNase (Ambion DNase-
free) and quantitated prior to reverse transcription, which was performed as 
described previously (24). Real time quantitative PCR was performed using AS 
specific primers ASL228 and ASR278 (24). Results were normalized to 18S 
rRNA.  
 
Argininosuccinate synthase activity assay: To assay AS activity in intact 
cells, BAEC were transfected with AS and control siRNA as described above. 
After incubation for 24 hours, cells were depleted of arginine by incubation in 
synthetic DMEM containing 500 µM citrulline and no arginine. Cells were 
incubated for 30 minutes in this medium and then stimulated with sodium 
orthovanadate (50 µM) and A23187 calcium ionophore (0.25 µM) (25) for 30 
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minutes. Nitric oxide production was measured as described below. Cells were 
counted by trypan blue exclusion following assay completion and data was 
normalized as nitrite produced per hour per 1 x 106 cells. In a separate 
experiment, in vitro AS activity was assayed by measuring conversion of 
[3H]aspartate to [3H]argininosuccinate in cell lysates as described by O’Brien (26) 
with the exception that [3H]aspartate (500 µM, 39 Ci/mmol) was used. Whole cell 
lysates were prepared by lysing the cells in 10 mM TrisHCl containing protease 
inhibitors, 0.5 mM citrulline and 0.5 mM aspartate followed by three cycles of 
freeze-thaw in a dry ice ethanol bath. Equal amounts of protein (50 µg) for AS 
siRNA and control siRNA samples was added to each reaction which contained 
citrulline (5mM), Tris-HCl (10 mM, pH 7.5), ATP (0.1 mM), MgCl2 (6 mM), KCl 
920 mM), phosphoenolpyruvate (1.5 mM), pyruvate kinase (4.5 units), myokinase 
(4 units), and pyrophosphatase (0.2 units) in a final volume of 150 µl. Reactions 
were run for 90 minutes at 37°C. At the end of the reaction period, 50 µl of 1M 
acetic acid was added and the tubes were heated to 90°C for 30 min. Samples 
were brought up to 1 ml with water and applied to AG 1-X8 resin (200-400 mesh, 
Bio-Rad) in 0.05M acetic acid. An additional 2 x 1 ml of 0.05 M acetic acid was 
applied to the columns. Radioactivity in the 3 ml of column flow-through 
([3H]argininosuccinate) was quantified by liquid scintillation counting in CytoScint 
(MP Biomedical). 
 
Cell viability: Twenty-four hours after transfection, cells were trypsinized and 
counted by trypan blue exclusion. Briefly, 20 µl of cell suspension was combined 
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with 180 µl trypan blue (Gibco) and cell counts were performed using a 
hemacytometer. Cell number was determined by averaging the cells in four 
squares, multiplying by the dilution factor (10), multiplying by 10,000 and 
adjusting for cell volume to determine cells/well. Viability was also detected using 
a colorimetric assay that measures tetrazolium dye reduction as follows (27). 
siRNA transfections were carried out in 96-well plate format. AS knockdown and 
control BAEC were incubated with 20 µl/well (5 mg/ml stock) MTT [3(4,5-
dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide] (Sigma) for 4 hours under 
normal culture conditions. The medium was removed without disturbing the 
formazan crystals, and 100 µl/well DMSO (Sigma) was used to resuspend the 
product. The plate was read on a µQuant spectrophotometer (Bio-tek 
instruments) at 570 nm. Necrotic cell death was measured using a commercially 
available cytotoxicity kit (Promega). Lactate dehydrogenase (LDH) activity was 
measured in cell culture supernatants from AS knockdown and control cells using 
a FLUOstar Galaxy spectrofluorometer (BMB Labtechnologies) with 544 nm 
excitation and 590 nm emission. Results were presented as percent of maximum 
LDH release, which was determined by complete lysis of cells.  
 
Apoptosis detection: Caspase 3/7 activity was measured using Apo-ONETM 
Homogenous Caspase-3/7 Assay (Promega). Cells were transfected in 96-well 
plates with AS and control siRNA as described above. Cells were lysed and 
caspase 3/7 activity was measured by cleavage of the caspase-3/7 substrate 
rhodamine 110 [bis-(N-CNZ-L-aspartyl-L-glutamyl-L-valyl-L-aspartic acid amide)] 
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(Z-DEVD-R110). Samples were measured on a FLUOstar Galaxy 
spectrofluorometer (BMB Labtechnologies) with 492 nm excitation and 520 nm 
emission. For analysis of the effect an NO donor had on AS siRNA-induced 
apoptosis, BAEC were transfected with siRNA as described above. Four hours 
after transfection, media was replaced with DMEM containing Glyco-SNAP-2 
(Calbiochem) and incubated for 48 h prior to Caspase 3/7 detection.  
 
Nitric oxide assay: Twenty-four hours after transfection with siRNA, BAEC were 
stimulated with sodium orthovanadate (50 µM) and A23187 calcium ionophore 
(0.25 µM) (25). Nitrite was measured in the medium as an indicator of cellular NO 
using a fluorometric method (28). Samples were read on a Jasco 
Spectrofluorometer exciting at 365 nm and detecting emission at 409 nm. 
Following stimulation, cells were counted by trypan blue exclusion and data is 
presented as nitrite produced per 1 x 106 cells. 
 
Statistical Analyses: Experimental data is expressed as the mean +/- SEM. 
Each experiment was performed independently at least three times. 
 
RESULTS 
Silencing of AS by siRNA transfection – AS is known to catalyze the rate-limiting 
step (13) in arginine synthesis from citrulline and aspartate. Argininosuccinate 
lyase (AL) is also required for this conversion (29). In order to further elucidate 
the function of AS in endothelial cells, particularly with respect to its role in NO 
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production, we utilized the recently developed technique of siRNA to selectively 
reduce AS expression. A 21 nt RNA duplex specific to AS sequence was 
identified as outlined by Tuschl and colleagues (23, 30) and compared to known 
sequences using BLAST search to eliminate any sequences homologous to 
other genes. The AS siRNA was transcribed in vitro using the SilencerTM siRNA 
Construction Kit (Ambion). A control siRNA was synthesized containing the same 
base composition as the AS siRNA, but in a scrambled sequence. BAEC were 
transfected with 10 nM AS or control siRNA (except where indicated in the 
figures) for 24 h. AS protein levels were monitored by immunoblot analysis and 
as shown in Figure 1A, AS siRNA treatment specifically reduced cellular AS 
protein levels to less than 50% of control levels.  
 
To determine whether reduction of AS protein correlated to the reduction of AS 
mRNA, total RNA was isolated and AS message quantitated by real-time RT-
PCR. As shown in Figure 1B, AS siRNA treatment resulted in a reduction of AS 
mRNA that correlated with the reduction of AS protein.  
 
Argininosuccinate synthase activity is reduced in AS siRNA treated cells – 
Previously we have demonstrated that citrulline was sufficient to sustain NO 
production in the absence of arginine, based on the presence of the recycling 
enzymes AS and AL. To confirm that the functional activity of AS was decreased 
in intact cells, corresponding to the observed decrease in protein expression, 
cells were equilibrated in arginine-free medium containing 500 µM citrulline for 30 
minutes and then stimulated with sodium orthovanadate and A23187 to give 
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maximal NO production (25). Nitric oxide production was measured as nitrite 
using the DAN assay (28). In the endothelial cells with reduced AS expression, 
nitric oxide production per cell was decreased by more than 80%, indicating a 
significant reduction in activity of the enzyme (Table I). For a direct measure of in 
vitro AS activity, conversion of [3H]aspartate to [3H]argininosuccinate in lysates 
from siRNA treated cells was assayed (26). Activity in control cells was 2.9 
pmol/min/mg, while activity in AS siRNA treated cells was only 0.8 pmol/min/mg, 
confirming that expression and activity of AS protein was reduced as a result of 
AS siRNA treatment. 
 
Reduction of stimulated NO production in AS-depleted BAEC – If production of 
arginine from citrulline, catalyzed by the enzymes AS and AL, provided an 
essential source of arginine for NO production in endothelial cells, reduction of 
AS protein expression should result in a decrease in the amount of NO produced 
upon stimulation (13-17), in spite of saturating levels of extracellular arginine. To 
test whether AS is essential for endothelial NO production, AS siRNA treated 
BAEC were stimulated with sodium orthovanadate and calcium ionophore in the 
presence of excess extracellular arginine (~500 µM) and NO release was 
determined. As shown in Table I, reduction in AS expression resulted in a 56% 
decrease in stimulated NO produced as compared to control. Since nitrite levels 
were normalized to the number of cells counted by trypan blue exclusion, the 
decrease in NO detected could be attributed to a decrease in production per 
viable cell as opposed to any effect on cell viability. These results demonstrate 
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that sufficient levels of AS must be expressed in order to maintain NO 
production, and that arginine regeneration plays an essential role in stimulated 
NO production in endothelial cells, even in the presence of excess arginine.  
 
AS silencing results in a reduced basal level of NO production – The significant 
effect of AS silencing on stimulated NO production in endothelial cells led us to 
investigate whether basal (unstimulated) levels of NO production in BAEC were 
also reduced by AS siRNA treatment. Twenty-four hours after transfection with 
AS and control siRNAs, media was replaced with fresh media (containing excess 
arginine and no phenol red indicator) and samples were collected after 24 h for 
nitrite determination. Cell number was assessed by trypan blue exclusion 
analysis and results are presented as nitrite produced per hour per 1 x 106 cells. 
As shown in Table I, significant reduction (70%) in basal production of NO was 
observed in BAEC where AS expression had been decreased by siRNA 
transfection. Thus, AS expression is also required to sustain unstimulated levels 
of NO produced by endothelial cells even in the presence of excess levels of 
extracellular arginine. 
 
Decrease in cell survival in AS depleted BAEC – Interestingly, AS siRNA 
treatment of endothelial cells resulted in a noticeable and unexpected decrease 
in cell viability over control cells. To confirm this observation, AS siRNA treated 
cells were evaluated for viability by trypan blue exclusion. As shown in Figure 2A, 
a 46% decrease in cell survival was observed compared to control. To further 
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substantiate this observation, cellular respiration was measured as a marker of 
viability using the MTT assay 24 h after AS siRNA transfection. MTT assay also 
showed a 40% decrease in cell survival in AS depleted endothelial cells (Figure 
2B). Reduction of AS protein beyond the levels achieved in this study was not 
possible due to extensive cell death associated with further increased 
concentrations of the AS siRNA.  
 
LDH release in AS-transfected BAEC – During necrosis, cells become 
permeable, allowing leakage of proteins into the media. A marker used to detect 
this phenomenon is release of lactate dehydrogenase (LDH) into the culture 
medium (31). After treatment with AS and control siRNA, cell cultures were 
assayed for LDH activity in the media. Although treatment with AS siRNA 
resulted in a loss of cell viability, there was no significant difference in LDH 
activity detected in the media in AS-siRNA transfected cells as compared to 
control (Figure 3). These results suggested that the loss of cell viability resulting 
from partial AS depletion was not necrosis. 
 
Reduction in Bcl-2 levels in cells with reduced AS expression – Since trypan blue 
exclusion analysis, as well as the absence of LDH release, suggested that 
necrosis was not the pathway directing cell death in cells with reduced AS 
expression, the possible involvement of apoptosis was investigated. Bcl-2 is 
known to be an important protein expressed in many cell types, including 
endothelial cells, that protects against apoptosis (32). To determine whether 
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apoptosis accounted for the loss of viability in AS knockdown cells, lysates from 
cells transfected with AS and control siRNAs were prepared and Bcl-2 
expression was determined by standard western blotting analysis. As shown in 
Figure 4, a significant decrease in Bcl-2 protein was detected in AS-depleted 
cells as compared to control, consistent with the suggestion that the observed 
loss of cell viability results from the induction of apoptosis.  
 
Apoptosis-inducing factor is unaffected by depletion of AS – In a recently 
described pathway in endothelial cells, apoptosis-inducing factor (AIF) was 
identified as an important regulator of apoptosis that circumvents the requirement 
for caspase 3 activation in the induction of apoptosis (33). To examine whether 
increased levels of AIF result from AS siRNA treatment, cell lysates from AS and 
control siRNA treated cells were subjected to western blot analysis to monitor 
changes in AIF protein expression. As shown in Figure 5A, there was no 
significant effect on AIF levels resulting from AS siRNA treatment that would 
account for the loss of cell viability induced by an apoptotic response.  
 
Increase in caspase-3/7 activation in BAEC depleted of AS – Due to the 
observed degradation of Bcl-2 protein and the lack of effect on AIF protein, the 
effect of AS silencing on caspase activation was investigated. Caspase-3 is a 
cysteine protease that on activation of the apoptotic cascade is proteolytically 
cleaved from an inactive, procaspase form, to an active caspase. Following 
partial AS depletion, there was over a 3-fold increase in caspase 3/7 activity 
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compared to control cells (Figure 5B). This finding strongly supports the proposal 
that reduction of AS expression results in induction of apoptosis.  
 
Treatment of AS siRNA transfected BAEC with an NO donor prevents apoptosis 
– Basal NO production in endothelial cells has been suggested to prevent 
induction of apoptosis (34); first by decreasing mRNA stability of MAP kinase 
phosphatase-3 (MPK-3)(35), and second, by directly inactivating caspase-3 via 
S-nitrosylation of its active site thiol (36)(see Figure 7). To determine whether a 
reduction in basal NO production caused by AS knockdown correlated with the 
observed increase in apoptosis, BAEC were treated with Glyco-SNAP-2 
(Calbiochem), an NO donor with a half-life of 27.4 h. Glyco-SNAP-2 (25-400 µM) 
was added to the media immediately following the transfection with AS siRNA. 
Forty-eight hours after transfection, caspase 3/7 activity was determined to 
quantitate the level of the apoptotic response. As shown in Figure 6, AS siRNA-
induced apoptosis in treated endothelial cells was decreased proportionately by 
the concentration of exogenous NO donor added. This correlation suggests that 
induction of apoptosis may be due, in part, to the reduction in basal NO 
production that results from AS knockdown, although a more direct effect of AS 
protein on apoptosis can not be excluded. 
 
DISCUSSION 
NO production appears to be limited by the availability of arginine, despite 
extracellular and intracellular concentrations that are much higher than the 
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reported Km for eNOS (13-19); thus, the source of arginine required to sustain 
NO production in endothelial cells has been investigated and debated. Part of 
this debate seemed to be resolved with the finding that the CAT1 transporter, the 
major transporter of arginine for endothelial cells, co-localizes with eNOS in 
caveolae (37). Thus, it was suggested that endothelial NO production was 
maintained through extracellular transport of arginine (37). This was a 
reasonable proposal since serum arginine levels normally vary from 80 to 90 µM, 
well above the Km for eNOS. Nevertheless, other evidence persisted, 
demonstrating that endothelial NO production was limited by the capacity to 
regenerate arginine from citrulline (13-19).  
 
For example, our laboratory has shown previously that extracellular citrulline was 
as effective as arginine in stimulating NO production (18), even in media 
containing saturating levels of arginine (~500 µM). Because extracellular citrulline 
levels had no effect on intracellular arginine levels, these results suggested that 
citrulline enhancement of NO production was mediated through regeneration of 
arginine directed to NO production, and therefore could be observed despite 
saturating levels of extracellular arginine. Similarly, Wu et al. (38) showed that 
synthesis of arginine from citrulline was stimulated by addition of exogenous 
citrulline. In this case, the authors speculated that the function of citrulline 
recycling was to salvage the carbon backbone in order to maintain sufficient L-
arginine to sustain prolonged NO synthesis. 
 
46 
Other lines of evidence that supported the requirement of arginine regeneration 
for NO production include the over expression of AS in vascular smooth muscle 
cells (13). As a result of AS over expression there was a dramatic enhancement 
in the ability of the transfected smooth muscle cells to produce NO over that of 
untransfected cells, again in spite of saturating levels of extracellular arginine. 
Thus, Xie et al. (13, 14) concluded that the capacity to recycle citrulline back to 
arginine is “rate-limiting” to NO production. Su et al. (17) arrived at a similar 
conclusion showing that hypoxia in pulmonary artery endothelial cells (PAEC) 
inhibited induction of AS by endotoxin. As a consequence, the production of NO, 
independent of sufficient extracellular arginine levels, was significantly impaired. 
While our studies focused on the role of recycling for endothelial NO production 
by eNOS, previous studies have demonstrated the importance of recycling for 
NO production by both iNOS and nNOS. For example, AS and iNOS are 
coinduced in immunostimulated macrophages (39, 40) as well as in stimulated 
RPE-J cells where the citrulline-NO cycle is shown to be functioning (41). In 
addition, coinduction of iNOS, CAT-2 and AS in rat microglial cells indicates that 
both arginine transport by CAT-2 and citrulline-arginine recycling are important in 
the production of large amounts of NO in activated microglial cells (42). In 
neurons, colocalization of nNOS, AS and AL was identified in the canine 
gastrointestinal tract providing morphological evidence of a citrulline-NO cycle 
(43). Finally, in the rat gastric fundus, functional evidence of recycling is 
supported by colocalization of AS, AL and nNOS (44). 
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Gene expression studies, using DNA microarray analyses, demonstrated that a 
significant and coordinate upregulation of AS gene expression occurred in 
response to fluid shear stress stimulation of NO production by human umbilical 
vein endothelial cells (21). Since extracellular arginine was again not limiting in 
these studies, the authors concluded that a prerequisite for shear-stress induced 
NO production, in the absence of synthesis of additional eNOS, was an increase 
in arginine regeneration via increased AS expression (21). In other words, 
increased expression of AS resulted in the increased capacity to provide the 
necessary substrate to sustain elevated NO production associated with the 
shear-stress response.  
 
Our results provide further evidence supporting the necessity for the regeneration 
of arginine for NO production. Specifically, AS expression was demonstrated to 
be necessary and sufficient to maintain both stimulated and resting levels of NO 
synthesis in endothelial cells. However, the finding that reduction of AS 
expression in endothelial cells resulted in a decrease in cell viability was 
unexpected. Initially, we speculated that cell death may be a consequence of 
superoxide toxicity which can result when eNOS is deprived of arginine (45). 
However, superoxide production was unaffected by partial AS depletion (data not 
shown). Moreover, since trypan blue exclusion and LDH release did not indicate 
that necrosis was the mechanism of cell death, we investigated the possibility 
that these AS depleted endothelial cells were being driven to apoptosis.  
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NO has a bi-functional role in cell death – it can either stimulate or inhibit 
cytotoxicity. The level of NO produced and the type of cell involved determines 
the effect NO has on cell viability (5, 6). High concentrations of NO have been 
shown to induce cell death via apoptosis. In a more complex pathway, NO can 
switch apoptosis to necrosis (4-7). In contrast, lower concentrations of NO have 
been shown to protect cells such as endothelial cells (34), thymocytes (46) and 
lymphocytes (47) from apoptosis. In endothelial cells, induction of NO by 
sphingosine-1-phosphate protects endothelial cells from serum-deprived 
apoptosis (8).  
 
There are several mechanisms that have been elucidated in the anti-apoptotic 
effects of NO (see Figure 7). Caspase-3 activation is inhibited by S-nitroslyation 
of the enzyme by NO (36, 48). In addition, Bcl-2 cleavage is inhibited by NO as 
well as subsequent release of cytochrome c (5, 47). Furthermore, MAP kinase 
phosphatase-3 (MKP-3) RNA is downregulated via an NO-dependent 
mechanism, maintaining active ERK1/2 and thus protecting the cell from the 
apoptotic cascade (35). Finally, NO can induce apoptosis by directly inhibiting 
cytochrome c oxidase, thus causing a decrease in the membrane potential of the 
mitochondria and release of cytochrome c (49). In our study, AS siRNA-induced 
apoptosis was modulated by the addition of an NO donor. This finding suggests 
that basal levels of NO in endothelial cells, sustained by the recycling of citrulline 
back to arginine, may provide protection against apoptosis. We recognize 
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however, that AS may be performing another function in the cell which is 
preventing apoptosis. The recent characterization of AS as a Jak-2 interacting 
protein (50), the regulation of AS by c-Myc (51) and the repression of AS 
expression by the anti-proliferative drug FAP48 (52) warrant investigation into an 
alternative role of the enzyme in maintaining cell viability. 
 
The maintenance of endothelial cell viability through basal NO production has 
important clinical implications. In atherosclerotic lesions there are regions 
characterized by reduced shear stress, which correlate with reduced NO 
synthesis (53, 54). High endothelial cell turn-over due to induction of apoptotic 
signaling pathways also characterize these regions (55). Importantly, NO 
production by endothelial cells may play a preventive role in atherosclerosis 
where cultured endothelial cell apoptosis is inhibited by increased endothelial NO 
production (56). All these studies, however, demonstrate a protection from 
induction of apoptosis, not simply maintenance of viability as we demonstrate in 
the current study. Basal levels of NO may provide maintenance of viability by 
keeping the proteins involved in cell cycle versus cell death in check, thus 
maintaining viability. 
 
A decrease in endothelial NO production associated with endothelial dysfunction, 
is a common feature in medical conditions such as hypertension, diabetes 
mellitus and atherosclerosis. Supplementation with arginine in humans has 
produced conflicting results. In some studies, dietary arginine supplementation 
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results in improved vascular function by providing substrate for eNOS and 
improving NO production (57-59). Other studies have not seen an improvement 
in condition and harmful effects may occur (60-63). We demonstrate in this study 
that a functional citrulline-NO cycle is essential for endothelial NO production; 
therefore, targeting an increase in AS activity in endothelial cells may provide a 
pharmaceutical alternative for improving endothelial dysfunction.  
 
In summary, NO production by endothelial cells plays an important role in the 
function of the endothelium and modulates cell survival signaling pathways such 
as Bcl-2 expression and caspase activity. This report supports our hypothesis 
that endothelial NO synthesis is dependent on the availability of a specific pool of 
arginine maintained through the conversion of citrulline to arginine by the 
enzymes AS and AL. 
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Table I: 
 
Effect of AS siRNA transfection on endothelial NO production 
 
BAEC were transfected with AS siRNA or with control siRNA as described in 
Methods. Transfected BAEC were equilibrated in synthetic DMEM that contained 
either no arginine and 500 µM citrulline or no citrulline and 500 µM arginine. 
Basal NO production was determined over a 24 hour period and stimulated NO 
production was determined over a one hour period following stimulation with 0.25 
µM A23187 and 20 µM sodium orthovanadate. NO was measured as nitrite 
produced per 1x106 cells. (Nitrite is a stable reaction product of NO and 
molecular oxygen). Control rates of NO production are not directly comparable   
because of different cell preparations. 
 
Condition Control siRNA nmol nitrite/h/ 
1x106 cells 
AS siRNA 
nmol nitrite/h/ 
1x106 cells 
Ratio 
AS siRNA/ 
Control siRNA 
Stimulated, 
+ Citrulline 0.98±0.20 0.14±0.09 0.14 
Stimulated, 
+ Arginine 5.40±0.96 2.38±0.37 0.44 
Basal, 
+ Arginine 0.35±0.08 0.12±0.01 0.34 
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Table II: 
 
Effect of AS siRNA transfection on AS activity 
 
BAEC were transfected with AS or control siRNA and lysates were prepared as 
described in Methods. In vitro activity was measured as described by O’Brien 
(26) and detailed in methods. 
 
 
 
Condition 
AS activity 
pmol/min/mg 
Ratio 
AS siRNA/ 
Control siRNA 
AS siRNA 
Control siRNA 
0.81±0.17 
2.89±0.58 
0.28 
- 
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Figure 1: Specific reduction of AS protein and mRNA by siRNA 
transfection. BAEC were transiently transfected with AS and control siRNA 
using Transit-TKO. (A) 24 h after transfection, cell lysates were prepared, 10 µg 
of each sample was loaded onto an SDS polyacrylamide gel and standard 
western blotting performed. Anti-AS and anti-actin antibodies were used to detect 
the amount of protein present. (B) 24 hours after transfection, total RNA was 
isolated using RNAqueousTM Total Isolation Kit (Ambion) and reverse 
transcribed with Superscript II (Invitrogen). AS message was detected using real 
time quantitiative PCR. Results were normalized to 18S rRNA. 
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Figure 2: Loss of AS in BAEC diminishes cell viability. BAEC were 
transiently transfected with Transit-TKO and 10 nM siRNA. Twenty-four hours 
after transfection, cell viability was measured by (A) trypan blue exclusion 
analysis or (B) MTT assay in siRNA transfected, non-transfected (NT) and 
liposome only (L) transfected cells. Results are presented as percent viability of 
NT cells. 
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Figure 3: Effect of partial AS silencing on necrotic cell death measured by 
LDH release. BAEC were transfected in 96-well plates with liposome only (L) or 
indicated siRNA. Twenty-four hours post-transfection, LDH release was 
measured using CytoTox-ONETM (Promega). Samples were measured using 544 
excitation and 590 emission. Results are presented as percentage of maximum 
LDH release (M) quantitated by lysis of non-transfected cells. 
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Figure 4: Reduced Bcl-2 protein levels in partially AS depleted endothelial 
cells. Following transfection of 1-10 nM AS or control siRNA, cell lysates were 
prepared and standard western blotting was performed. Blots were probed with 
anti-AS (1:2500), anti-Bcl-2 (1:1000) and anti-Actin (1:7500) antibodies.  
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Figure 5: Apoptosis induction in BAEC transfected with AS siRNA. (A) 
Following siRNA transfection in 24-well plates, total protein was prepared and 
analyzed by SDS-PAGE and immunoblotted with anti-AIF antibody. (B) BAEC 
were transfected with AS and control siRNA in 96 well plates. 24 h after 
transfection, caspase 3/7 activity was measured using Apo-ONETM (Promega) on 
a Fluostar Galaxy spectrofluorometer using an excitation of 490 nm and 
detecting at 520 nm. Control wells were transfected with liposome only. Results 
are presented as fold increase in caspase activity over control wells. 
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Figure 6: Prevention of AS siRNA-induced apoptosis with an NO donor. 
BAEC were transfected with AS siRNA in 96 well plates. Immediately following 
transfection increasing concentrations of the NO donor, Glyco-SNAP-2, was 
added to the media. Caspase 3/7 activity was measured as an indicator of 
apoptosis.  
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Figure 7: Mechanism of NO suppression of apoptosis. Activation of map 
kinase phosphatase-3 (MKP-3) induces ERK 1/2 activation. ERK 1/2 activation 
results in degradation of the apoptotic protective protein Bcl-2. NO prevents 
cascade activation by destabilizing MKP-3 RNA thus blocking the apoptotic 
cascade prior to cytochrome C release (35). In addition, NO can also inactivate 
caspase-3 through s-nitrosylation of the active cysteine (36).  
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SUMMARY 
Endothelial dysfunction associated with increased serum levels of tumor necrosis 
factor (TNF)-α observed in diabetes, obesity and congenital heart disease 
results, in part, from the impaired production of endothelial nitric oxide (NO). 
Cellular NO production depends absolutely on the availability of arginine, the 
substrate of endothelial nitric oxide synthase (eNOS). In this report, evidence is 
provided demonstrating that treatment with tumor TNF-α (10 ng/ml) suppresses 
not only eNOS expression, but also the availability of arginine via the coordinate 
suppression of argininosuccinate synthase (AS) expression in aortic endothelial 
cells. Western blot analysis demonstrated a significant and dose dependent 
reduction of AS protein when treated with TNF-α with a corresponding decrease 
in NO production. Reporter gene analysis demonstrated that the suppression of 
AS expression by TNF-α involves the proximal promoter, and EMSA analysis 
showed reduced binding to three essential Sp1 elements. Inhibitor studies 
showed that the repression of AS by TNF-α is mediated via the NFκB signaling 
pathway. These findings demonstrate that TNF-α coordinately down-regulates 
eNOS and AS expression, resulting in a severely impaired citrulline-NO cycle. 
The down-regulation of AS by TNF-α is an added insult to endothelial function 
due to its essential role in NO production and in endothelial viability.  
 
 INTRODUCTION 
The endothelium plays a crucial role in the maintenance of vascular tone and 
structure. The major endothelium-derived vasoactive mediator is nitric oxide 
(NO)1, which is formed from the amino acid precursor L-arginine by nitric oxide 
synthase (NOS). NO is involved in a wide variety of regulatory mechanisms of the 
cardiovascular system, including vascular tone (i.e, it is the major mediator of 
endothelium-dependent vasodilation), vascular structure (e.g., inhibition of 
smooth muscle cell proliferation), and cell-cell interactions in blood vessels (e.g., 
inhibition of platelet adhesion and aggregation, inhibition of monocyte adhesion) 
(1-3). Because of these functions, NO has been designated as an endogenous 
anti-atherosclerotic molecule (4-6). 
 
Dysfunction of the endothelial citrulline-NO cycle is a common mechanism by 
which several cardiovascular risk factors mediate their deleterious effects on the 
vascular wall (4-7). Among them are hypercholesterolemia, hypertension, 
smoking, diabetes mellitus, homocysteinemia, and vascular inflammation (4-7). 
In particular, the multi-functional cytokine tumor necrosis factor alpha (TNF-α) 
has been linked to endothelial dysfunction in type 2 diabetes (8), obesity (9) and 
congenital heart failure (10, 11). Clinical studies have shown that elevated levels 
of plasma TNF-α in patients with type I diabetes are associated with cardiological 
risk factors (12). In vivo studies have also revealed that administration of TNF-α 
depresses endothelium-dependent relaxation (13) and reduces levels of 
80 
 81 
endothelial NO (14). The impairment of endothelial NO production by TNF-α was 
initially linked to the reduction in eNOS expression in bovine aortic endothelial 
cells (BAECs) (15-18). Therefore it is not surprising that impairment in endothelial 
NO production leads to endothelial dysfunction. In fact, loss of endothelium-
derived NO is associated with the prothrombotic and hyperproliferative states 
present in hypertensive, diabetic and atherosclerotic states (19). 
 
Although the production of NO is directly related to the enzyme eNOS, overall 
production of NO by endothelial cells has been shown to be dependent on a 
functional citrulline-nitric oxide cycle (20-23). Both NO and citrulline are 
generated from arginine by eNOS. The NO is utilized in signaling, whereas, the 
citrulline is recycled back to arginine by two enzymes, AS and argininosuccinate 
lyase (AL), to complete the cycle. Argininosuccinate synthase (AS) catalyzes the 
rate-limiting step in the arginine regeneration side of the citrulline-nitric oxide 
cycle (21), and appears to be coordinately regulated with eNOS activity (19, 24).  
 
DNA microarray analysis of shear stress-induced NO production has 
demonstrated up-regulation of AS (19, 25), supporting an important role for AS in 
endothelial NO production. More recent results from our laboratory using siRNA 
knockdown of AS expression demonstrated that AS is essential for both basal 
and stimulated endothelial NO production, even in the presence of excess 
arginine, as well as for maintenance of endothelial viability (20). A recent study of 
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transgenic rat blood-brain barrier endothelial cells supported our conclusions that 
regeneration of citrulline from intracellular arginine via AS provides the major 
arginine pool for stimulated NO production (26). Collectively, these results 
demonstrated the essential role of AS in endothelial NO production and 
endothelial cell viability. Thus, our work and the work from other laboratories has 
developed a strong evidential case supporting the proposal that substrate 
availability, governed by arginine-regeneration as part of the citrulline-nitric oxide 
cycle, plays a key role in NO production thus affecting vascular endothelium 
function and viability (20-23). 
 
In this report, we demonstrate that TNF-α, which represses NO production in 
endothelial cells, does so, not only by down-regulating eNOS expression, but 
also by suppressing the availability of arginine. Moreover, evidence is provided 
that the mechanism by which TNF-α transcriptionally represses eNOS 
expression is mimicked in the down-regulation of AS expression through similar 
transcriptional factors. Thus, TNF-α depresses endothelial NO production via the 
coordinate down-regulation of both eNOS and AS. 
 
EXPERIMENTAL PROCEDURES 
Cell Culture: Bovine aortic endothelial cells (BAEC) were cultured in Dulbecco’s 
modified Eagle’s medium (1 g/L glucose, Mediatech) containing 10% fetal bovine 
serum (Hyclone Laboratories), 100 units/ml penicillin and 100 µg/ml streptomycin 
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(Mediatech) at 37°C and 5% CO2. For cytokine treatment, cells in control medium 
were treated with the indicated concentrations of TNF-α for up to 48 hours.  
 
Cell lysate preparation and immunoblotting: Following treatment, BAEC were 
removed from the plate with trypsin, washed in ice-cold phosphate-buffered 
saline (PBS) and resuspended in RIPA buffer (1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS, 1X protease inhibitors in PBS) by vigorous pipetting 
followed by brief vortexing. The lysate was incubated on ice for 30 minutes and 
protein concentration was determined by bicinchoninic acid reagent (BCA) 
(Pierce). Ten µg of protein were resolved on 4-15% polyacrylamide gels (Bio-
Rad) and blotted onto PVDF membranes (Immobilon-P). Western blotting was 
performed as previously described (27). Briefly, membranes were blocked for 1 
hour in 5% blocking solution (Bio-Rad) in TBS-T (20 mM Tris-HCl, 137 mM NaCl, 
0.1% Tween-20) and subsequently washed in TBS-T. Membranes were 
incubated with primary antibody (1:2500 anti-AS (BD Transduction Labs), 1:1000 
anti-GAPDH (Abcam), 1:7500 anti-Actin (Sigma), 1:1000 anti-eNOS 
(Transduction Labs)) for 1 hour to overnight. Membranes were incubated with 
secondary antibody for 1 hour and signal was detected by chemiluminescence 
using ECL reagent (Amersham Biosciences) and exposed to film. Pre-stained 
protein markers were used for molecular mass determination. Band intensities 
were quantitated using ImageQuant software (Molecular Dynamics). 
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RNA isolation and quantitative RT-PCR: Total RNA was isolated using a 
modified guanidinium thiocyanate-phenol-chloroform method using Tri Reagent 
according to the manufacturer’s recommendations (Sigma). RNA was treated 
with DNase (Ambion DNA-free) and quantitated prior to reverse transcription, 
which was performed as described previously (27). Real time quantitative PCR 
was performed using AS specific primers ASL228 and ASR278 (27). Results 
were normalized to 18S rRNA.  
 
Vector construction: Luciferase reporter constructs were designed to include 
the AS promoter and 5´-UTR up to the AUG start codon cloned upstream of the 
luciferase gene. Left primer ASL-189 (5´-
GCACTCGAGATCTGCAGGTGGCTGTGAA) was combined with ASRluc (5´-
ATAGAATGGCGCCGGGCGTTTCTTTATGTTTTTGGCGTCTTCCATCGTGACG
GGTGACCAGCGGC) to amplify the AS promoter with an Xho I site on the 5´ 
end and an Nco I site on the 3´ end which were used to clone into the vector 
pGL3Basic (Promega) to create the plasmid p3ASP189. This strategy takes 
advantage of a Nco I site within the luciferase gene, close to the start codon, to 
allow for the AS 5´-UTR to be cloned adjacent to the start codon. For mutant 
constructs, mutations were made in the three Sp1 sites in the p3ASP189 
construct using a three-way PCR method (28). Primers AS189mut1 (5´-
CTCCAGGCGGGTTCCGGGCCCGGG-3´), AS189mut2 (5´-
CCGGGTTCGGGGTCTGTGGC-3´) and AS189mut3 (5´-
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ACCGGACCTGACCCCGGG-3´) were combined with ASRluc to amplify 
fragments that contained the mutations. This PCR product was then used as a 
right primer and paired with ASL-189 to produce a second product. A third round 
of PCR was used with the second product as a template with primers ASL-189 
and ASRluc to enrich for the target with the mutation in the center and the 
restriction sites Xho I and Nco I on either end for cloning into the pGL3Basic 
vector. Amplified products were purified after agarose gel electrophoresis and 
restriction digestion and ligated into pGL3Basic to create the mutated plasmids 
p3ASP189M1, p3ASP189M2 and p3ASP189M3. All constructs were verified by 
sequencing. Sp1 and Sp3 plasmids were a kind gift from Dr. Jonathan M. 
Horowitz at North Carolina State University. 
 
Luciferase Assay analysis: BAEC were plated at 2x104 cells per well in a 24 
well plate twenty-four hours prior to transfection. pRL-TK, a renilla expression 
vector, was used as an internal transfection control where indicated. 
Experimental plasmids (200 ng each) and pRL-TK (50 ng) were transiently 
transfected into BAEC using Transit-LT1 (Mirus) in serum free media. Media was 
replaced with complete media after 4 hours and cells were cultured for 48 hours. 
Lysates generated with passive lysis buffer (Promega) were assayed for 
luciferase and renilla activity using a Dual-Luciferase Reporter Assay System 
(Promega) according to the manufacturer’s recommendations. Luciferase and 
renilla activity were measured as relative light units using a luminometer (Turner 
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Designs). Experiments were carried out three times in triplicate. Luciferase 
expression was normalized to renilla activity. 
 
Nuclear extract preparation: Nuclear extracts were prepared from BAEC as 
described previously (29) with the following modifications: Cells were plated in 10 
cm dishes and treated once they reached confluence. The culture monolayer 
was rinsed twice with PBS (phosphate buffered saline), once with PBS 
containing 1mM Na3VO4 and 5 mM NaF and once with 1X hypotonic buffer (20 
mM HEPES, pH 7.9, 1 mM EDTA, 1 mM EGTA, 20 mM NaF, 1 mM Na3VO4, 1 
mM Na4P2O7, 1 mM DTT, and 1X protease inhibitors (CalBiochem)). Cells were 
scraped into 1X hypotonic buffer containing 0.2% NP40 and resuspended by 
gentle pipetting. Samples were centrifuged for 20 seconds at 12,000 x g at 4°C. 
The nuclear pellet was resuspended in high salt buffer (420 mM NaCl, 20 mM 
HEPES, pH 7.9, 1 mM EDTA, 1 mM EGTA, 20% glycerol, 20 mM NaF, 1 mM 
Na3VO4, 1 mM Na4P2O7, 1 mM DTT, and 1X protease inhibitors (CalBiochem)) 
and rotated for 30 minutes at 4°C. Samples were centrifuged at 12,000 x g, 4°C 
for 20 minutes. 
 
Electrophoretic Mobility Shift Assay: Nuclear extracts were combined with or 
without cold competitors or specific antibodies and incubated for 20 minutes at 
room temperature. Probes were labeled by combining equimolar amounts of 
complementary oligonucleotides (2x10-10 mols of each) which were heated to 
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70°C and allowed to cool to room temperature slowly. The oligos were labeled 
using 10 µl [α-32P]dCTP (3000 Ci/mmol) and Klenow enzyme and unincorporated 
label was removed using Nuc Away (Ambion). The reaction mixture, composed 
of binding buffer (10 mM HEPES, pH 7.9, 10% glycerol, 1 mM DTT, 0.1 µg/µl 
poly(dI:dC), 0.5 µg/µl BSA and 4000 dpm/µl radiolabeled probe) and nuclear 
extract (5 µg) in a total volume of 10 µl, was incubated at 30°C for 30 minutes. 
Samples were loaded onto a 5% polyacrylamide gel and run at 180 V. Gels were 
dried under vacuum and exposed to film. The oligonucleotides for EMSA analysis 
included Sp1 site 1 (5´-GCTCCAGGCGGGGGCCGGGCCCGGGGGCG-3´); Sp1 
site 2 (5´-GGCCGGGCCCGGGGGCGGGGTCTGTGGCGC-3´); and Sp1 site 3 
(5´-CCGGTCACCGGCCCTGCCCCCGGGCCCTG-3´);   
 
Nitric oxide assay: BAEC were treated with 10 ng/ml TNF-α in serum-free 
medium in the absence of phenol red and L-glutamine. Aliquots were removed at 
the time points indicated and nitrite was measured in the medium as an indicator 
of cellular NO using a fluorometric method (30). Briefly, freshly prepared DAN 
was added to culture supernatant, mixed immediately and incubated for 10 
minutes. The reaction was stopped by adding NaOH to a final concentration of 
2.8 M. The samples were read on a BMG Fluostar Galaxy spectrofluorometer in 
a 96-well plate using the excitation wavelength of 360 nm and emission 
wavelength of 405 nm. Cells were counted by trypan blue exclusion analysis and 
data is presented as quantity of nitrite produced in pmols per 1 x 106 cells.  
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Statistical Analyses: Experimental data is expressed as the mean +/- SEM. 
Each experiment was performed independently at least three times. 
 
RESULTS 
Coordinate reduction of AS and eNOS expression by TNF-α – Previous results 
have indicated that the expression of AS is required for NO production and also 
for endothelial cell viability (20-23). Therefore, we investigated whether AS 
expression was coordinately down-regulated with eNOS by TNF-α Initially, 
conditions were chosen that were known to suppress eNOS expression in BAEC 
(16, 31, 32). BAECs were treated with increasing concentrations of TNF-α and 
subsequently lysed and analyzed by western blotting. As shown in Figure 1A, 
TNF-α, treatment resulted in a dose-dependent reduction of both eNOS and AS 
protein expression. For all subsequent experiments, 10 ng/mL of TNF-α was 
used since at higher concentrations AS was not decreased further and cell 
viability was severely affected (data not shown). This concentration of TNF-α 
also reasonably mimics serum levels found in the inflammatory environment of 
chronic disease states such as diabetes and obesity (6, 33-35). It is also 
important to note, that under these treatment conditions, there was no apparent 
induction of iNOS (data not shown).  
 
To examine whether the decrease in AS protein that resulted from TNF-α 
treatment correlated with a reduction in steady-state AS mRNA levels, total RNA 
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was isolated and AS message quantitated by real-time RT-PCR. As shown in 
Figure 1B, TNF-α treatment resulted in a 74% reduction (P = 0.003) of AS mRNA 
that correlated with the reduction of AS protein.  
 
Consistent with the reduction in both AS and eNOS protein expression, basal 
levels (unstimulated) of NO were reduced to 34% of controls (P = 0.01) when 
endothelial cells were treated with TNF-α (Figure 2). NO production was 
measured as nitrite using a fluorescent assay (30), and nitrite levels were 
normalized to the number of cells counted by trypan blue exclusion in order to 
account for cell viability. 
 
Regulation of the proximal AS promoter by TNF-α – To assess the effect of TNF-
α on AS promoter activity, the reporter construct p3ASP189 was used. Plasmid 
constructs were transiently transfected into BAECs and treated for 48 hours with 
increasing concentrations (0-10 ng/ml) of TNF-α. Luciferase expression was 
measured as relative luciferase units (RLU) and data presented as relative 
change in expression. As shown in Figure 3, TNF-α treatment resulted in a dose-
dependent decrease in luciferase activity.  
 
Characterization of the cis-elements in the AS proximal promoter responsible for 
regulating AS expression – Previous work characterizing the AS proximal 
promoter, which was shown to be repressed by TNF-α treatment, was done in a 
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human carcinoma cell line, RPMI2650 (36). In vitro DNase I footprinting with 
affinity-purified Sp1 identified three essential Sp1 binding sites that act 
synergistically to affect AS expression in a region 150 bp upstream of the start 
codon (36). Further analysis of these sites by CAT assay determined that they 
acted independently to promote transcription in vivo (36). Ablation of the second 
Sp1 site led to the greatest reduction in promoter activity and was determined to 
be a high affinity binding site required for AS expression in RPMI2650 (36). To 
confirm these results and expand the knowledge of regulation of the AS promoter 
specifically in endothelial cells, a luciferase reporter construct containing the 
proximal 189 base pair region of the AS promoter which included the three 
identified Sp1 binding elements (p3ASP189) was used. First, BAEC were co-
transfected with p3ASP189 and either a control vector (pcDNA3), Sp1 or Sp3 
expression plasmids and luciferase activity was monitored. Both Sp1 and Sp3 
bind to the same element and can work together, or in opposition of each other 
on a single site (37). When Sp1 and Sp3 were over-expressed with the reporter 
construct, both transcription factors were able to activate the AS promoter to a 
similar extent (Figure 4A). 
 
To delineate the involvement of these Sp1/Sp3 elements individually in the 
control of AS expression in BAEC, each site was mutated independently. 
Mutation of the three Sp1 sites identified by Anderson, et al. (36) (site 1 (M1), site 
2 (M2) and site 3 (M3)) resulted in a 60-94% decrease in AS promoter activity 
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(Figure 4B), supporting the essential role of Sp1/Sp3 in AS expression. 
Anderson, et al. (36) identified a fourth Sp1 element that did not bind purified Sp1 
by genomic footprinting. Mutation of this site resulted in a 2-fold increase in AS 
promoter activity, indicating this site may also be involved in transcriptional 
suppression of the AS promoter in endothelial cells (data not shown). Our results 
also indicated that site 3 is absolutely essential for AS expression in endothelial 
cells, in contrast to the results described previously in RPMI 2650 cells (36).   
 
Regulation of the proximal AS promoter by TNF-α – Anderson et al (16) showed 
that TNF-α mediated transcriptional suppression of eNOS via two Sp1-binding 
sites positioned in the proximal eNOS promoter. These findings, combined with 
our results showing that TNF-α treatment transcriptionally suppressed AS 
expression, led to the detailed examination of the proximal region of the AS 
promoter to see if it was regulated similarly to the eNOS promoter to account for 
the apparent coordinate down-regulation of both genes by TNF-α. To further 
define the locus regulated by the cytokine, the three Sp1 sites in the proximal 
promoter were mutated. Mutation of two of the Sp1 sites (M1 and M2) restored 
luciferase activity to a small extent while mutation of Sp1 site 3 (M3) resulted in 
complete ablation of the TNF-α affects (Figure 5). It is interesting to note that 
mutation of this site also reduced the promoter activity to less than 4% (Figure 
4B). This is similar to the situation that has been identified in the eNOS promoter 
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(16) where TNF-α acted to suppress promoter activity by reducing binding to an 
Sp1 site that is essential to basal eNOS promoter activity.  
 
TNF-α reduces Sp1 binding to AS promoter elements – To investigate the effect 
of TNF-α on the binding of Sp factors to the basal promoter, BAEC were cultured 
in the presence or absence of 10 ng/ml TNF-α for 15-60 minutes and nuclear 
extracts were isolated. Electrophoretic mobility shift analysis was carried out 
using labled oligonucleotides for each of the three Sp1 sequences combined with 
treated and untreated nuclear extracts. Immunoperturbation studies using 
antibodies directed against Sp1, Sp3 and Egr-1 indicated that Sp3 bound to all 
three elements while Sp1 bound to site 3 only (Figure 6 A-F). Although TNF-α 
reduced formation of the Sp1/3 complex at all three sites, it did not alter the 
binding pattern, indicating that a decrease in binding is responsible for the down-
regulation of the promoter without a change in factor binding to that site. As 
shown in Figure 6, there is a significant time-dependent decrease in binding to 
Sp1 sites 1-3 probes in BAEC nuclear extracts exposed to TNF-α treatment 
(Figure 6). These results show that all three elements that bind Sp1/3 
transcription factors (36) are affected by TNF-α treatment.  
 
Role of NFκB in signaling TNF-α-mediated suppression of AS – TNF-α is known 
to activate the nuclear factor κB (NFκB) pathway in order to exert its 
proinflammatory effects (38). Activation of kinases known as IKKs results in the 
 93 
phosphorylation of IκB, an inhibitory protein that complexes with NFκB in the 
cytoplasm and blocks its entry into and action within the nucleus. The 
phosphorylation of IκB targets the protein for degradation (39) and results in an 
increased nuclear localization of NFκB and subsequent gene regulation. 
Previous work in BAEC has demonstrated TNF-α-mediated, time-dependent 
reduction in IκBα, reflecting degradation of the inhibitor and activation of the 
NFκB signaling pathway (16). TNF-α has also been shown to stimulate the 
translocation of NFκB to the nucleus in BAEC (40). To demonstrate the 
involvement of NFκB in signaling the TNF-α-dependent down-regulation of AS 
expression, the NFκB inhibitor Bay-7082 was used in an attempt to block TNF-α-
mediated AS expression. Endothelial cells were treated with TNF-α in the 
presence or absence of the NFκB inhibitor BAY-7082. Whole cell lysates were 
isolated and subjected to western blot analysis. Figure 7A-B show that NFκB 
inhibitors blocked the down-regulation of AS expression by TNF-α. To investigate 
this further, BAECs were transiently transfected with the vector pGL3-AS189 and 
treated with TNF-α in the presence and absence of the inhibitor. Treatment with 
BAY-7082 inhibited the suppression of the AS promoter activity by TNF-α (Figure 
7C) further supporting the role of NFκB in signaling the TNF-α mediated 
transcriptional suppression of AS expression.  
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DISCUSSION 
TNF-α is a multifunctional cytokine involved in the regulation of important 
physiological functions including the development of tissues, the coordinate 
activation of immune responses, and in the onset and progression of pathological 
conditions (41, 42). TNF-α has been linked to insulin resistance (19) by directly 
inhibiting insulin signaling and is known to contribute to endothelial dysfunction in 
type 2 diabetes (8), obesity (9) and congenital heart failure (10). This pro-
inflammatory cytokine has also been implicated in the pathogenesis of 
cardiovascular diseases such as congestive heart failure, acute myocardial 
infarction, myocarditis and dilated cardiomyopathy (43). Serum TNF-α levels are 
elevated in patients with congestive heart failure (44). In fact, incubation of 
endothelial cells with serum from patients with congestive heart failure was 
shown to down-regulate eNOS expression in a TNF-α-dependent manner (11). 
Other studies have shown that TNF-α administration in vivo depresses 
endothelium-dependent relaxation (13) and reduces levels of endothelial NO 
(14).  
 
Recent reports by our laboratory and others have sparked new interest relative to 
the function and regulation of AS in endothelial NO production (20, 21, 26). As 
reported previously by our laboratory and others (20, 21, 45), AS is essential for 
the regeneration of arginine required for endothelial NO production, even in the 
presence of excess exogenous arginine. Thus, the capacity of endothelial cells to 
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sustain NO production is severely limited not only by the down-regulation of 
eNOS (16, 18, 31), but also by the availability of arginine provided by AS via the 
citrulline–nitric oxide cycle. Coordinate up-regulation of AS and eNOS expression 
has been identified previously in a number of systems (19, 24). For example, AS 
and eNOS are coordinately induced in the aorta of diabetic rats following 
streptozotocin treatment (24). TGF-Β1 induces both enzymes in human umbilical 
vein endothelial cells (24). In addition, sheer stress induces both AS and eNOS 
mRNA expression (19). In the present study, both eNOS and AS protein 
expression were found to be coordinately down-regulated by TNF-α in cultured 
bovine aortic endothelial cells. A model can be proposed whereby TNF-α 
reduces endothelial NO production by both a down-regulation of eNOS 
expression and also by reduction in substrate availability via the down-regulation 
of AS expression (Figure 8). Although TNF-α also has the potential to upregulate 
iNOS expression, previous work has shown that TNF-α effects on iNOS 
expression in endothelial cells under the conditions used, is negligible (16, 32, 
46, 47). 
 
AS expression was significantly reduced at levels of TNF-α found in an 
inflammatory environment caused by chronic disease states such as diabetes 
and obesity. Not surprisingly, the loss of eNOS and AS protein expression was 
accompanied by a dramatic decrease in the capacity of the TNF-α-treated cells 
to produce NO. Transcriptionally, eNOS is down-regulated via reduced binding to 
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two Sp1 elements which are required for basal promoter activity (16). A strikingly 
similar situation was identified in the AS promoter. TNF-α-mediated suppression 
of the AS promoter was found to be through Sp1 site 3, which is required for 
basal AS promoter activity. Site 3 was the most important site regulated by TNF-
α, as is the case for eNOS.  
 
In cultured endothelial cells, NFκB resides in the cytoplasm and is associated 
with an inhibitory protein, IκB (48, 49). Inflammatory cytokines, such as TNF-α, 
activate IKKs which phosphorylate IκB, targeting IκB for degradation. As a result, 
NFκB translocates to the nucleus where it transcriptionally provokes a 
proinflammatory response. Previous work in BAECs showed that TNF-α signaled 
a time-dependent reduction in IκBα expression in endothelial cells (16) resulting 
in NFκB mediated inhibition of the eNOS promoter (16). More recently, activation 
of NFκB by IL-1Β was also shown to suppress AS expression at the 
transcriptional level via a functional NFκB site (50). Interestingly, we did not find 
this NFκB binding site to be necessary for the suppression of the proximal AS 
promoter by TNF-α, although binding to this element was increased by TNF-α 
treatment as indicated by gel shift analysis (data not shown). Rather, we have 
shown that TNF-α regulates AS transcription through reduced binding of the 
transcription factors Sp1 and Sp3, consistent with the findings of Anderson et al 
(36) showing that Sp1/3 elements in the proximal promoter are required for basal 
AS expression. More importantly, though, was our finding that the regulation of 
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the AS promoter by TNF-α through an Sp1/3 element was similar to that reported 
for the TNF-α-mediated down-regulation of the eNOS promoter (16). Therefore, 
the expression of AS and eNOS, both essential components of the citrulline-NO 
cycle, are coordinately down-regulated by TNF-α through decreased binding at a 
proximal Sp1 element that is required for basal promoter activity for both genes 
(16). 
 
Thus, overall, the results of this paper provide additional evidence as to how an 
increase in TNF-α which is associated with a number of disease states, 
decreases the production of NO through enzyme and substrate depletion, and as 
a consequence promotes endothelial dysfunction. Because the intracellular pool 
of arginine that is directed to NO production is maintained by the recycling of 
citrulline to arginine this may suggest a novel therapeutic target to improve 
endothelial function (51). This concept suggests that drugs designed to reduce 
TNF-α expression may restore endothelial function at two levels, one by restoring 
substrate availability for NO production, and two, by restoring the enzyme, 
eNOS, which catalyzes the production of NO.  
 
FOOTNOTES 
*This work was supported by the American Heart Association, Florida Affiliate 
Grant 0455228B. 
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1Abbreviations used include: NO, nitric oxide eNOS, endothelial nitric oxide 
synthase; TNF, tumor necrosis factor; AS, argininosuccinate synthetase; AS, 
argininosuccinate lyase; NFkB, nuclear factor kB; BAEC, bovine aortic 
endothelial cell;  
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Figure 1: Specific reduction of AS protein and mRNA by TNF-α. At 
confluence, BAEC were incubated with 0 (lane 1), 0.1(lane 2), 1 (lane 3) or 10 
(lane 4) ng/ml TNF-α for 24 hours. (A) Cell lysates were prepared, 10 µg of each 
sample was loaded onto an SDS polyacrylamide gel and standard western 
blotting performed. Anti-AS, anti-eNOS and anti-GAPDH antibodies were used to 
detect the amount of protein present. These results are representative of three 
independent experiments. (B) BAEC were untreated (U) or treated (T) with 10 
ng/ml TNF-α. Total RNA was isolated using Tri Reagent (Sigma) and reverse 
transcribed with Superscript II (Invitrogen). AS message was detected using real 
time quantitative RT-PCR. Results were normalized to 18S rRNA and represent 
the average ± the standard error of the mean. 
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Figure 2: TNF-α reduces endothelial NO production. BAEC were untreated 
(U) or treated (T) with 10 ng/ml TNF-α for 24 hours. Subsequently media was 
collected at time points 0 and 24 hours. NO was measured as nitrite 
produced/1x106 cells. (Nitrite is a stable reaction product of NO and molecular 
oxygen.) Results are expressed as NO produced per 1x106 cells and error bars 
represent the standard error of the mean. 
  
TNF-α (ng/ml)
U T
N
O
 p
ro
du
ce
d 
pe
r 1
06
 c
el
ls
 
(P
er
ce
nt
 o
f C
on
tro
l)
0
20
40
60
80
100
120
  
102 
 103 
Figure 3: TNF-α reduces AS proximal promoter activity. BAEC were 
transiently transfected with the AS promoter construct p3ASP189 and treated 
with increasing concentrations of TNF-α (0-10 ng/ml). Results are presented as 
relative luciferase activity and represent the average ± the standard error of the 
mean of at least four experiments conducted in triplicate. 
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Figure 4: Characterization of the AS promoter. (A) BAEC were transiently co-
transfected with p3ASP189 and either pcDNA3, pCMVSp1 or pCMVSp3. 
Luciferase activity was assayed 48 hours after transfection. (B) p3ASP189 was 
mutated in three Sp1 transcriptional elements. Vectors were transfected into 
BAEC and luciferase activity was detected 48 hours later. All results are 
presented as fold luciferase activity relative to p3ASP189. Error bars indicate the 
standard error of the mean of at least three experiments conducted in triplicate. 
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Figure 5: TNF-α down-regulates AS promoter activity via Sp1 site 3. Vectors 
containing mutations in the Sp1 binding elements (M1-M3) of p3ASP189 were 
transfected into BAEC and were either left untreated (U) or treated (T) with 10 
ng/ml TNF-α. Results are presented as relative luciferase activity and represent 
the average ± the standard error of the mean of at least four experiments 
conducted in triplicate. 
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Figure 6: TNF-α reduces binding to Sp1 sites. (A-F) Electrophoretic mobility 
shift assays were performed using nuclear extracts prepared from untreated 
BAEC. Oligonucleotide probes contained the three Sp1 elements of the proximal 
AS promoter sequence: site 1 (A and D), site 2 (B and E), site 3 (C and F). 
Antibodies were used to determine the proteins binding to each site. For each 
oligonucleotide probe, extracts were incubated without antibody (N), two different 
Sp1 antibodies, an Sp3 antibody and an Egr-1 antibody. Spot density for each 
graph is presented underneath each radiograph (D, E, F). (G-L) Electrophoretic 
mobility shift assays were performed using nuclear extracts prepared from BAEC 
treated with 10 ng/ml TNF-α for 0, 15, 30, and 60 minutes. Probe only is 
presented in lane 1 (P). Oligonucleotide probes used contained the three Sp1 
elements of the proximal AS promoter sequence: site 1 (G and J), site 2 (H and 
K), site 3 (I and L). Spot density for each graph is presented underneath each 
radiograph (J, K, L). 
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Figure 7: The NFκB inhibitor BAY-7082 blocks the effect of TNF-α on AS 
expression and promoter activity. (A) Confluent BAEC were cultured in 
complete media containing vehicle alone (DMSO) (lane 1) or 10 ng/ml TNF-α 
with (lane 2) or without (lane 3) 10 µM BAY-7082. Twenty-four hours following 
treatment, lysates were prepared and 10 µg protein was loaded onto an SDS-
PAGE gel. Western blot analysis was performed as described in detail under 
“Experimental Procedures”. Spot density analysis is shown in (B). (C) BAEC 
were transfected with p3ASP189. Cells were treated with vehicle alone (lane 1), 
or 10 ng/ml TNF-α with 0, 5 and 10 µM BAY-7082 (lanes 2-4 respectively) for 48 
hours. Cell extracts were subsequently assayed for luciferase activity. 
Normalized luciferase activity is presented as fold increase over control 
conditions. Data represents the average ± the standard error of the mean of 
assays performed in triplicate in three independent experiments.  
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Figure 8:  The Citrulline NO Cycle. Circulating effectors in the serum, such as 
acetylcholine, serotonin, thrombin and bradykinin, signal the production of NO via 
up-regulation of the citrulline NO cycle. NO then diffuses into the smooth muscle 
layer and induces relaxation of the vessel wall. In the endothelial cell, 
argininosuccinate synthase (AS) and argininosuccinate lyase (AL) catalyze the 
generation of arginine from citrulline and aspartate. This arginine is utilized by 
endothelial nitric oxide synthase (eNOS) to produce NO and citrulline. TFN-α 
down-regulates NO production by decreasing eNOS and AS expression. 
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SUMMARY 
Impaired NO production has been associated with endothelial dysfunction in a 
number of disease states including diabetes, hypertension, atherosclerosis, and 
heart failure. Previous work in our laboratory has demonstrated that the arginine 
utilized in the production of endothelial NO is maintained through the recycling of 
citrulline by the enzymes argininosuccinate synthase (AS) and argininosuccinate 
lyase. In the present study we demonstrate that exposure of endothelial cells to 
the peroxisome proliferator-activated receptor gamma (PPARγ) agonists 
troglitazone and ciglitazone coordinately induces NO production and AS 
expression. An increase in AS protein was detected by western blot analysis 
while real time quantitative PCR demonstrated a corresponding increase in AS 
mRNA. The increase in AS mRNA was blocked with the transcriptional inhibitor 
1-D-ribofuranosylbenzimidazole (DRB), indicating that PPARγ agonists act at the 
level of transcription. A PPARγ response element was identified in the distal AS 
promoter. Reporter gene assays and EMSA analysis confirmed this element was 
responsible for the PPARγ agonist-mediated increase in AS promoter activity. 
Interestingly, PPARγ agonists were shown to restore AS expression and NO 
production following down-regulation by TNF-α, an inflammatory cytokine 
associated with endothelial dysfunction. Overall, this study defines a molecular 
mechanism whereby PPARγ agonists improve endothelial function by increasing 
the availability of arginine through the up-regulation of AS expression. This study 
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also provides additional support for the essential role of arginine regeneration in 
maintaining endothelial NO production.  
INTRODUCTION 
Nitric oxide (NO) is produced in the endothelium in response to circulating 
effectors such as bradykinin. It then diffuses into the smooth muscle layer and 
induces relaxation of the vessel wall. In endothelial cells the primary role of AS 
and AL is in the generation of arginine, which is utilized by endothelial nitric oxide 
synthase (eNOS) to produce NO and citrulline. Although both extracellular and 
intracellular concentrations of arginine are much higher than the reported Km of 
arginine for eNOS, NO production still appears to be limited by the availability of 
arginine (1-8). Recent results from our laboratory have demonstrated the 
importance of argininosuccinate synthase (AS) in the maintenance of basal and 
stimulated endothelial NO production via arginine regeneration as well as in the 
viability of the endothelial cell (9). Reduced levels of endothelial NO have been 
associated with several medical conditions such as hypertension, heart failure, 
atherosclerosis and diabetes (10). Thus, the regulation of AS, as it relates to 
arginine regeneration and NO production in endothelial cells has gained 
considerable importance.  
Peroxisome proliferator-activated receptor gamma (PPARγ) is a member of the 
nuclear receptor superfamily of ligand-activated transcription factors. PPARγ is 
involved in transcription of genes involved in lipid metabolism (11-14), 
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differentiation (11, 14) and cell growth (15). It is required for adipose, kidney and 
placental development, and knockout of PPARγ results in embryonic lethality 
(16). Both naturally derived ligands, including a number of fatty acid metabolites 
such as eicosanoid derivatives (11) and 15-deoxy-∆12,14-prostaglandin J2 (15d-
PGJ2) (17, 18), as well as synthetic ligands have been described.  
Thiazolidinediones (TZDs), a group of synthetic PPARγ agonists, provide 
cardiovascular benefits in addition to their well-known insulin-sensitizing 
properties. Moreover, TZDs have a number of cardioprotective properties such 
as the reduction of blood pressure in mammalian models (19-21) and diabetic 
patients (22) and an improvement in vasodilation in human patients (23). In 
addition, TZDs reduce lesion formation in animal models of atherosclerosis (24-
27). These anti-diabetic compounds are also known to counter the effects of the 
inflammatory response related to elevated serum levels of tumor necrosis factor 
alpha (TNF-α), which contribute to endothelial dysfunction (28, 29). Finally, TZDs 
improve flow-mediated vasodilation and decrease vascular smooth muscle cell 
activation, in part, by stimulating endothelial NO production without inducing 
eNOS protein expression (30, 31). A recent report links the stimulation of 
endothelial NO production by PPARγ agonists to a reduction in superoxide 
through the suppression of NADPH oxidase and induction of super oxide 
dismutase, resulting in an enhanced bioavailability of endothelial NO (32). An 
additional mechanism by which PPARγ agonists could increase endothelial NO 
production is through the up-regulation of AS expression and thus an increase in 
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the regeneration of arginine by AS and AL. Since it has been shown in many 
disease states that arginine availability for NO production becomes limiting, we 
examined in this report whether PPARγ agonists may promote arginine 
regeneration and relieve, in part, impairment of NO production. 
EXPERIMENTAL PROCEDURES 
Cell Culture: Bovine aortic endothelial cells (BAEC) were cultured in complete 
Dulbecco’s modified Eagle’s medium (DMEM)(1 g/L glucose, Mediatech) which 
contained 10% fetal bovine serum (Hyclone Laboratories), 100 units/ml penicillin 
and 100 µg/ml streptomycin (Mediatech) at 37°C and 5% CO2. For TZD 
treatment, cells in complete DMEM were treated with the indicated 
concentrations of drug for up to 24 hours as indicated in the figure legends.  
Western blot analysis: Following treatment with TZDs, TNF-α or both, as 
indicated in the figure legends, BAEC were harvested in 500 µl PBS, centrifuged 
briefly and lysed in RIPA buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% 
SDS, 1X protease inhibitors in PBS) by vigorous pipetting followed by brief 
vortexing. The cell lysate was incubated on ice for 30 minutes and protein 
concentration was determined by BCA reagent (Pierce). Ten µg of protein was 
electrophoresed on 4-15% polyacrylamide gels (Bio-Rad) and transferred onto 
polyvinylidene difluoride transfer membrane (Immobilon-P). Membranes were 
incubated with antibody (1:2500 anti-AS (BD Transduction Labs)), 1:1000 anti-
GAPDH, 1:1000 anti-eNOS (Transduction Labs)) in 5% blocking solution (Bio-
 129 
Rad) in TBS-T (20 mM Tris-HCl, 137 mM NaCl, 0.1% Tween-20) and 
subsequently washed in TBS-T. Membranes were incubated with horseradish 
peroxidase-conjugated anti-rabbit or anti-mouse antibody for 1 h, washed with 
TBS-T, immersed in ECL reagent for 1 minute and then exposed to film. Pre-
stained protein markers were used for molecular mass determination. Band 
intensities were quantitated using ImageQuant software (Molecular Dynamics). 
RNA isolation and quantitative RT-PCR: Total RNA was isolated using Tri 
Reagent following the manufacturer’s instructions (Sigma). RNA was treated with 
DNase (Ambion DNA-free). Five hundred ng of RNA was reverse transcribed 
using Superscript II as described previously (33). Real time quantitative PCR was 
performed using AS specific primers ASL228 and ASR278 (33). Results were 
normalized to 18S rRNA.  
Vector construction: Luciferase reporter constructs were designed to include 
the AS promoter and 5´-UTR up to the AUG start codon cloned upstream of the 
luciferase gene. Luciferase reporter construct p3ASP189 was described 
previously (9). Left primer ASL-2616, (5´-
GCACTCGAGGAAAGTCAAAGGCCATGGTG) was combined with ASRluc (5´-
ATAGAATGGCGCCGGGCGTTTCTTTATGTTTTTGGCGTCTTCCATCGTGACG
GGTG ACCAGCGGC) to amplify the AS promoter with an Xho I site on the 5´ 
end and an Nco I site on the 3´ end which were used to clone into the vector 
pGL3Basic (Promega) and create the vector p3ASP2616. For mutant constructs, 
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mutations were made in the PPRE sites in the ASL-189 construct using a three-
way PCR method  (34). Primer PPREmut (5´-
GCTGGTCTTGATCTCCTGATCTCAGGTGA) was combined with primer ASRluc 
to amplify a fragment that contained the mutations. This PCR product was then 
used as a right primer and paired with ASL-2616 to produce a second product. A 
third round of PCR was used with the second product as a template with primers 
ASL-2616 and ASRluc to enrich for the target. Amplified products were purified 
after restriction digestion and agarose gel electrophoresis and ligated into 
pGL3Basic to create the mutated plasmids p3ASP2616PPREmut. All constructs 
were verified by sequencing. 
Luciferase Assay analysis: BAEC were cultured as described above and plated 
in a 24 well plate prior to transfection. Experimental plasmids (200 ng each) and 
renilla control plasmid pRL-TK (50 ng) were transiently transfected into BAEC 
using Transit-LT1 (Mirus) in serum free media. All results were normalized to 
renilla expression. After 4 hours liposomes were removed and cells were cultured 
for an additional 48 hr in media containing troglitazone or ciglitazone. Cells were 
lysed using passive lysis buffer (Promega). Ten µl lysate was assayed for 
luciferase and renilla activity using a Dual-Luciferase Reporter Assay System 
(Promega) according to the manufacturer’s instructions. Luciferase and renilla 
activity were measured as relative light units (RLUs) using a luminometer (Turner 
Designs). Each data point is the result of at least three independent experiments 
performed in triplicate.  
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Nuclear extract preparation: Nuclear extracts were prepared from BAEC as 
described previously (35, 36). Briefly, confluent monolayers were treated with 
troglitazone for 6 h. The culture monolayer was rinsed twice with PBS, once with 
PBS containing 1mM Na3VO4 and 5 mM sodium fluoride and once with 1X 
hypotonic buffer. Cells were scraped into 1X hypotonic buffer containing 0.2% 
NP40 and resuspended by gentle pipetting. Samples were centrifuged, 
resuspended in high salt buffer and rotated for 30 minutes at 4°C. Samples were 
centrifuged at 12,000xg, 4°C for 20 minutes, aliquoted and stored at -80˚C. 
Electrophoretic Mobility Shift Assay: Nuclear extracts were combined with or 
without cold competitors or specific antibodies and incubated for 20 minutes at 
room temperature. Probes were labeled by combining equimolar amounts of 
complementary oligonucleotides (2x10-10 moles of each) which were heated to 
70°C and allowed to cool to room temperature slowly. The oligos were labeled 
using 10 µl [α-32P]dCTP (3000 Ci/mmol) and Klenow enzyme. Unincorporated 
label was removed using Nuc Away spin columns (Ambion). The reaction mixture 
contains binding buffer (10 mM HEPES, pH 7.9, 10% glycerol, 1 mM DTT, 0.1 
µg/µl poly(dI:dC), 0.5 µg/µl BSA and 4000 dpm/µl radiolabeled probe) and 
nuclear extract (5 µg) in a total volume of 10 µl, which is incubated at 30°C for 30 
minutes. Samples were loaded onto a 5% non-denaturing polyacrylamide gel and 
run at 180 V. Gels were dried under vacuum and exposed to film. Double 
stranded oligonucleotides composed of the following sequences were used for 
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EMSA analysis: PPRE (5´-ACCTGAGGTCAGGAGTTCAAGACC-3´); PPREmut 
(5´-ACCTGAGAACAGGAGAACAAGACC-3´).  
Nitric oxide assay: BAEC were treated with 20 µM troglitazone, ciglitazone or 
TNF-α in serum-free medium as described in the figure legends. Aliquots were 
removed at the time points indicated and nitrite was measured in the medium as 
an indicator of cellular NO using a fluorometric method (37). Briefly, freshly 
prepared DAN reagent was added to culture supernatant, mixed immediately and 
incubated for 10 minutes. The reaction was stopped with a final concentration of 
2.8 M NaOH and the samples were read on a BMG Fluostar Galaxy 
spectrofluorometer in a 96-well plate using an excitation wavelength of 360 nm 
and emission wavelength of 405 nm. Cells were counted by trypan blue 
exclusion analysis and data is presented as quantity of nitrite produced in pmols 
per 1 x 106 cells.  
Statistical Analyses: Experimental data is expressed as the mean of 
experiments plus or minus the standard error of the mean. Each experiment was 
performed independently at least three times. 
RESULTS 
PPARγ ligands increase endothelial NO production – To confirm that PPARγ 
agonists stimulate NO production in BAEC; confluent cells were incubated with 
increasing concentrations of either troglitazone or ciglitazone. A dose-dependent 
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increase in NO production was observed following treatment with either 
troglitazone or ciglitazone (Figure 1A and B). A higher level of stimulation was 
observed in response to ciglitazone than to troglitazone. 
Troglitazone and ciglitazone increase AS but not eNOS expression – AS 
expression is necessary to provide the substrate, arginine, to eNOS through the 
recycling of citrulline (1, 2, 7, 9). To investigate the effect of PPARγ activation by 
TZDs on AS protein expression in BAECs, confluent BAEC were treated with 
increasing concentrations of troglitazone and ciglitazone for 24 hours and protein 
expression was determined by western blotting. Treatment with either of the 
TZDs resulted in a concentration-dependent increase in AS protein levels (Figure 
2A-D). Neither TZD significantly increased eNOS levels. In contrast, the TZD 
rosiglitazone, which is also noted to stimulated NO production (38), had no 
detectable effect on AS expression (data not shown). 
To investigate the effect of PPARγ activation on steady-state AS mRNA 
expression, BAECs were allowed to grow to confluence and were then stimulated 
with troglitazone for twenty four hours. RNA was prepared from treated and 
untreated cells and then reverse transcribed. Real time PCR showed that 
stimulated cells had a 3.3-fold increase in AS mRNA expression with 20 µM 
troglitazone (Figure 3A). This effect could be inhibited by treatment with the 
transcriptional inhibitor 1-D-ribofuranosylbenzimidazole (DRB), suggesting that 
the increase in steady state mRNA levels was due to an increase in transcription 
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rather than decreased turnover of AS mRNA. Cells treated with 50 µM ciglitazone 
showed a 1.8-fold increase in AS mRNA (Figure 3B). This was also inhibited with 
treatment of DRB, supporting transcriptional regulation by Ciglitazone as well. 
Identification of a putative PPRE in the promoter of the AS gene – Since 
troglitazone stimulated AS protein expression through an increase in 
transcription, the AS promoter was examined to identify regions regulated by 
PPARγ agonists. AS promoter activity was assessed using luciferase reporter 
gene constructs. Previous work by others (39) and by our laboratory (40) has 
shown that the proximal AS promoter required for AS expression contains three 
Sp1/3 elements (39). Since TZDs have been shown to mediate transcriptional 
effects through Sp1 (41, 42), we examined whether the proximal promoter was 
regulated by PPARγ agonists. First, a construct containing 189 bp of the AS 
promoter, p3ASP189, was transfected into BAEC and stimulated with 
troglitazone or ciglitazone. Reporter gene assays showed no increase in 
promoter activity indicating that the regulation via PPARγ agonists was not 
through the proximal promoter and thus another element must be involved 
(Figure 4A).  
Since the proximal promoter was not regulated by PPARγ agonists, a series of 
constructs containing increasing lengths of the AS promoter were created and 
transfected into BAEC. Cells transfected with AS promoter constructs containing 
up to 2088 bp showed no change in reporter gene activity (data not shown). 
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However, when a construct containing 2616 bp of the AS promoter was 
transfected into BAEC and subsequently treated with troglitazone or ciglitazone, 
a significant increase in reporter gene expression was detected after stimulation. 
(Figure 4A). The construct containing 2616 base pairs of the promoter was 
activated 3.8 fold by 50 µM ciglitazone (p = .015) and 2.7 fold by 20 µM 
troglitazone (p=.028) (Figure 4A). While 50 µM ciglitazone was required to 
stimulate reporter gene activity, 20 µM of troglitazone was sufficient to stimulate 
activity. Increasing the concentration of troglitazone did not further stimulate 
promoter activity. This comparative analysis of luciferase activity between treated 
and untreated transfections of the construct p3ASP2616 revealed PPARγ 
responsiveness in the region from -2616 to -2088 bp upstream of the 
transcriptional start. 
DNA sequence analysis identified a near-consensus peroxisome proliferator-
activated receptor response element (PPRE) that occurs at bp –2471 to –2458 
(AGGTCAGGAGTTCA) in the p3ASP2616 construct. Transient transfection 
assays were performed using a construct mutated in the PPRE and compared to 
transfection of the wild type construct. Mutation of the putative PPRE site in 
p3ASP2616 completely abolished the activating effects of ciglitazone and 
troglitazone on the promoter (Figure 4B). These data suggest that this PPRE site 
mediates the induction of the AS promoter by TZDs in endothelial cells. 
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PPARγ binds to the AS PPRE – To determine whether PPARγ binds to the 
putative AS PPRE, gel mobility shift assays were performed with oligonucleotides 
containing the AS PPRE. Nuclear extracts from ciglitazone, troglitazone and 
untreated BAEC were combined with 32P-radiolabled AS PPRE oligonucleotides. 
The addition of excess unlabeled PPREwt oligonucleotides reduced the signal 
(Figure 5, lane 4). In contrast, addition of the PPREmut oligonucleotide, which 
should not bind to the PPARγ-RXRα complex, did not reduce the specific signal 
(lane 5), indicating the specificity of the complex. Ciglitazone treatment mediated 
a 50% increase in binding to the PPRE (Figure 5 C and D) while troglitazone 
mediated a 260% increase in binding (Figure 5 A and B).  
Effect of TZDs on TNF-α-induced repression of AS expression – Previous work 
has indicated that TZDs can counteract the effects of inflammatory conditions 
such as TNF-α (43-46). To examine the direct effects of TZDs on TNF-α-
mediated AS repression, BAEC were cultured in media containing 2.5-10 ng/ml 
TNF-α with or without troglitazone or ciglitazone in the presence of TNF-α (10 
ng/ml) for 24 hours. As shown in Figure 6, TNF-α treatment resulted in a dose-
dependent decrease in AS and eNOS protein expression. When cultures were 
incubated with 10 ng/ml TNF-α in addition to troglitazone or ciglitazone (20 and 
50 µM), the ciglitazone showed a small increase in AS and eNOS expression 
while troglitazone reversed TNF-α-mediated reduction in AS and eNOS 
expression (Figure 6). 
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Effect of TZDs on TNF-α-mediated repression of NO production – Since 
troglitazone was able to block TNF-α-mediated suppression of AS expression, 
the ability of this TZD to block TNF-α-mediated repression of endothelial NO 
production was investigated. Confluent BAEC were untreated or treated with 
TNF-α with or without 20 µM troglitazone for 5 hours. NO was measured as 
nitrite and normalized to cell number to account for differences in viability. Cells 
treated with TNF-α in the presence of troglitazone did not show any decreased 
NO production (Figure 7). 
DISCUSSION 
The synthetic PPARγ agonists, TZDs, provide benefits to diabetic patients which 
include improved glucose tolerance, as well as decreased insulin resistance and 
dyslipidemia (47). Additional benefits include reduced triglycerides in the plasma, 
improved plasma lipid profile, lower blood pressure in hypertensive diabetics and 
a reversal of the proinflammatory and procoagulant state (48). Altogether, this 
class of compounds improves insulin sensitivity and restores metabolic 
homeostasis in type II diabetic patients. TZDs have also been shown to act on 
vascular cells directly by inhibiting glucose-induced proliferation and migration of 
coronary smooth muscle cells (49), inhibiting intimal hyperplasia in the rat aorta 
(50), inhibiting endothelial proliferation (51) and inhibiting TNF-α-induced 
plasminogen activator inhibitor type I secretion (52). Additional vascular benefits 
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include protection against endothelial dysfunction via the inhibition of cytokine-
induced MCP-1 in human endothelial cells (53).  
This study focuses on the regulation of AS by the TZDs troglitazone and 
ciglitazone, as a functional support system for endothelial NO production. Our 
laboratory has provided substantial evidence that the arginine utilized for 
endothelial NO production is provided by the recycling of citrulline to arginine, via 
the enzymes AS and argininosuccinate lyase (7, 9). If this system is impaired, 
reduced arginine availability can lead to a decrease in NO production and 
bioavailability in the endothelium. Impaired NO production and bioavailability in 
the endothelium is referred to as endothelial dysfunction and is predictive of 
clinical cardiovascular events (10, 54). PPARγ agonists provide cardiovascular 
benefits by increasing endothelial NO production (31). This occurs without a 
significant increase in eNOS expression (Figure 1), but is rather through an 
increase in eNOS phosphorylation (31). In this report we provide evidence 
demonstrating that troglitazone and ciglitazone also increase the production of 
endothelial NO by increasing the available arginine. This occurs via an increase 
in expression of AS, providing increased arginine as a substrate for eNOS. 
The increase in AS expression induced by treatment with the PPARγ agonists, 
troglitazone and ciglitazone (Figure 2) is associated with an overall induction of 
NO production (Figure 1) without a significant increase in eNOS expression. The 
increase in AS expression is related to an increase in AS mRNA. The use of 
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DRB, a transcriptional inhibitor, blocked induction of AS mRNA, indicating that 
the increase in AS was transcriptionally regulated. Delineation of the 
transcriptional element regulated via the TZDs involved the use of reporter gene 
assays and gel shift analysis. These experiments identified a PPRE in the AS 
promoter that mediates the transcriptional effects of ciglitazone and troglitazone. 
Interestingly, rosiglitazone, which was shown to have no effect on AS protein 
expression, also had no effect on the AS promoter (data not shown). To our 
knowledge, this is the first report of a functional PPRE identified in the AS 
promoter. 
TNF-α is an inflammatory cytokine implicated in the pathogenesis of 
cardiovascular diseases such as congestive heart failure, acute myocardial 
infarction, atherogenesis, myocarditis and dilated cardiomyopathy. Previous work 
has demonstrated that TZDs can reverse the effects of TNF-α on a number of 
genes (28, 29, 55). It has been shown in endothelial cells, that the TZD MCC-
555, modulates TNF-α-induced expression via down-regulation of NFκB binding 
to the promoter of vascular cell adhesion molecule-1 (29). Another TZD, 
pioglitazone, is able to block TNF-α-mediated apoptosis in human coronary 
artery endothelial cells (55). In addition, troglitazone can prevent TNF-α-induced 
and NFκB-dependent and –independent pathways leading to stimulation of 
plasminogen activator inhibitor type 1 (PAI-1), which plays a role in development 
of atherosclerosis in diabetic patients (52). Previous work in our laboratory has 
shown that TNF-α acts to decrease AS expression via decreased Sp1/3 binding 
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to the proximal AS promoter in an NFκB-dependent manner (40). The expression 
of AS and eNOS, both essential components of the citrulline-NO cycle, were 
shown to be coordinately down-regulated by TNF-α through decreased binding at 
a proximal Sp1 element that is required for basal promoter activity for both genes 
(40, 56).  
The current study demonstrates that PPARγ agonists are able to block the effects 
of TNF-α on AS transcription. AS is required by endothelial cells for the 
production of NO and for cell viability (9), thus the down-regulation of AS by TNF-
α severely limits capacity of the endothelium to produce NO and to maintain 
viability. Therefore, TNF-α decreases the production of NO through enzyme and 
substrate depletion, and as a consequence promotes endothelial dysfunction. 
Because the intracellular pool of arginine that is directed to NO production is 
maintained by the recycling of citrulline to arginine this may suggest a novel 
therapeutic target to improve endothelial function. We present in this study two 
TZDs, troglitazone, and to a lesser extent ciglitazone, which were able to block 
the down-regulation of AS by TNF-α thus allowing the EC to remain functional in 
the presence of this damaging molecule.  
These results further support the essential role of arginine regeneration in 
maintaining NO production in endothelial cells and suggest the possible efficacy 
of TZDs or similar derivatives as a therapeutic treatment of endothelial 
dysfunction may be mediated, in part, through the stimulation of AS expression. 
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In addition, a mechanism by which two different PPARγ agonists induce NO 
production is presented. The results indicate that TZDs may each act through 
independent mechanisms to achieve the up-regulation of AS. This is important in 
light of the fact that rosiglitazone (38), a currently prescribed TZD, did not show 
any of the above benefits to endothelial function. In addition, troglitazone was 
better able to reverse the effects of TNF-α on AS and eNOS expression (Figure 
6). It has previously been shown that while several TZDs induce NO production, 
they do so via discrete mechanisms (38). 15d-PGJ2 increases hsp90 expression 
while ciglitazone and rosiglitazone do not have the same effect (38). In addition, 
15d-PGJ2 and rosiglitazone increase binding of hsp90 to eNOS while ciglitazone 
does not (38). Finally, both 15d-PGJ2 and rosiglitazone, but not ciglitazone 
increased phosphorylation of eNOS at ser1177, which is linked to enhanced 
enzyme activity (38). Here, we have shown an additional mechanism by which 
select TZDs induce NO production via the up-regulation of AS expression. Thus, 
the mechanisms used by TZDs to up-regulate NO production are not the same 
for all TZDs and need to be investigated further. 
Future studies in our laboratory will address the differential mechanisms by which 
these PPARγ agonists act to improve endothelial function via substrate 
availability for NO production. These studies will further elucidate the role of 
PPARγ ligands in vascular health and the development of new therapeutics for 
the treatment of endothelial dysfunction. The functional consequences of the 
observed changes in AS expression under proinflammatory conditions such as 
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increased TNF-α, is a reduction in endothelial NO production due to a decrease 
in substrate availability. This study provides a molecular mechanism by which 
endothelial dysfunction, due to decreased NO bioavailability, can be reversed 
using a class of compounds used for treatment of type II diabetes. 
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Figure 1: PPARγ agonists stimulate endothelial NO production. BAEC were 
treated with increasing concentrations of ciglitazone (A) and troglitazone (B). 
Media was collected at 0 and 24 hours. NO was measured as nitrite 
produced/1x106 cells. (Nitrite is a stable reaction product of NO and molecular 
oxygen.) Results are expressed as relative NO produced per 1x106 cells and 
error bars represent the standard error of the mean. 
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Figure 2: Troglitazone and ciglitazone stimulate AS protein expression. At 
confluence, BAEC were incubated with 0, 20, 30, 50, 100 µM troglitazone (A,B) 
or ciglitazone (C,D) for 24 hours. 10 µg of whole cell lysate was loaded onto an 
SDS polyacrylamide gel and western blotting performed. Anti-AS (1:2500), eNOS 
(1:1000) and anti-GAPDH (1:1000) antibodies were used to detect the amount of 
protein present. These results are representative of three independent 
experiments.  
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Figure 3: Troglitazone and ciglitazone induce transcription of AS mRNA. (A) 
BAEC were treated with increasing concentrations of troglitazone. Total RNA 
was isolated using Tri Reagent and reverse transcribed. AS message was 
detected using real time quantitative RT-PCR. (A) BAEC were untreated (U) or 
treated with 20 µM troglitazone in the absence (T) or presence (T+D) of DRB, an 
inhibitor of transcription. RNA was isolated and quantitated by real time RT-PCR. 
(B) BAEC were untreated (U) or treated with 50 µM ciglitazone in the absence 
(C) or presence (C+D) of DRB, an inhibitor of transcription. RNA was isolated 
and quantitated by real time RT-PCR. All results were normalized to 18S rRNA 
and represent the average ± the standard error of the mean. 
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Figure 4: PPARγ agonists induce a distal element in the AS promoter. (A) 
BAEC were transiently transfected with the AS promoter constructs p3ASP189 or 
p3ASP2616 and treated with 20 µM troglitazone (Tr) or 50 µM ciglitazone (Ci). 
(B) BAEC were transfected with wild type p3ASP2616 (W) or 
p3ASP2616PPREmut, which contains a mutation in the PPRE (M). Following 
transfection, cells were untreated or treated with 20 µM troglitazone (Trog) or 50 
µM ciglitazone (Cig). All results are presented as relative luciferase activity and 
represent the average ± the standard error of the mean of at least four 
experiments conducted in triplicate. 
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Figure 5: PPARγ agonists increase binding to the AS PPRE. (A-D) 
Electrophoretic mobility shift assays were performed using nuclear extracts 
prepared from untreated, ciglitazone treated (A and B) and troglitazone treated 
(C and D) BAEC. Extracts were combined with an oligonucleotide probe 
containing the putative PPRE sequence of the AS promoter and 100X cold or 
wildtype oligos where indicated. Spot density for each graph is presented 
underneath each radiograph (B and D). 
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Figure 6: Troglitazone and ciglitazone block the effect of TNF-α on AS 
expression. (A) Confluent BAEC were cultured in complete media containing 
vehicle alone (DMSO) (lane 1) or 2-10 ng/ml TNF-α with (lanes 2-9) in the 
absence or presence of 20 (+) or 50 (++) µM troglitazone and 20 (+) or 50 (++) 
µM ciglitazone. Twenty-four hours following treatment, lysates were prepared 
and 10 µg protein was loaded onto an SDS-PAGE gel. Western blot analysis was 
performed as described in detail under “Experimental Procedures”. Spot density 
was analyzed for the AS (B) and eNOS (B) blots and normalized to GAPDH. 
Blots are representative of three experiments carried out independently.  
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Figure 7: Troglitazone inhibits TNF-α-mediated suppression of NO 
production. Confluent BAEC were cultured in media containing TNF-α (TNF) or 
TNF-α plus troglitazone (TNF+TGZ). Media was collected at time points 0 and 24 
hours. NO was measured as nitrite produced/1x106 cells. Results are expressed 
as NO produced per 1x106 cells and error bars represent the standard error of 
the mean. 
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DISCUSSION 
 
The ‘arginine paradox’ describes a situation where NO production appears to be 
limited by the availability of arginine, despite extracellular and intracellular 
concentrations that are much higher than the reported Km for eNOS (1-7). A 
significant amount of evidence supports the proposal that the recycling of 
arginine by the enzymes AS and AL provides the substrate for endothelial NO 
production. For example, our laboratory has shown previously that extracellular 
citrulline was as effective as arginine in stimulating NO production (6), even in 
the presence of saturating levels of arginine. Extracellular citrulline levels were 
found to have no effect on intracellular arginine levels, suggesting that citrulline 
enhancement of NO production was mediated through regeneration of arginine 
directed to NO production. In support of this study, Wu et al. (8) showed that 
synthesis of arginine from citrulline was stimulated by addition of exogenous 
citrulline. Further evidence which indicates that arginine regeneration is required 
for NO production is the over expression of AS in vascular smooth muscle cells 
(2). Xie, et al. reported a significant increase in NO production in the transfected 
smooth muscle cells over that of untransfected cells, again in spite of saturating 
levels of extracellular arginine. Thus, Xie et al. (1, 2) concluded that the capacity 
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to recycle citrulline back to arginine is “rate-limiting” to NO production. Su et al. 
(5) arrived at a similar conclusion showing that hypoxia in pulmonary artery 
endothelial cells (PAEC) inhibited induction of AS by endotoxin. As a 
consequence, the production of NO, independent of sufficient extracellular 
arginine levels, was significantly impaired.  
 
While our studies focused on the role of recycling for endothelial NO production 
by eNOS, previous studies have demonstrated the importance of recycling for 
NO production by both iNOS and nNOS. For example, AS and iNOS are 
coinduced in immunostimulated macrophages (9, 10) as well as in stimulated 
RPE-J cells where the citrulline-NO cycle is shown to be functioning (11). In rat 
aortic smooth muscle cells LPS and IFN-γ stimulate both iNOS and AS (4). 
Coinduction also occurs in pancreatic β-cells treated with cytokines (12). In 
addition, coinduction of iNOS, CAT-2 and AS in rat microglial cells indicates that 
both arginine transport by CAT-2 and citrulline-arginine recycling are important in 
the production of large amounts of NO (13). In neurons, colocalization of nNOS, 
AS and AL was identified in the canine gastrointestinal tract providing 
morphological evidence of a citrulline-NO cycle (14). Finally, in the rat gastric 
fundus, functional evidence of recycling is supported by colocalization of AS, AL 
and nNOS (15). 
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The results of my research demonstrated the important role AS plays in 
endothelial function, and the regulation of AS by relevant vascular effectors. To 
provide direct evidence for the essential role of citrulline recycling and the 
importance for a functional citrulline-nitric oxide cycle, I carried out a series of 
experiments using RNA interference to specifically silence AS expression in 
endothelial cells (16). By using this approach to knock down AS expression, I 
have shown that AS is essential for both basal and stimulated endothelial NO 
production, even in the presence of excess arginine (16). A significant and dose-
dependent reduction of AS protein and activity following siRNA transfection 
correlated with a concomitant decrease in stimulated and basal NO production in 
endothelial cells with reduced AS expression, in spite of excess arginine in the 
media (16). Unexpectedly, the viability of these endothelial cells was 
compromised compared to control cells, based on cell count and MTT viability 
assay. Two indicators of apoptosis, reduced expression of Bcl-2 and an increase 
in caspase activity suggested that the loss in cell viability was due to an induction 
of apoptosis. Exposure of the cells to an NO donor prevented this apoptosis, 
indicating that regeneration of arginine may be supporting production of anti-
apoptotic levels of NO to maintain endothelial cell viability. Overall, these results 
provide further evidence supporting the necessity for the regeneration of arginine 
for NO production. Specifically, AS expression was demonstrated to be 
necessary and sufficient to maintain both stimulated and resting levels of NO 
synthesis in endothelial cells.  
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An unexpected discovery was that reduced AS expression in endothelial cells 
resulted in a decrease in cell viability. NO has a bi-functional role in cell death – it 
can either stimulate or inhibit cytotoxicity. The level of NO produced and the type 
of cell involved determines the effect NO has on cell viability (17, 18). High 
concentrations of NO have been shown to induce cell death via apoptosis. In a 
more complex pathway, NO can switch apoptosis to necrosis (17-20). In contrast, 
lower concentrations of NO have been shown to protect cells such as endothelial 
cells (21), thymocytes (22) and lymphocytes (23) from apoptosis. In endothelial 
cells, induction of NO by sphingosine-1-phosphate protects endothelial cells from 
serum-deprived apoptosis (24). While previous work depicted a role of NO in 
protection from apoptosis, the current work designated NO as an important 
modulator in the maintenance of viability as well as protection against apoptosis. 
 
In the first paper, endothelial viability following AS siRNA-induced apoptosis was 
partially restored by the addition of an NO donor. This finding suggests that basal 
levels of NO in endothelial cells, sustained by the recycling of citrulline back to 
arginine, may provide protection against apoptosis. However, AS may be 
performing an as-yet undescribed function in the cell which is preventing 
apoptosis. Recently AS was described as a Jak-2 interacting protein (25). In 
addition, microarray analysis identified AS as a Myc-regulated protein (26). C-
Myc is a protooncogene that is involved in cell proliferation, differentiation and 
apoptosis (27). Many reported Myc-targeted genes are involved in apoptosis, 
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metabolism and cell growth (28). AS expression has also been shown to be 
repressed by the anti-proliferative protein FAP48 (29). This preliminary evidence 
is merely suggestive of an alternative role for AS expression in maintaining cell 
viability, further studies are warranted.  
 
Thus, having established the importance of AS in endothelial cells, I went on to 
investigate the regulation of expression of this gene in response to the 
inflammatory cytokine TNF-α. TNF-α is a multifunctional cytokine involved in the 
regulation of important physiological functions, including the development of 
tissues, the coordinate activation of immune responses, and in the onset and 
progression of pathological conditions (30, 31). TNF-α has been implicated in the 
pathogenesis of cardiovascular diseases such as congestive heart failure, acute 
myocardial infarction, myocarditis and dilated cardiomyopathy (32). Serum TNF-
α levels are elevated in patients with congestive heart failure (33). Other studies 
have shown that TNF-α administration in vivo depresses endothelium-dependent 
relaxation (34) and reduces levels of endothelial NO (35).  
 
TNF-α has been shown to reduce NO production in endothelial cells by 
destabilization of eNOS mRNA (36). In addition, TNF-α inhibits eNOS promoter 
activity, through inhibition of the NFκB signaling pathway and reduced binding of 
Sp1 to the eNOS promoter (37). In my studies, I chose conditions that mimic the 
inflammatory environment of chronic disease states such as diabetes and/or 
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obesity. Under these experimental conditions, TNF-α signals the coordinate 
down-regulation of eNOS and AS protein expression. Steady-state levels of AS 
mRNA were also reduced significantly by TNF- α. As a consequence, the 
endothelial cell is severely limited in its capacity to sustain NO production.  
 
Transcriptionally, eNOS is down-regulated via reduced binding to two Sp1 
elements which are required for basal promoter activity (38). A strikingly similar 
situation was identified in the AS promoter. Reporter gene assays indicated that 
TNF-α exerts its effects on the proximal AS promoter, which contains three 
Sp1/Sp3 binding sites. Specifically, TNF-α-mediated suppression of the AS 
promoter was found to be through site 3, which is required for basal AS promoter 
activity. Site 3 was the most important site regulated by TNF-α, as is the case for 
eNOS. These results indicate that an increase in inflammatory markers 
associated with a number of disease states can effectively inhibit the optimal 
functioning of the citrulline-NO cycle by decreasing the level of eNOS expression 
and AS expression. 
 
Coordinate up-regulation of AS and eNOS expression has been identified 
previously in a number of systems (39, 40). For example, AS and eNOS are 
coordinately induced in the aorta of diabetic rats following streptozotocin 
treatment (40). TGF-Β1 induces both enzymes in human umbilical vein 
endothelial cells (40). In addition, sheer stress induces both AS and eNOS 
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mRNA expression (39). In the present study, both eNOS and AS protein 
expression were found to be coordinately down-regulated by TNF-α in cultured 
bovine aortic endothelial cells. A model can be proposed whereby TNF-α 
modulates endothelial NO production by regulation of both eNOS expression and 
also by reduction in substrate availability via regulation of AS expression. This 
model can also be extended to the up-regulation of both AS and eNOS by 
PPARγ agonists. 
 
Given the requirement of arginine regeneration by AS and AL in the production of 
NO (16), in the third paper I assessed the hypothesis that up-regulation of AS 
expression by PPARγ agonists supports the induction of endothelial NO 
production. A dose-dependent increase in NO production was observed following 
treatment with the TZDs troglitazone and ciglitazone. Western blot analysis 
demonstrated a dose-dependent up-regulation of AS and eNOS protein 
expression using these PPARγ agonists. In addition, real-time quantitative RT-
PCR showed a coordinate dose-response increase in steady state AS mRNA 
levels. This effect could be mediated by treatment with the transcriptional 
inhibitor 1-D-ribofuranosylbenzimidazole (DRB), suggesting that an increase in 
transcription resulted in the increase in steady state mRNA levels. Since the 
TZDs had a transcriptional effect on AS, I went on to demonstrate the presence 
of a PPARγ response element (PPRE) in the human AS promoter and confirmed 
PPARγ binding by gel shift analysis. DNA sequence analysis detected a near-
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consensus peroxisome proliferator-activated receptor response element (PPRE) 
that occurs at bp –2471 to –2458 (AGGTCAGGAGTTCA). Treatment with 
ciglitazone and troglitazone demonstrated a significant increase in promoter 
activity of this construct. Mutation of the PPRE ablated the effects of the TZDs on 
the promoter. These reporter gene assays revealed that the identified PPRE is 
likely involved in regulation of the AS promoter by troglitazone and ciglitazone. 
EMSA analysis indicated increased binding to the PPRE DNA when cells were 
treated with troglitazone or ciglitazone. These results provide a mechanism for 
the PPARγ agonist induction of NO production and indicate that TZDs may each 
act through independent mechanisms to achieve the up-regulation of AS, 
especially considering that rosiglitazone, a currently prescribed TZD, did not 
show any of the above affects. These results further support the essential role of 
arginine regeneration in maintaining NO production in endothelial cells and 
suggest the possible efficacy of TZDs or similar derivatives as a therapeutic 
treatment of endothelial dysfunction. They also demonstrate the importance of 
identifying the mechanisms of action of the individual TZDs on endothelial 
function. 
 
Since PPARγ activators have been shown to inhibit the TNF-α signaling pathway 
in a number of systems, I investigated the role of the PPARγ agonists 
troglitazone, ciglitazone and rosiglitazone in regulating NO production through 
the regulation of AS expression. Western blot analysis demonstrated that 
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troglitazone and ciglitazone, but not rosiglitazone are able to restore AS and 
eNOS expression following TNF-α repression. These results provide support for 
the use of TZDs in the treatment of endothelial dysfunction and the recovery of 
reduced bioavailability of NO. The delineation of the signaling pathway utilized by 
each of these TZDs, may direct the derivation of a more specific strategy for 
reversing the damaging effects of TNF-α on the endothelium as seen in many 
disease states. 
 
Significance 
Despite the prevalence of cardiovascular disease, many of the mechanisms 
associated with development and pathophysiology of vascular dysfunction 
remain undetermined. One significant mechanism that holds particular promise in 
understanding the processes which lead to vascular dysfunction is the role of 
NO. NO generated by the vascular endothelium maintains normal vascular tone, 
regulates leukocyte-endothelial cell interactions, inhibits platelet aggregation, 
limits smooth muscle cell proliferation, and may even affect myocyte function. 
Thus, deciphering the molecular mechanisms involved in the constitutive and 
stimulated production of NO by endothelial cells is critical to the understanding of 
vascular health and disease. The work in our laboratory highlights the 
contribution of transcriptional regulation of AS as the rate-limiting step in the 
citrulline-NO cycle, introducing a new paradigm to NO regulation in vascular 
health and disease. I have developed a strong evidential case supporting the 
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proposal that substrate availability, governed by arginine regeneration, as part of 
the citrulline-nitric oxide cycle, plays a key role in NO production in vascular 
endothelial cells.  
 
The fact that a unique intracellular pool of arginine is maintained by recycling 
citrulline suggests that citrulline or a citrulline analog, rather than arginine, may 
offer a therapeutic advantage to affect vasodilation in hypertensive patients (41). 
This concept is particularly important in light of more recent information 
suggesting that arginine supplementation, rather than improving endothelial 
function and inhibiting atherogenesis, may in fact worsen existing vascular 
dysfunction and disease (42, 43). Supplementation with arginine in humans has 
produced conflicting results. In some studies, dietary arginine supplementation 
results in improved vascular function by providing substrate for eNOS and 
improving NO production (44-46). Other studies have not seen an improvement 
in condition and harmful effects may occur (43, 47-49). Since the intracellular 
pool of arginine directed to NO production is maintained by the recycling of 
citrulline to arginine through the enzymes AS and AL, AS may be a viable 
therapeutic target for pharmaceuticals that could be used in the treatment of 
hypertension and related cardiovascular disease, particularly since I have shown 
that the regulation of the endothelial machinery can be distinguished from the 
hepatic enzymes involved in urea production. Moreover, impairment of NO 
production has been suggested to be an early, causative event in 
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atherosclerosis, compromising endothelial cell regulation of vascular function, 
homeostasis, and activating cellular suicide pathways (50). 
 
 My findings indicate that one deleterious effect of TNF-α is the coordinate 
suppression of eNOS and AS expression, effectively reducing eNO production by 
the endothelium. The complexity of responses under this deleterious 
environment reflected by elevated TNF-α levels, such as in obesity, 
inflammation, diabetes and metabolic syndrome manifest an environment which 
promotes endothelial dysfunction, including reduced bioavailability of protective 
levels of NO. Also intriguing are the findings demonstrating PPARγ agonist 
induction of NO production via the apparent coordinate up-regulation of both 
eNOS and AS and the recovery of these enzymes by PPARγ agonists following 
suppression by TNF-α. A more complete understanding of these findings may 
possibly suggest the use of TZDs, or derivatives, as a therapeutic treatment for 
endothelial dysfunction. 
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SUMMARY 
 RNA interference (RNAi) is an evolutionarily conserved process in which a 
double-stranded RNA (dsRNA) induces sequence-specific, gene silencing. The 
natural roles of RNAi have been suggested to include defense against viral 
infection and regulation of the expression of cellular genes. The mechanism by 
which dsRNA induces gene silencing involves a two-step process. First, the 
dsRNA is recognized by the ribonuclease-III like enzyme Dicer, which cleaves 
the dsRNA into smaller dsRNAs of 21-23 nt. These interfering RNAs are then 
incorporated into a multi-component complex which recognizes and targets a 
related sequence for either transcriptional inhibition, mRNA destruction, or mRNA 
translational inhibition. Although the use of these small RNAs to silence genes in 
vertebrate cells was only reported a few years ago, the emerging literature now 
supports the view that most vertebrate genes can be studied using this 
technology.  This report provides a brief introduction and discussion of the RNA 
interference system, the mechanisms that underlie the ability of these small 
RNAs to target specific silencing of mRNAs, approaches to generate interfering 
RNAs and deliver them to target cells, and their potential analytical and 
therapeutic use. 
 
 
 
KEYWORDS: small noncoding RNA, dsRNA, siRNA, miRNA, miRNP, shRNA, 
RISC, RNAi, RNA interference, Dicer  
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BACKGROUND: In the early 1990s, investigators studying the development of a 
nematode worm, Caenorhabditis elegans, made an unexpected discovery. They 
found that a mutation in a single gene disrupted developmental timing, 
preventing C. elegans from passing through the first larval stage to the second. A 
gene search ultimately led to the identification of the mutated gene. The identity 
of this gene was confirmed by removing the mutation which restored the ability of 
C. elegans to pass through all four larval stages into mature adults (1). However, 
the subsequent characterization of the gene and gene product proved to be 
somewhat surprising. The gene did not encode a protein, but rather a small 
molecular RNA. A few years later, this finding was further supported by work 
published on another gene encoding a small RNA. Mutation of this gene 
prevented C. elegans’ transition from the fourth larval stage to adulthood (2). 
Together, these results led investigators to suggest that these genes which 
encode a small double stranded (dsRNA) (~21-23 nt), may be universal 
regulators of development. Consequently, genes like these were soon shown to 
be expressed from bacteria to man (3-6). Importantly, many of the genes 
encoding this type of small RNA were shown to be similar in mammals, insects 
and worms.  
 
The discovery of a new class of genes that encode a small RNA led to their being 
called the “biological equivalent to dark matter” (7), comparing their recognition 
and discovery with the finding that the universe contains large quantities of so-
called “dark matter” that makes up a significant portion of unaccounted mass. 
Similarly, the discovery of a new class of genes that encode these small 
noncoding RNAs, in part, seemed to help explain the unexpected and lower than 
anticipated number of genes encoded by the human genome. Functional roles 
for these small noncoding RNAs include developmental timing, cell death, cell 
proliferation, hematopoiesis and patterning of the nervous system (8). 
 
Computational methods estimate the total number of small noncoding RNA 
genes in humans to be 200-255 (9) and in C. elegans up to 123 (10). Analysis of 
the genomic position of 60 human small noncoding RNAs showed that 33 were 
localized in intergenic regions. Of the remaining small noncoding RNAs, 13 were 
found in sense orientation within introns of coding transcripts, 7 in sense 
orientation within introns of noncoding genes, and 7 in the reverse orientation 
within an intronic region (5). These results suggested that small noncoding RNAs 
were either transcribed from their own promoters or derived from a pre-mRNA.  
 
Overall, small noncoding RNAs appeared to play an important role in two 
phenomena; gene inactivation and the control of gene expression during 
development. Two types of naturally occurring small noncoding RNAs that 
mediate these processes will be discussed in the following review. Short 
interfering RNAs (siRNAs) are created by a mechanism that produces dsRNA by 
RNA polymerization of a primed single-stranded RNA template, or by 
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hybridization of overlapping transcripts. These small RNAs direct mRNA 
degradation and have been implicated in chromatin modification (11). MicroRNAs 
(miRNAs) are created from endogenous transcripts that have complementary 
inverted repeats that form RNA hairpins. The hairpin is processed into dsRNA 
and subsequently mediates translational repression. While gene inactivation 
seems to be implemented by siRNAs, developmental control seems to depend 
on miRNAs (12-14). Given the similarities in the two systems, parallel research 
efforts seeking to understand the molecular and genetic basis for these 
ostensibly separate RNA-based systems of gene regulation ultimately provided 
evidence that gene inactivation and control of developmental timing are 
interrelated (11, 15). 
 
RNA INTERFERENCE MECHANISM: SiRNAs occurring in nature are cleaved 
from long dsRNA by the dsRNA-specific RNase-III-type enzyme Dicer (16). Dicer 
cleaves the duplexes into 21- to 28-nucleotide siRNA duplexes which are 
recognized by components of the RNAi machinery. The RNA-induced silencing 
complex (RISC) incorporates a single siRNA strand and cleaves the mRNAs that 
contain complementary sequence (17, 18). MiRNAs are 21- to 22-nucleotide 
molecules processed from double-stranded hairpin precursors. Although small 
noncoding RNAs were initially distinguished as microRNAs (miRNAs) and short 
interfering RNAs (siRNA) based on their apparently different functional roles, this 
distinction has become increasingly less clear. For example, both classes of 
small noncoding RNAs are derived via a common pathway that is ultimately 
mediated by the Dicer ribonuclease. Cleavage of dsRNA into siRNA occurs in the 
cytoplasm by the Dicer ribonuclease.  In contrast, a single stranded RNA hairpin 
precursor is cleaved to produce a miRNA precursor by the endonuclease Drosha 
as part of  a nuclear  complex called the Microprocessor (19, 20).  The miRNA 
precursor is then exported to the cytoplasm and further processed by Dicer (14). 
Both siRNA and miRNA form functional ribonucleoprotein particles (RNPs) 
containing only one strand of the small noncoding RNA. Although these RNP 
complexes may not be easily distinguishable functional units, RISC refers to a 
siRNA-containing complex (17) and miRNP refers to an miRNA-containing 
complex  (Figure 1) (21).  
 
What has become evident is that the translational inhibition induced by miRNAs 
and the targeted mRNA degradation induced by siRNAs are not due to intrinsic 
differences between these classes of small RNAs, but rather result from the level 
of sequence homology between the small noncoding RNA and its target mRNA 
(reviewed in (22)).  A few centrally located mismatches target the mRNA to the 
translational inhibition pathway, which appears representative of most animal 
miRNAs (23-25). In contrast, perfect complementarity, represented by a siRNA, 
leads to targeted mRNA degradation. Thus miRNAs are most often viewed to 
downregulate gene expression by inhibiting translation through imperfect or 
consensus complementarity to a targeted mRNA, while siRNAs are most often 
Appendix A (Continued) 
193 
viewed to downregulate gene expression by targeting the mRNA for degradation 
through perfect complementarity  (Figure 1) (11).  
 
Targeted Gene Silencing: Since the discovery of RNAi in C. elegans (26), an 
increasing knowledge of RNAi has provided researchers with a new and powerful 
tool that can be used in vitro, as well as in vivo, to analyze gene function. There 
were, however, several potential obstacles to RNAi use in mammalian cells. Most 
mammalian cells harbor a potent antiviral response that is triggered by the 
presence of dsRNA viral replication intermediates. A key component of this 
response is a dsRNA-activated protein kinase, PKR, which phosphorylates and 
inactivates EIF-2α, inducing, in turn, the generalized inhibition of translation (18, 
27). In addition, dsRNA activates the 2,5´-oligoadenylate polymerase/RNase L 
system and represses IκB, resulting in programmed cell death (28, 29) . 
However, Elbashir and colleagues (27, 30) found that they could trigger the RNA 
interference machinery in mammalian cells using in vitro-synthesized siRNAs 
(27) without inducing the interferon response and consequent apoptotic 
response, a problem inherent in antisense RNA experiments. To target a gene 
for silencing, the design of the siRNA duplex was shown to require accurate 
knowledge of at least a 20 nucleotide segment of the target mRNA. 
  
SiRNAs induce post-transcriptional silencing with great specificity through RNA-
RNA sequence recognition, and are optimal when they resemble the naturally 
active products of Dicer; which are between 21 and 23 nucleotides in length, 
contain 5´-phosphate and 3´ -hydroxyl termini and have a symmetric two-
nucleotide 3´-overhang (typically TT). The 3´-overhang helps to ensure that the 
silencing ribonucleoprotein particles formed have equal ratios of sense and 
antisense target sequence (18, 31). Regions of a targeted mRNA can be 
identified by selecting a DNA sequence at least 50 bases downstream of the 
translational start codon (27). The cDNA sequence that is typically searched for 
is a 23 nucleotide motif consisting of AA(N19)TT with between 30 and 50% GC 
content (27). A Blast search (www.ncbi.nlm.nih.gov/BLAST) should be conducted 
to ensure the uniqueness of the targeted sequence in the mRNA. The use of a 
scrambled siRNA, which contains the same nucleotide composition as the 
siRNA, but lacks significant sequence homology to the target gene or to any 
other gene in the genome, is an important negative control.  
 
Optimization of Silencing Conditions: There are a number of design issues to 
be considered when planning a siRNA experiment. The transfection conditions 
should be optimized depending on the transfection system used.  These 
conditions include siRNA concentration, cell density and efficiency of knockdown 
versus non-specific affects. There are several methods of siRNA silencing that 
can be utilized for both transient and stable gene knockdown. These include 
vector-based methods, PCR-based methods, in vitro translation of siRNAs and 
chemical synthesis of siRNAs by commercial sources. 
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General considerations: Since the efficiency of transfection of cells varies greatly, 
different transfection reagents and conditions should be tested for each cell type. 
In addition, the serum content of the media should be considered since some 
systems require reduced serum content for optimal transfection. Ideally, for a 
new target, three to four potential siRNAs should be designed and screened, and 
to maximize efficiency of siRNA delivery, transfection parameters should also be 
optimized. A time course is usually established in order to define the optimal time 
required to effectively silence the gene.  Parameters such as the relative 
abundance and turnover rate of the targeted mRNA can affect the optimal time 
for silencing to occur. Typically, effects can be seen as soon as four hours, but 
maximum inhibition most often is observed in 24 to 72 hours.  Interestingly, the 
targeted mRNA can be depleted without reduction of the encoded protein.  This 
result may suggest that the protein is either very stable, abundant or both.  
 
siRNA Concentration: Titration of the siRNA should be used to determine the 
most efficient concentration that will produce effective gene silencing while 
minimizing potential unwanted effects such as non-specific targeting and cell 
death. A critical assumption of this approach is that the siRNA will selectively 
inhibit the complementary gene. However, it has been shown using expression 
profiling, that conventional siRNAs can, in a concentration-dependent manner, 
nonspecifically stimulate or repress expression of >1000 genes with protein 
products that are involved in diverse cellular functions (32, 33). These 
nonspecific effects on gene expression are not transient, and once initiated, are 
sustained throughout the course of siRNA treatment. Importantly, nonspecific 
effects do not simply result from cross-hybridization of transcripts containing 
regions of partial homology with the siRNA sequence. Rather, a characteristic 
feature of nonspecific effects on gene expression is the dependence on siRNA 
concentration. For example, Semizarov (34) reported that nonspecific effects 
occurred at an siRNA concentration of 100 nM, but not at 20 nM. Significantly, 
100 nM siRNA, a concentration often suggested by manufacturers of siRNAs and 
siRNA-related products, is a concentration at which nonspecific effects were 
found to most often occur (32). These and other studies (35, 36), therefore, 
underscore the importance of determining the lowest concentration that can be 
achieved to avoid nonspecific effects. The most effective concentration of siRNA 
can be influenced by the gene to be targeted, the type of cell transfected, and the 
siRNA itself. The proper negative control is also important in the design and 
interpretation of the results. The negative control should have the same 
composition of nucleotides as the designed siRNA, thus the use of a scrambled 
siRNA control can ensure that effects measured are indeed specific. In addition, 
a homology search should be conducted to ensure there is no homology of either 
the siRNA or the scrambled siRNA control to other genes. 
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Cell density: Optimal plating density should be determined by transfection of cells 
plated at different levels of confluence. Confluency should be between 30 and 
70%, depending on the transfection agent and the cell type used. If the cell 
density is too high or too low, transfection efficiency can be reduced. For 
reproducibility, cells should be transfected at a similar density for each 
experiment following a defined time period after trypsinization and plating. This 
density should be used for all future experiments. The volume of the transfection 
agent should also be investigated to optimize transfection efficiency.  
 
Efficiency of knockdown: When designing siRNA experiments, it is important to 
consider the issue of efficiency of knockdown versus undesired non-specific 
effects. For example, the turnover rate of the target protein should be taken into 
consideration when designing the experiment. Proteins with a long half-life 
require a longer incubation to see an effective knock-down at the protein level. 
Thus, proteins with half-lives measured in weeks would not make good targets 
for this technique. In addition, the abundance of the protein should be 
considered. Knockdown of a highly abundant protein would require a higher 
dosage of siRNA. Practicality dictates that this technique would not be applicable 
for targeting essential genes where the silencing of such genes would reduce 
viability of the cell.  
 
Transient suppression of targeted gene expression: There are a number of 
methods to produce siRNAs for use in mammalian systems. siRNAs can be 
produced by chemical synthesis, in vitro transcription, amplification of a PCR-
derived siRNA expression cassette or digestion of long dsRNA by an RNase III 
family enzyme. All of these forms of siRNA can then be transfected into cells 
using a number of commercially available lipid transfection reagents that provide 
optimal siRNA transfection efficiency. A number of companies provide chemically 
synthesized siRNA of high quality, and there are an increasing number of pre-
validated siRNAs available. However, since several siRNAs may need to be 
screened to find an efficient knockdown target, chemical synthesis may be an 
expensive option when designing the initial experiment. Alternatively, siRNAs can 
be transcribed in vitro using oligonucleotides that have been designed to contain 
a RNA-polymerase recognition site (37). This method is a more cost-effective 
choice since the siRNAs can be produced quickly and used to screen multiple 
targeted sequences or silence multiple genes. The limitations of siRNAs relate to 
the transient nature of suppression and the restriction imposed by the rate of cell 
division. SiRNAs are not amplified, nor are they propagated, in mammalian cells. 
 
Another system that can be used to produce siRNAs for transient transfection 
involves the use of long RNAs which are transcribed in vitro and then digested 
with an RNase III enzyme (or Dicer) to produce a population of siRNAs specific 
to the targeted transcript. This technique overcomes the need to design and test 
several siRNA sequences in order to find an effective one to silence the target 
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gene. However, this approach also leaves open the possibility of nonspecific 
silencing of genes with related sequence. Finally, siRNA expression cassettes 
can be created by PCR using primers designed to contain an RNA pol III 
promoter, an siRNA hairpin sequence, and a RNA pol III termination site (38). 
 
It is important to consider that transient suppression of targeted gene expression 
can result in a restricted analysis due to low transfection efficiencies and 
transient knockdown of gene expression. Typically in a transient experiment, only 
a fraction of the cells are expressing siRNA and therefore undergo silencing the 
desired gene product. Thus, while this technique is fast and straightforward, the 
effect is time-limited and restricted to cells which can be easily transfected.  
 
Stable suppression of targeted gene expression: To address the limitations of 
transient transfection of siRNAs, plasmid constructs have been designed to 
express short hairpin RNAs (shRNAs) that permit stable transfection of the 
siRNA (14, 39-44). The construct typically consists of a strong promoter, such as 
the U6 and H1 promoters, which drives the expression of a shRNA insert. The 
shRNA contains two inverted repeats that mimic siRNA structure separated by a 
short spacer region that makes up the loop. These shRNAs are processed by 
Dicer into siRNAs, thus producing effective gene silencing (review on vector 
design (45)). While more time-consuming than transient transfection analyses, 
the stable suppression of targeted gene expression allows for the selection of 
established cell lines with persistent phenotypes (40). This technique also 
permits the development of stable gene knockdown in a variety of cell types, and 
constructs expressing shRNA are easily delivered to cells via conventional 
transfection methods.  
 
In addition to its role in initiating RNAi, Dicer can also cleave 70 nt precursor 
stem-loop structure into single-stranded 21-23 nt RNAs (43).  Interestingly, 
adenoviral (46, 47), adeno-associated (48, 49) and lentiviral (50, 51) vectors 
have also been developed to allow the use of siRNAs in cell types which are 
difficult to transfect. Transgenic viruses have nearly 100% efficacy in penetration 
of all kinds of cells, including primary, somatic and differentiated cells of whole 
organisms. Transgenic siRNA-expressing mice and rats developed to stably 
display knockdown phenotypes (52) demonstrate the immense potential of RNAi 
for the development of whole animal model organisms.  
 
Therapeutic Uses: Recent developments have highlighted the enormous 
potential for RNAi as a therapeutic approach(53). The use of RNAi in human 
cells leaves open the potential for a powerful new approach to gene therapy in 
human diseases (54). Vector-mediated RNAi may lead to future therapeutic 
applications by persistent suppression of pathogenic proteins. The prospective 
use of siRNAs in a clinical setting has been strengthened by several studies 
targeting disease-related genes. Qin and colleagues (55) transfected human T 
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cells with a lentiviral construct containing siRNA targeting the CCR5 gene 
product. Treated cells showed a significant reduction in expression of the CCR5 
protein, as well as reduction in the rate of infection.  
 
Suppression by siRNAs directed against several regions of the HIV-1 genome, 
including the long-terminal repeat, and the accessory genes vif and nef, reduced 
viral replication 30-50 fold in human cell lines and primary lymphocytes (56). 
When cells were pre-treated with virus-specific siRNAs, HIV was taken-up 
normally, but expressed viral RNA levels were significantly reduced (56).  
 
In another study, siRNA was targeted to the BCR-ABL fusion gene product from 
the Philadelphia chromosome in patients with chronic myelogenous leukemia 
and acute lymphoblastic leukemia (57). This produced an apoptotic response in 
the targeted myeloid cells demonstrating that an RNAi strategy could possibly be 
used to specifically target tumor cells.  
 
SCA1 transgenic mice, a model for the neurodegenerative disorder 
spinocerebellar ataxia type 1 (SCA1)(58), were injected in the brain with 
shRNAs. Expressed from an adeno-associated virus vector, the shRNA targeted 
the mutant SCA1 protein. Treatment resulted in protection from neuronal loss 
and improved neurological function.  
 
Overall, an important key to the therapeutic use of siRNAs will be effective 
delivery of vectors to the targeted tissue, while ensuring specificity and adequate 
dose. Nevertheless, whole animal studies have shown that siRNAs can be 
applied by hydrodynamic delivery resulting in gene silencing in a variety of 
tissues (59, 60). Human trials delivering adeno-associated viral vectors have 
been used in cystic fibrosis and hemophilia B (61). Ongoing trials of delivery into 
the brain of Parkinson and Alzheimer patients may also help to assess the 
feasibility of this approach in humans (62). Recently, Soutschek et al. (63) 
reported on the intravenous delivery of a chemically modified siRNA targeted 
against apolipoprotein B mRNA in mice.  This siRNA was able to silence 
expression of apolipoprotein B in both the liver and jejunum which resulted in 
decreased levels of apolipoprotein B in plasma.  In addition, there was also an 
effective reduction in total serum cholesterol. 
 
RNA INTERFERENCE AND HETEROCHROMATIN SILENCING: Since RNA is 
able to base-pair with DNA, the potential use of RNAi to target specific DNA 
sequences and silence transcription has been investigated. In yeast, small RNAs 
(64) and the RNA-silencing machinery have been shown to direct the formation 
of silent heterochromatin via methylation of histone H3 lysine-9 (65). In another 
study, RNAi was targeted to CpG islands of the E-cadherin promoter (66).  This 
RNAi treatment resulted in silencing of expression through methylation at CpG 
sites, as well as methylation of histone H3 at lysine 9.  
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Conclusion: RNAi technology has revolutionized the field of gene silencing in a 
variety of organisms. This natural phenomenon provides a relatively new and 
extremely powerful tool to analyze gene function by specific silencing of the gene 
product of interest. The technology has rapidly become an invaluable tool for 
experimental biology in deciphering the molecular function of vast numbers of 
genes. Ongoing research continues to improve and expand the applications of 
RNAi, both experimentally and therapeutically.  
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Figure 1:  Proposed mechanisms for post-transcriptional targeted RNA 
interference. Long dsRNA and shRNA precursors are processed to 
siRNA/miRNA duplexes by the RNase III-like DICER. The short dsRNAs are 
subsequently unwound and assembled into effector complexes: RISC (RNA 
induced silencing complex) or miRNP. RISC mediates mRNA-targeted 
degradation and miRNP guides translational inhibition of targeted mRNAs.  In 
animals, siRNAs guide cleavage of complementary target mRNAs, whereas 
miRNAs mediate translational inhibition of mRNA targets. 
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SUMMARY 
 
Argininosuccinate synthase (AS) catalyzes the rate-limiting step in the recycling 
of citrulline to arginine, which in endothelial cells, is tightly coupled to the 
production of nitric oxide (NO). In previous work, we established that endothelial 
AS mRNA can be initiated from multiple start sites, generating co-expressed 
mRNA variants with different 5´-untranslated regions (5´-UTRs). One of the 5´-
UTRs, the shortest form, represents greater than 90% of the total AS mRNA. 
Two other extended 5´-UTR forms of AS mRNA, resulting from upstream 
initiations, contain an out-of-frame, upstream open-reading-frame (uORF). In this 
study, the function of the extended 5´-UTRs of AS mRNA was investigated. 
Single base insertions to place the uORF in-frame, and mutations to extend the 
uORF, demonstrated functionality, both in vitro with AS constructs and in vivo 
with luciferase constructs. Over-expression of the uORF suppressed endothelial 
AS protein expression, while specific silencing of the uORF AS mRNAs resulted 
in the coordinate upregulation of AS protein and NO production. Expression of 
the full-length of the uORF was necessary to mediate a trans-suppressive effect 
on endothelial AS expression, demonstrating that the translation product itself 
affects regulation. In conclusion, the uORF found in the extended, overlapping 
5´-UTR AS mRNA species suppresses endothelial AS expression, providing a 
novel mechanism for regulating endothelial NO production by limiting the 
availability of arginine.  
 
INTRODUCTION 
 
Nitric oxide (NO) synthesized from arginine by endothelial nitric oxide synthase 
(eNOS) is a potent vasodilator and a critical modulator of blood flow and blood 
pressure. In addition, it mediates vasoprotective actions through inhibiting 
smooth muscle proliferation, platelet aggregation, and leukocyte adhesion [1-3]. 
Under pathophysiological conditions associated with endothelial dysfunction, 
such as heart failure [4], hypertension, hypercholesterolemia, atherosclerosis [5], 
and diabetes [6], the ability to produce NO seems to be impaired. Paradoxically, 
NO production can be impaired by limited availability of the substrate arginine, in 
spite of apparently saturating levels of intracellular and extracellular arginine [7-
10]. We have previously shown that under normal conditions, the essential 
arginine available for NO production is derived from the recycling of citrulline to 
arginine, catalyzed by two enzymes, argininosuccinate synthase (AS) and 
argininosuccinate lyase (AL) [11, 12]. Although these two enzymes have been 
studied extensively in liver, where they participate in the urea cycle [13], it was 
not until the discovery of NO that their function in non-hepatic tissues was 
clarified. In  endothelial cells, AS and AL play a critical role in the operation of a 
citrulline-NO cycle, which supports endothelial NO production [14-17].  
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Because AS catalyzes the rate-limiting step in the citrulline-NO cycle [15], our 
initial studies have focused on the molecular basis for the functional role of 
endothelial AS. Endothelial and hepatic AS appear to have the same primary 
structure [18, 19], but differ in cellular location and level of expression [11, 18]. 
Hepatic urea cycle AS and AL are associated with the mitochondria [20], while in 
endothelial cells, AS and AL co-localize with eNOS in caveolae [11]. AS 
expression in liver also differs from AS expression in endothelial cells as 
demonstrated by the diversity of co-expressed 5´-UTR AS mRNA species in 
endothelial cells [18]. Three transcription initiation sites identified in endothelial 
cells result in overlapping 5´-UTR regions of 92, 66 and 43 nucleotides (nt). The 
longer forms make up ~7% of the total AS message, with the shortest 43 nt 5´-
UTR AS mRNA being the predominant species in endothelial cells, and the only 
detectable form found in liver. Interestingly, the extended 92 and 66 nt 5´-UTR 
AS mRNAs contain an out-of-frame, upstream overlapping ORF that is 
terminated by a stop codon 70 nt past the in-frame start codon for the 
downstream ORF encoding AS. Previously we reported that in vitro translation of 
AS mRNA containing the extended 5´-UTRs was suppressed compared to the 
shortest and most predominant 43 nt 5´-UTR AS mRNA species [18]. Moreover, 
we also showed that the translational efficiency of the extended 5´-UTR AS 
mRNA species was restored to the short form level when the uAUG was mutated 
to AAG, thus eliminating the uORF [18]. This suppression of expression through 
cis-effects was further demonstrated in vivo when the three forms of the AS 5´-
UTR were placed in front of a luciferase ORF and transfected into endothelial 
cells. Here again, the presence of the uAUG found in the extended AS 5´-UTRs 
suppressed expression of luciferase in a cis-dependent manner. 
 
Upstream ORF’s can affect the translation of a downstream ORF in a variety of 
ways [21]. In higher eukaryotes, initiation of translation generally occurs at the 
first AUG that resides in a favorable context. When the first AUG context is 
suboptimal, a portion of the scanning ribosomes may continue past the first AUG 
and initiate translation downstream at subsequent AUGs via leaky scanning [22]. 
Several eukaryotic mRNAs have been shown to contain one or more ORFs that 
affect the translational efficiency of the main, downstream ORF [21]. Depending 
on factors such as intercistronic length and secondary structure, scanning 
ribosomes, upon initiation at the uAUG, can either translate the uORF and 
reinitiate downstream or stall on the mRNA during elongation, thus preventing 
initiation at other sites [21]. In other cases, partial translation of the nascent 
peptide prevents downstream re-initiation by interaction of the peptide with a 
protein or RNA in the ribosome preventing termination from proceeding efficiently 
[23]. However, another less common event is for the uORF to be translated and 
for the peptide product to affect translation of the downstream cistron via a trans 
mechanism [24]. Based on these examples and our previous findings, we show 
in this report that the uORF in the extended 5´-UTR AS mRNA species is 
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functional and acts to limit overall AS expression as well as NO production, thus 
providing a novel mechanism for regulating endothelial NO production. 
 
 
EXPERIMENTAL PROCEDURES 
 
Cell Culture- Bovine aortic endothelial cells (BAEC) were cultured in Dulbecco’s 
modified Eagle’s medium (1g/L glucose, Mediatech) supplemented with 10% 
fetal bovine serum (Hyclone Laboratories), 100 units/ml penicillin and 100 µg/ml 
streptomycin (Mediatech) at 37°C and 5% CO2.  
 
Preparation of AS Constructs- Full-length AS cDNA was constructed to contain 
either the 92 nt or the 43 nt 5´-UTR, shown in Fig. 1, and subcloned into the 
vector pPDM-2 (Epicentre Technologies) as previously described [18]. Mutations 
were created in the constructs by multiple rounds of PCR amplification using Pfu 
Turbo DNA Polymerase (Stratagene) in a reaction containing 1X Pfu reaction 
buffer (10 mM KCl, 10 mM (NH4)SO4, 20 mM Tris-HCl, pH 8.75, 2 mM MgSO4, 
0.1% Triton X-100, and 0.1 mg/ml BSA), 200 µM each dNTP, 50 pmol of each 
primer, 10 ng digested plasmid template and 2.5 units of Pfu Polymerase. PCR 
reactions consisted of 30 cycles at 95°C for 1 min, 50°C for 1 min and 72°C for 2 
min. In the 92 nt construct, single base insertions of A residues were made at 
positions -1 (Ins 1) and -39 (Ins 2) relative to the AS AUG (Fig. 1). These 
mutations placed the uAUG and the AS AUG in the same frame. A left primer 
containing the insertion in the center, either ASL-11MFS (5´ CAC CCG TCA CGA 
ATG TCC GGC AA 3´) for Ins 1 or ASL-48MFS (5´ AAC CCG CCC TAG CTC 
CGC CGA CT 3´) for Ins 2 were paired up with ASR429 (5´ GAG CGA TGA CCT 
TGA TCT GT 3´) to amplify a section of the 92 nt 5´-UTR construct (inserted 
bases are underlined). This PCR product was then used as a right primer and 
paired with ASL-92T7 [18] to produce a fragment with the mutation in the center 
and the restriction sites BamH I and Nar I on either end for cloning back into the 
pPDM-2 vector in place of the wild-type fragment. Because the yield of product in 
the second round of PCR was typically very low, a third round of PCR was 
performed using the second round product as template, and using the primers 
ASL-92T7 and ASR429 to re-amplify the target fragment before restriction 
digestion and subcloning.  
 
Mutations were also made in the 92 and 43 nt constructs to convert two uORF 
stop codons to lysine residues thereby extending the product encoded by the 
uORF from 4.5 kDa to 21 kDa. The two UGA codons at positions +70 and +153 
relative to, but out-of-frame with, the AS AUG were changed to AAA codons. 
Primers ASL59MStop (5´ TCC TCG TGT GGC AAA AGG AGC AAG GCT 3´) 
and ASR168MStop (5´ GGC CCC AAG CTT TTG CGC CTT CTT CC 3´) were 
combined to amplify a fragment of AS that contained both of the stop mutations 
(mutated bases are underlined). This fragment was then used as a right primer in 
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the same strategy used for the insertion mutations, followed by a third round 
PCR reaction using ASL-92T7 and ASR169MStop to enrich for the target 
fragment. BamH I (incorporated in ASL-92T7) and Hind III (site marked by 
dashed underline in ASR168MStop primer) restriction enzymes were used to 
clone the mutated fragment into the AS 92 nt 5´-UTR plasmid. All constructs 
were verified by sequencing. 
 
In Vitro Transcription/Translation- AS constructs were digested with Eco RV at a 
site past the 3´-end to prevent run-on transcription. Template DNAs were 
transcribed using T7 RNA polymerase with the addition of Ribo m7G Cap Analog 
(Promega) following the manufacturer’s protocol recommended for m7G cap 
incorporation. Transcribed RNA was DNase treated and purified using minispin 
G50 Sephadex (CPG) columns. The Flexi Rabbit Reticulocyte Lysate System 
(Promega) was used for the translation reaction following the manufacturer’s 
protocol, with the addition of 10 µCi [35S]-L-methionine (GE Healthcare) and 500 
ng capped RNA. KCl conditions were optimized to 40 mM. Translated proteins 
were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) on 10% Tris-HCl Ready Gels (Bio-Rad Laboratories). Gels were 
fixed in 50% methanol and 10% acetic acid for 30 min, followed by a second 
solution of 7% methanol, 7% acetic acid, 1% glycerol for 5 min, dried on a gel 
dryer for 2 hr, and exposed to film. Band intensities were quantitated using a 
ChemiImager 4400 (Alpha Innotech). 
 
 
Preparation of Luciferase Constructs- Luciferase reporter constructs were 
designed to include different sections of the AS 5´-UTR cloned directly after the 
simian virus 40 promoter and before the start codon of the luciferase gene. One 
set of clones contained truncated forms of the 5´-UTR, the sequence spanning 
the region from either the -66 or -92 nt positions to the uAUG at position -57 
relative to the AS AUG. Left primers LucASL-66 (5´ AGA AAG CTT ACC CGG 
GAT GGA AGA CGC CAA AAA CAT 3´) and LucASL-92 (5´ AGA AAG CTT CCC 
TGC CCC CCG GCC CCG AGC TTA TAA CCC GGG ATG GAA GAC GCC AAA 
AAC ATA 3´) both contain a Hind III site on the 5´-end, AS 5´-UTR sequence 
(underlined), and the first 17 bases of the luciferase gene after the AUG on the 
3´-end. These primers were combined with RTLuc1R (5´ CAC CTC GAT ATG 
TGC ATC TG 3´) to amplify a small fragment of the luciferase gene which was 
then cloned into pGL3Control vector (Promega), using Hind III and Nar I, so that 
the various AS 5´-UTR segments replaced the luciferase 5´-UTR. 
 
Another luciferase construct, described previously [18], was designed to contain 
the entire 92 nt of the AS 5´-UTR in front of the luciferase gene. This construct 
was mutated, using the three round PCR method described in the preparation of 
AS constructs, to contain a single base insertion at position -39 (Ins 2 in Fig.1). 
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Similar to the AS Ins 2 mutation, this mutation put the AS uAUG and the 
luciferase AUG in-frame. Constructs were verified by sequencing. 
 
Luciferase Assays- BAEC to be used for transfections were plated at 6 x 104 cells 
per well in a 24-well plate, twenty-four hours prior to transfection. Control 
plasmids (Promega) included pGL3Control as a positive control, pGL3Basic as a 
promoterless negative control, and pRL-TK, a renilla expression vector, as an 
internal transfection control. Control, Basic, and experimental plasmids (200 ng 
each), and pRL-TK (50 ng) were transiently transfected into BAEC using Transit-
LT1 (Mirus) in serum-free media. After 4.5 hr, media was replaced with media 
containing 10% serum and cells were cultured for 48 hr. Lysates generated with 
Passive  Lysis Buffer (Promega) were assayed for luciferase and renilla activity 
using Promega’s Dual-Luciferase Reporter Assay System according to the 
manufacturer’s recommendations. Luciferase and renilla activity were measured 
as relative light units using a luminometer (Turner Designs). Experiments were 
carried out three times in triplicate. Luciferase expression was normalized to 
renilla activity. Passive Lysis Buffer lysates were separated by SDS-PAGE on 
10% Tris-HCl Ready Gels and blotted onto Immobilon-P PVDF membranes 
(Millipore). Western blotting was performed as previously described [18]. Primary 
antibody used was anti-luciferase (Cortex Biochem) at a 1:500 dilution. 
Secondary antibody used was peroxidase-conjugated goat anti-mouse IgG 
(Jackson ImmunoResearch Labs) at a 1:50,000 dilution. Blots were visualized by 
chemiluminescence using ECL reagent (GE Healthcare) and exposed to film. 
Band intensities were quantitated using a ChemiImager 4400. 
 
Preparation and Transfection of ASuORF Contructs- For transfection studies with 
the AS uORF, AS sequence covering the region from -92 to +70 relative to the 
AS AUG was cloned into pcDNA 3.1/V5-His B expression vector (Invitrogen). 
Primers ASL-92BamHI (5´ AGT CGG ATC CCC CTG CCC CCC GGC CCC 
GAG 3´) and ASR73EcoRI (5´ TGC AGA ATT CCC GCC ACA CGA GGA TGC 
AGG AGG 3´) were used to amplify this region. Both primers contained 
restriction sites inserted for cloning into the pcDNA vector and the right primer 
was designed to eliminate the uORF stop codon at position 72, thereby linking 
the uORF to the V5 and His tags in the vector (ASuORF). For a negative control, 
this same region was amplified from a previously described construct in which 
the uAUG at position -59 was mutated to AAG [18], thereby rendering the AS 
uORF non-functional (AAGNegC). BAEC to be used for transfections were plated 
at 2 x 105 cells per well in a 12-well plate twenty-four hours prior to transfection. 
Experimental plasmids, ASuORF, AAGNegC, and the empty vector (0.8, 1.6 and 
2.4 µg each) were transiently transfected into BAEC using Lipofectamine 2000 
(Invitrogen) in serum free Opti-MEM I (Invitrogen). After 4 hr, media was replaced 
with DMEM containing 10% serum and cells were cultured for 24 hr. 
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Additional constructs of the AS uORF were used to investigate the effects of 
sequence and/or length of the uORF relative to its ability to suppress AS 
expression. Mutations were made that deleted a residue at position -53 and 
inserted a residue at position +69 relative to the AS AUG in order to cause a 
frame-shift in the peptide sequence of the AS uORF. Primers uORFfsleft (5´ ACC 
CCG GGA TGC GC/C CGA AAC CCG 3´) and uORFfsright (5´ CAG AAT TCC 
CGC CCA CAC GAG GAT 3´) were used to amplify by PCR the mutated 
fragment. The deletion and insertion sites are marked by a hash mark and an 
underline, respectively. A Sma I site in the left primer and EcoR I site in the right 
primer were used to clone the fragment into the ASuORF expression vector in 
place of the wild-type fragment. Similarly, mutations were introduced to move the 
AS uORF start codon downstream to position +1 relative to the AS start codon 
and to move the ASuORF stop codon upstream to position +11. Using primers 
uORFdnsAUG (5´ GCT GGT CAC CCG TCA CGA ATG CCG GCA AAG GCT C 
3´) and uORFupsStop (5´ GCT GGT CAC CCG TCA CGA TGT CCG GCA TAG 
GCT CCG TGG 3´) combined with ASR73EcoRI, the mutated fragments were 
amplified and cloned using the BstE II site in the forward primers and the EcoR I 
site in the reverse primer. The dnsAUG (downstream AUG) mutation fragment 
was cloned into the AAGNegC construct that was lacking the normal uAUG. The 
upsStop (upstream stop) fragment was cloned into the wild-type ASuORF 
construct. BAEC were transfected as described in the previous section. 
 
AS uORF constructs were developed which allowed the protein product to be 
easily resolved and visualized by SDS-PAGE analysis. Green fluorescent protein 
(GFP) was amplified from the pGreen Lantern plasmid (Invitrogen) using the 
primers GFPleft (5´ AGT CGG CGG CCG CCG CCA CAT GAG CAA GGG C 3´) 
and GFPright (5´ CTA GAG CGG CCG CAC TTG TAC AGC 3´). The left primer 
contained a Not I site for cloning and deleted a base between the Not I site and 
the AUG to place GFP and the AS uORF in-frame. The right primer also 
contained a Not I site for cloning and deleted a base at the GFP stop codon to 
mutate out the stop codon and also to put GFP in-frame with the V5 and His 
tags. GFP was cloned into the ASuORF construct at the Not I site between the 
uORF and the V5/His tags. GFP was also cloned into the uORFfs (frame-shift) 
construct in the same manner. Constructs were verified by sequencing, and 
BAEC were transfected as described in the previous section. 
 
RNA Duplex Preparation and Transfection- Ambion’s Silencer siRNA 
Construction Kit was used to synthesize 21-nucleotide RNA duplexes. Target 
sequences were chosen following the guidelines described by Tuschl et al. [25]. 
The siRNA sequence specific to AS corresponded to nt -65 to -47 (Fig. 1) relative 
to the first nucleotide of the AS start codon (5´CCC GGG AUG CGC GCC GAA 
Att 3´). A control siRNA was designed by scrambling the bases of the AS siRNA 
(5´ACA GAG GGA CUC GCC CGC Gtt 3´). Both sequences were subjected to 
BLAST search to rule out homology to mRNAs encoding known proteins. 
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Twenty-four hours prior to transfection, BAEC were seeded in a 24-well plate at 1 
x 105 cells per well. Transfection of siRNA was carried out with TransIT-TKO 
(Mirus) as described by the manufacturer. For each well, 10-25 nM siRNA duplex 
was combined with 3 µl liposome in serum-free DMEM and applied to cells at 80-
90% confluency. Cells were assayed 24 hr after transfection. 
 
Cell Lysate Preparation and Immunoblotting- BAEC were trypsinized and then 
washed in ice cold phosphate-buffered saline (PBS) and resuspended in RIPA 
buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1X protease inhibitors 
(Calbiochem) in PBS) by vigorous pipetting followed by brief vortexing. The 
lysate was incubated on ice for 30 minutes and the protein concentration was 
determined by BCA assay (Pierce). Equal amounts (5-10 µg) of protein were 
resolved on 4-15% Tris-HCl Ready Gels and blotted onto Immobilon-P PVDF 
membranes. Western blotting was performed as previously described. 
Membranes were incubated with primary antibody, 1:2500 anti-AS (BD 
Transduction Labs), 1:5000 anti-V5 (Invitrogen), 1:7500 anti-ß-Actin (Sigma 
Chemical Co.), or 1:2000 anti-GAPDH (Novus Biologicals). Secondary antibody 
used was peroxidase-conjugated goat anti-mouse or anti-rabbit IgG (Jackson 
ImmunoResearch Labs) at 1:50,000 dilution for all primary antibodies except ß-
Actin, where the secondary antibody dilution used was 1:75,000. Blots were 
visualized by chemiluminescence using ECL reagent and exposed to film. 
 
RNA Isolation and Quantitative RT-PCR- Total RNA was isolated from BAEC by 
the method of Chomczynski and Sacchi [26] using Tri Reagent (Molecular 
Research Center) according to the manufacturer’s protocol. Pellet Paint Co-
Precipitant (Novagen) was added to help visualize the small RNA pellets. RNA 
was treated with DNase using the DNA-free Kit (Ambion) and quantitated prior to 
reverse transcription with oligo (dT) primers using the Superscript First Strand 
cDNA Synthesis Kit (Invitrogen) following the manufacturer’s protocol. Real time 
quantitative PCR was performed as previously described using AS specific 
primer sets ASL228 and ASR278 for detecting all AS mRNA, and ASL-62 and 
ASR-12 for detecting the extended 5´-UTR forms of AS mRNA [18]. Results were 
normalized to ß-Actin using primers ßactinfor (5´ GAG GCA TCC TGA CCC TCA 
AG 3´) and ßactinrev (5´ TCC ATG TCG TCC CAG TTG GT 3´). 
 
Nitric Oxide Assay- Basal levels of nitrite were measured in the cell culture media 
twenty-four hours after transfection with siRNA as an indicator of cellular NO 
production using a fluorometric method [27]. Twenty-four hours after transfection 
of the AS uORF overexpression constructs, BAEC were stimulated with 50 µM 
sodium orthovanadate and 0.5 µM A23187 calcium ionophore for two hours [28], 
and media was collected for nitrite assay. Samples were read on a BMG 
FLUOstar Galaxy spectrofluorometer plate reader exciting at 360 nm and 
detecting emission at 405 nm. Cells were counted by trypan blue exclusion, and 
data is presented as nitrite produced per 1 x 106 cells. 
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RESULTS 
 
Functionality of the AS uAUG in an In Vitro Transcription/Translation System- 
Since the extended AS 5´-UTRs, containing an uAUG, were shown to act in cis 
to downregulate the translation of AS mRNA [18], studies were carried out to 
determine whether the cis-effect was due to initiation at the uAUG and/or 
translation of the uORF. To examine the functionality of the uAUG in the 
extended 5´-UTR AS mRNAs, two different mutations were made in a full-length 
AS construct containing the 92 nt 5´-UTR. A single nucleotide was inserted 
between the uAUG and the downstream AS AUG, placing the uORF in-frame 
with the AS ORF so that initiation at either AUG would produce AS protein. One 
insertion was placed in close proximity to the AS AUG (Ins 1), while the other 
was placed more distal, 39 nt upstream from the AS AUG (Ins 2) as shown in 
Figure 1. The two different nucleotide insertions were chosen such that 
secondary structure (folding pattern) of the RNA was predicted to be essentially 
the same for mutated and wild-type versions. Transcribed RNA from each 
construct was verified to be a single band by agarose gel electrophoresis and 
ethidium bromide staining (Fig. 2). All constructs were transcribed and translated 
in vitro in the presence of [35S]-L-methionine. Translated products were 
separated on SDS-PAGE as shown in Figure 2. The wild-type AS 92 nt 5´-UTR 
construct yielded a single product of ~47 kDa, the expected size of AS [29]. Both 
of the insertion mutant constructs yielded doublets of ~47 kDa and ~49 kDa, 
where the 49 kDa band represented the calculated size of the AS protein if 
translation was initiated using the uAUG. The amount of label observed in the 
~47 kD bands reflects not only the cis-negative influence of the uORF as 
observed in the intact 92 nt extended AS mRNA, but also the relative efficiency 
of downstream initiation observed in the case of the two insertion mutations. In 
addition, the slight decrease in the Ins 1 ~47 kDa band may indicate the influence 
of an inserted nucleotide within the boundaries of the Kozak consensus 
sequence [30] at the downstream AUG, diminishing the efficiency of translational 
initiation. Western blot analysis confirmed that both bands represented AS 
sequence (data not shown). For the Ins 1 mutation, quantitation of the two bands 
showed that initiation from the uAUG was 1.8 times greater than from the 
downstream AUG. For the Ins 2 mutation, the level of initiation from the uAUG 
was 1.4 times the level of the AS AUG. When the context of the uAUG was 
further altered by changing nucleotides -3 to A and +4 to G relative to the uAUG 
to better match a consensus Kozak sequence [30], initiation of translation shifted 
almost entirely to the uAUG (data not shown). These results suggest that the cis-
effects of the uAUG in the extended length 5´-UTR AS mRNAs resulted from its 
functional use, and that the low level of translation from the downstream AS AUG 
may result from leaky scanning [22] due to the moderately suboptimal context of 
the uAUG [18]. 
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To demonstrate that the uORF was functional in its normal out-of-frame mode, 
two mutations were created in the full-length AS mRNA construct containing the 
92 nt 5´-UTR. These mutations changed the first two stop codons in the uORF to 
lysine residues, thus extending the translation product of the out-of-frame uORF 
from an ~4 kDa to an ~21 kDa protein that could be easily visualized on an SDS-
polyacrylamide gel by [35S]-L-methionine incorporation. To control for the effect of 
these mutations, which changed two leucines to glutamines in the downstream 
ORF encoding AS protein, the same mutations were introduced into the 43 nt 5´-
UTR AS mRNA construct. All constructs were transcribed and translated in vitro 
in the presence of label, and the translated products were analyzed by SDS-
PAGE analysis (Fig. 3). Translation of the 43 nt 5´-UTR AS mRNA construct 
yielded a single band of the correct size (~47 kDa) for AS, showing that the 
mutations (two amino acid changes) did not affect translation. Translation of the 
92 nt 5´-UTR AS mRNA construct, however, resulted in two [35S]-L-methionine 
labeled bands; an ~47 kDa and a second smaller protein product at ~21 kDa, 
demonstrating that the out-of-frame uORF is functional. The broad darkened 
region at about 30 kDa was considered to be unrelated to the in vitro translation 
of the extended 92 nt 5´-UTR AS mRNA species since it was most predominant 
in the translation of the 43 nt 5´-UTR AS mRNA. These results provide further 
evidence that ribosomes can translate the entire uORF rather than prevent the 
translation of the downstream ORF encoding AS by stalling at the uAUG [21, 30].  
 
In Vivo Functionality of the AS uAUG When Placed Immediately Upstream of a 
Luciferase ORF- To demonstrate the functionality of the AS uAUG in endothelial 
cells, luciferase constructs were generated that replaced the luciferase 5´-UTR 
with forms of the extended AS 5´-UTRs, spanning the region from either the -66 
or -92 nt positions to the uAUG. As shown in Figure 4, the construct containing 
the sequence from position -66 to -57 (the site of the uAUG) expressed luciferase 
activity at ~60% of control, while the -92 to -57 nt construct expressed luciferase 
activity at a lower level, ~36% of control. The fact that luciferase expression with 
the extended AS 5´-UTRs was lower than that of the control may reflect 
differences in the influence of the normal 5´-UTR  versus the replacement AS 5´-
UTRs. These results demonstrated that the uAUG is sufficient to support 
luciferase expression in endothelial cells.  
 
In Vivo Functionality of the AS uAUG in Relation to a Downstream Luciferase 
ORF- To determine the in vivo functionality of the AS uAUG in the presence of a 
downstream ORF, a full-length luciferase ORF construct was modified to contain 
the 92 nt AS 5´-UTR with the out-of-frame uAUG. An additional luciferase 
construct was generated that contained an Ins 2 mutation in the 92 nt AS 5´-UTR 
which positioned the AS upstream AUG and the downstream luciferase AUG in-
frame. As shown in Figure 5, there was no significant difference in luciferase 
activity levels for the control construct and the insertion mutation (lns 2) 
luciferase construct. However, the luciferase activity level for the 92 nt AS 5´-
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UTR luciferase construct containing an out-of-frame uAUG was approximately 
20% of the control activity. Western blot analysis to follow luciferase protein 
levels showed a single band of ~61 kDa for the control construct and a barely 
detectable 61 kDa band for the 92nt AS 5´-UTR/luciferase construct containing 
the out-of-frame uAUG. In contrast, the 92 nt AS 5´-UTR/luciferase construct with 
the lns 2 mutation placing the uAUG in-frame, showed a doublet of ~61 and ~63 
kDa. The 61 kDa protein corresponded to the luciferase ORF initiated from the 
downstream AUG, whereas the 63 kDa protein corresponded to a luciferase 
protein initiated from the in-frame uAUG in the 92 nt AS 5´-UTR Ins 2 construct. 
These results demonstrated that the uAUG in the extended 5´-UTR’s of AS 
mRNA can function in the presence of a functional downstream ORF in 
endothelial cells.  
 
The Effect of Overexpression of the AS uORF on Endothelial AS Expression and 
NO Production- To investigate possible trans-effects of the AS uORF, AS 
sequence from -92 to +70, relative to the AS AUG, was cloned into pcDNA3.1 
vector so that the uORF was fused to a V5/His tag (ASuORF). For a negative 
control construct, the uAUG at position -59 was mutated to AAG, thereby 
rendering the AS uORF non-functional (AAGNegC). Equal amounts of protein 
from endothelial cells transfected with 0.8, 1.6, and 2.4 µg of ASuORF, 
AAGNegC, and vector plasmid DNA, along with a lipofectamine-alone control, 
were analyzed by western blot analysis with anti-V5 and anti-AS antibodies. The 
putative product of the uORF, approximately 7 kDa protein with the V5/His tag, 
could not be visualized by western blotting with the V5 antibody. However, 
transfection of the AS uORF reduced endogenous AS protein levels, in a dose 
dependent fashion when compared to transfection reagent alone (Fig. 6). 
Transfection of the pcDNA empty vector had no effect on endogenous AS protein 
levels, and the AS uORF negative control with the uAUG mutated to AAG had, at 
most, only a slight effect on AS expression. These results indicate that the 
overexpression of the AS uORF elicited a profound trans-suppressive effect on 
endothelial AS expression. This suppression was not due to the presence of AS 
uORF transfected RNA alone since overexpression of the mutant that deleted the 
uORF by converting the start codon to AAG (designed to be transcribed but not 
translated) had essentially no effect on AS expression.  
 
The production of arginine by AS and AL in endothelial cells provides an 
essential source of arginine for NO production [11, 12]. To examine whether the 
overexpression of the AS uORF and the accompanying decrease in AS protein 
had an effect on NO production, cells were stimulated twenty-fours after 
transfection with sodium orthovanadate and calcium ionophore [28]. Aliquots 
were removed two hours after stimulation to measure nitrite as an indicator of 
cellular NO production. At the highest plasmid concentration of the ASuORF 
transfected, NO production was decreased to 5% of a control with lipofectamine 
alone (Fig. 6). Although the empty vector and the AAG mutant showed some 
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negative effect relative to the lipofectamine control, the magnitude and dose 
dependent decrease in NO production correlated significantly only with the loss 
of AS protein in AS uORF treated cells. These results were also in keeping with 
those from previous work demonstrating the essential role of AS in endothelial 
NO production [12], despite excessive levels of intracellular and extracellular 
arginine. 
 
Requirement for AS uORF Sequence and Length for Suppression of Endothelial 
AS Protein Levels and NO Production- To investigate whether sequence and/or 
length of the uORF are prerequisites for the trans-suppressive effects of the 
uORF on endogenous AS expression, we examined the overexpression of point 
mutation constructs with altered uORF structures. The first mutation was 
constructed with the initiation codon of the uORF left unchanged, but a deletion 
in the third codon and an insertion at the last codon caused a frame-shift in the 
amino acid sequence. This frame-shift mutation (uORFfs) yielded an ORF 
potentially encoding the same length peptide (44 amino acids), but where only 
the first two amino acids of the AS uORF were conserved. A second mutation 
was constructed with a new start codon for the AS uORF introduced 60 
nucleotides downstream of the original, so as to potentially encode only 23 amino 
acids of the C-terminus of the putative peptide (dnsAUG). A third mutation 
generated a construct where the stop codon was moved upstream in order to 
potentially encode 23 amino acids from the N-terminus (upsStop) of the putative 
peptide.  
 
 
As shown in Figure 7, none of the mutated constructs showed the degree of 
suppression of AS expression or NO production exhibited by the wild-type AS 
uORF. These series of experiments demonstrated that both the sequence and 
the length of the AS uORF found in the extended 5´-UTR AS mRNAs are 
necessary to elicit negative trans-effects on endothelial AS expression and NO 
production. 
 
Regulation of AS Expression by the Translation Product of the AS uORF- To 
demonstrate that the translation product of the AS uORF suppresses overall AS 
expression in endothelial cells and to facilitate detection of the translation 
product, the protein was tagged by cloning green fluorescent protein (GFP) 
between the AS uORF and the V5/His tags of the ASuORF pcDNA3.1/V5-His B 
construct. An additional construct involved GFP cloned into the AS uORF frame-
shift construct (uORFfs). Equal amounts of protein from lysates of endothelial 
cells transfected with 0.8, 1.6, and 2.4 µg of ASuORF-GFP and uORFfs-GFP, in 
addition to a lipofectamine alone control, were analyzed by western blot analysis. 
As shown in Figure 8, a dose dependent increase in the ASuORF-GFP-V5/His 
tag fusion protein ( ~37 kDa) directly correlated with a decrease in endogenous 
AS protein levels. Expression of the frame-shift  uORF construct, which produced 
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a protein of equal size but different amino acid content  had no effect on AS 
protein levels. These results demonstrated that the protein encoded by the AS 
uORF mediates the negative trans-effects on endothelial AS expression. 
 
Effect of Silencing of the Extended 5´-UTR AS mRNAs on Endothelial AS 
Expression- To further demonstrate the trans-suppressive effect of the uORF on 
endothelial AS expression, an siRNA was designed to selectively knock down the 
92 and 66 nt 5´-UTR AS mRNA species. Analysis of AS mRNA in transfected 
endothelial cells by real-time RT-PCR demonstrated that a scrambled form of the 
siRNA (control) had no effect on the levels of the extended forms of AS mRNA. 
In contrast, an siRNA directed against the extended 5´-UTR AS mRNA species 
decreased both the 92 and 66 nt 5´-UTR AS mRNAs to ~20% of transfection 
reagent alone (Fig. 9). Importantly, the level of total AS mRNA was essentially 
unaffected, consistent with the fact that the extended 5´-UTR forms of AS mRNA 
containing the uORF represent less than 7% of the total message. Equal 
amounts of protein from the extended AS 5´-UTR siRNA and from scrambled 
siRNA transfected endothelial cells were examined by western blot analysis 
using anti-AS antibody. AS protein levels, normalized to GAPDH expression, 
were markedly increased in response to selective silencing of the 92 and 66 nt 
5´-UTR AS mRNAs. An ~2.3-fold increase in expressed AS protein was seen 
compared to the scrambled siRNA at the 25 nM concentration of siRNA (Fig. 9). 
These results suggest that the trans-effects of the  uORF found in the extended 
5´-UTR AS mRNA forms are mediated post-transcriptionally, and most likely at 
the translational level. 
 
Effect of Silencing of the Extended 5´-UTR AS mRNAs on NO Production- Based 
on the previous results demonstrating that AS expression levels are coordinately 
linked to the production of NO in endothelial cells, we examined whether the 
knockdown of the endogenous extended 5´-UTR AS mRNA species and the 
accompanying increase in AS protein had an effect on the NO produced in these 
cells. Aliquots of media were removed twenty-four hours after transfection of 25 
nM siRNA specific for the extended AS 5´-UTR or a scrambled negative control 
siRNA, and nitrite as an indicator of cellular NO production was measured.  As 
shown in Table I, an ~2.2 fold increase in basal cellular NO produced (measured 
as nitrite) in the extended AS 5´-UTR siRNA treated cells was observed 
compared to the scrambled siRNA treated cells. This increase in NO production 
correlated closely with the increased expression of AS in response to the 
knockdown of extended 5´-UTR AS mRNA forms (Fig. 9).  
 
DISCUSSION 
 
We previously established that the recycling of citrulline to arginine is essential to 
provide the substrate arginine for NO production, even in the presence of 
saturating levels of intra- and extracellular arginine [11, 12]. We demonstrate in 
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this study that expression of the extended 5´-UTR forms of AS mRNA, containing 
an uORF, mediates a trans-effect, suppressing overall endothelial AS expression 
and causing a corresponding suppression of  endothelial NO production. This 
suppression of AS expression requires a functional, out-of-frame, uORF 
represented in the 5´-UTR regions of the co-expressed extended forms of 
endothelial AS mRNA [18]. The uORF AUG was shown to be functional both in 
vitro and in vivo. When the uAUG was put in-frame with the downstream AUG by 
inserting a nucleotide, two in vitro translated [35S]-labeled products were 
evidenced by electrophoretic SDS-polyacrylamide gel analysis. The larger AS 
species (~49 kDa) was initiated from the uAUG, while the smaller (~47 kDa) 
species represented the translation product initiated from the normal, 
downstream reading frame encoding AS. Interestingly, the ratio of products in 
this case favored use of the uAUG. Moreover, when the context of this uAUG 
was altered to better match the Kozak consensus initiation sequence [22], 
translation significantly improved from the uAUG. To demonstrate that this uORF, 
when positioned out-of-frame, was still translated, two putative stop codons for 
the uORF were mutated to allow production of a larger, more easily identifiable 
translation product (~21 kDa). Although the difference in methionine content did 
not permit a quantitative comparison by [35S]-labeling, the results clearly 
demonstrated a 21 kDa product, confirming the functionality of the uORF in its 
natural context.  
 
With the support of in vitro results, we then assessed the in vivo functionality of 
the uORF in endothelial cells using a luciferase reporter assay. Expression of 
luciferase from the uAUG demonstrated that the context of the uAUG is sufficient 
to support initiation of translation. Moreover, when the AS uAUG start codon was 
positioned in-frame, in the context of the entire 5´-UTR and preceding the normal 
start codon for a luciferase gene, our results again demonstrated functionality. In 
this case, two luciferase products were identified by western blot analysis 
consistent with the interpretation that both the uAUG and the downstream 
luciferase AUG are recognized in endothelial cells.  
 
Previous work from our laboratory suggested that AS mRNA species containing 
the uORF in the extended 5´-UTR sequence do not express AS well, either in 
vitro or in vivo, due to cis-effects of the uORF [18]. In this paper, we have 
clarified not only the functionality of the uORF, but also its trans-mediated effects, 
showing that overexpression of this uORF resulted in a dramatic decrease in AS 
expression in endothelial cells. This result suggested that the co-expression of 
the extended 5´-UTR forms of AS mRNA, containing an out-of-frame uORF, may 
play a role in suppressing the overall expression of endothelial AS. Additionally 
we showed that NO production is significantly reduced when the AS uORF is 
overexpressed, further linking the requirement for AS expression to NO 
production in endothelial cells. The fact that AS expression was not suppressed 
when the uORF was rendered non-functional, via loss of an operational start 
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codon, or by overexpression of ASuORF containing either a frame-shift mutation, 
or altered start or stop codons, demonstrated that the entire sequence of the 
uORF is required to mediate the trans-effects that decrease endothelial AS 
expression and  NO production.  Furthermore, a direct effect was observed that 
related expression of the translational product encoded by the uORF to the 
suppression of endothelial AS expression. 
 
When expression of the endothelial extended 5´-UTR AS mRNA species were 
specifically silenced by siRNA treatment, expression of AS increased 
dramatically (~2-fold), despite the fact that these species represent less than 7% 
of the total AS mRNA. Consistent with the rate-limiting role of AS in recycling 
citrulline to arginine and in maintaining the essential arginine for NO production, 
knockdown of the extended 5´-UTR AS mRNA species containing this uORF 
resulted in an increased capacity of endothelial cells to produce NO.  Thus, the 
overall results suggest that the uORF found in the extended 5´-UTR forms of 
endothelial AS mRNA is functional, and as such expresses a protein product that 
acts to suppress expression of the predominant short form of the AS mRNA.  
 
In summary, a small protein produced through expression of the uORF of the 
extended 5´-UTRs of two minor forms of AS mRNA, unique to endothelial cells, 
suppresses AS expression. The overall effect of this suppression of AS 
expression is to decrease NO production in endothelial cells by limiting the 
availability of the substrate arginine. These results provide evidence for a novel 
mechanism for the regulation of endothelial AS protein expression and further 
support the essential role of the citrulline-NO cycle in endothelial NO production. 
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Table I 
 
Effect of Silencing of the Extended 5´-UTR AS mRNAs on NO Production 
  
       Condition    Relative NO Produced 
      25 nM scrambled siRNA    1.0 
       25 nM siRNA        2.2 ± 0.33 
 
BAEC were transiently transfected with siRNA specific for the 92 and 66 nt 5´-
UTR species of AS mRNA and a scrambled negative control siRNA. Basal NO 
production was determined over a twenty-four hour period. NO was measured as 
nitrite produced per 1 x 106 cells and normalized to scrambled siRNA levels. 
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Fig. 1. Diverse 5´- leader sequence of endothelial AS mRNA. The three 
endothelial AS transcription start sites are indicated by arrows and labeled. The 
AS AUG and the upstream out-of-frame AUG are in bold type. The upstream 
AUG and the uORF are underlined. Insertion mutation sites are marked by 
arrows and labeled Ins 1 and Ins 2. The site of the RNA duplex designed to 
knock down the extended 5´-UTR forms of AS mRNA is underlined by a dashed 
line. 
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Fig. 2. Mutational analysis to determine the functionality of the AS uAUG by 
in vitro transcription/translation. AS constructs containing the 92 nt 5´-UTR 
(92 nt) and two single base insertion mutations (Ins 1 and Ins 2) that put the AS 
AUG and the uAUG in-frame were transcribed and translated in vitro. 
Transcribed RNA was verified by agarose gel electrophoresis (panel A top). 
Translated [35S]-L-methionine labeled proteins were separated by SDS-PAGE, 
and gels were dried and exposed to film (panel A bottom). The quantitation of the 
bands is shown in panel B. Expression levels are normalized to the 92 nt band. 
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Fig. 3. Visualization of AS uORF expression in vitro by mutagenesis of 
uORF stop codons. AS constructs containing the 92 nt and 43 nt 5´-UTRs were 
mutated to extend the uORF from 4 to 21 kDa. Translated [35S]-L-methionine 
labeled proteins were separated by SDS-PAGE, and gels were dried and 
exposed to film (panel A) . The panel B schematic shows the uORF stop codons, 
marked by X, that were mutated to lysine residues and the location of the new 
uORF stop codon. 
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Fig. 4. In vivo functionality of the AS uAUG when placed immediately 
upstream of a luciferase ORF. In order to direct expression of luciferase from 
the AS uAUG, AS 5´-UTR sequence spanning the region from either the 66 or 92 
nt positions to the uAUG were cloned in front of luciferase in the pGL3 control 
vector to replace the luciferase 5´-UTR, (panel A). Constructs were transfected 
into BAEC. pGL3 Basic (Basic) was transfected as a negative control, pGL3 
Control (Control) as a positive control and pRL-TK (Renilla) was co-transfected 
as an internal control. Luciferase activity (panel B) was assayed 48 hr after 
transfection, and results were normalized to renilla activity. Error bars indicate 
the standard error of the mean from nine experiments. 
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Fig. 5. In vivo functionality of the AS uAUG in relation to a downstream 
luciferase ORF. A luciferase construct containing the entire 92nt AS 5´-UTR in 
place of the luciferase 5´-UTR in pGL3 Control vector (92nt) was constructed and 
mutated by inserting a single nucleotide at position -39 relative to the luciferase 
AUG (Ins 2) in order to put the uAUG and the luciferase AUG in-frame. 
Constructs were transfected into BAEC. pGL3 Basic (Basic) was transfected as a 
negative control, pGL3 Control (Control) as a positive control and pRL-TK 
(Renilla) was co-transfected as an internal control. Luciferase activity (panel A) 
was assayed 48 hr after transfection, and results were normalized to renilla 
activity. Error bars indicate the standard error of the mean from nine 
experiments. Equal amounts of cell lysate protein were separated by SDS-PAGE 
and standard western blotting was performed using anti-luciferase antibody 
(panel B). 
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Fig. 6. The effect of overexpression of the AS uORF on endothelial AS 
expression and NO production. The AS upstream open-reading-frame 
(ASuORF) was cloned into pcDNA3.1V5/His and transfected into BAEC. The 
ASuORF was compared to the AAGNegC construct where the uAUG is mutated 
to AAG, the empty vector (Vector) and a lipofectamine alone control (Lipo). 
Twenty-four hours after transfection, equal amounts of protein were separated by 
SDS-PAGE and standard western blotting was performed using anti-AS and anti-
ß-Actin antibodies (panel A). Quantitation of AS protein expression from three 
separate experiments, normalized to ß-Actin, is indicated as a fraction of the 
lipofectamine alone control (panel B). Twenty-four hours after transfection, NO 
production was determined 2 hours after stimulation with 0.5 µM calcium 
ionophore and 50 µM sodium orthovanadate (panel C). NO was measured as 
nitrite produced per 1 x 106 cells and normalized to lipofectamine alone levels. 
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Fig. 7. Requirement for AS uORF sequence and length for suppression of 
endothelial AS protein levels and NO production. Additional ASuORF 
pcDNA3.1V5/His constructs, transfected into BAEC , were compared to the AS 
upstream open-reading-frame (ASuORF) construct and lipofectamine alone 
(Lipo) control. The uORFfs construct was engineered to frame-shift the entire 
sequence of the uORF so that only the first two amino acids were conserved, but 
the sequence length of 44 amino acids remained the same. The dnsAUG and 
upsStop constructs were designed to contain the C-terminal 23 amino acids and 
N-terminal 23 amino acids of the AS uORF, respectively. Twenty-four hours after 
transfection, equal amounts of protein were separated by SDS-PAGE and 
standard western blotting was performed using anti-AS and anti-ß-Actin 
antibodies (panel A). Quantitation of AS protein expression from three separate 
experiments, normalized to ß-Actin, is indicated as a fraction of the lipofectamine 
alone control (panel B). Twenty-four hours after transfection, NO production was 
determined 2 hours after stimulation with 0.5 µM calcium ionophore and 50 µM 
sodium orthovanadate (panel C). NO was measured as nitrite produced per 1 x 
106 cells and normalized to lipofectamine alone levels. 
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Fig. 8. Regulation of AS expression by the translation product of the AS 
uORF. An AS uORF construct was prepared in which green fluorescent protein 
(GFP) was cloned into the ASuORF pcDNA3.1V5/His construct in between and 
in-frame with the AS uORF and the V5/His tags (ASuORF-GFP). GFP was also 
inserted into the uORFfs (frame-shift) construct (uORFfs-GFP). The GFP 
constructs were transfected into BAEC and compared to a lipofectamine alone 
control (Lipo). Twenty-four hours after transfection, equal amounts of protein 
were separated by SDS-PAGE and standard western blotting was performed 
using anti-V5, anti-AS, and anti-ß-Actin antibodies (panel A). Quantitation of AS 
protein expression, normalized to ß-Actin, is indicated as a fraction of the 
lipofectamine alone control (panel B).  
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Fig. 9. Effect of silencing of the extended 5´-UTR AS mRNAs on endothelial 
AS expression. BAEC were transiently transfected with siRNA specific for the 
92 and 66 nt 5´-UTR species of AS mRNA ( ) and a scrambled negative control 
siRNA (ο). Total RNA was isolated and AS mRNA was detected by real time 
RT-PCR. Primer sets were designed to specifically amplify the 66 and 92 nt 5´-
UTR species (panel A), or total AS message (Panel B). Equal amounts of protein 
were separated by SDS-PAGE and standard western blotting was performed 
using anti-AS and anti-GAPDH antibodies. Quantitation of AS protein expression 
from four separate experiments, normalized to GAPDH, is indicated as a fraction 
of the transfection reagent alone (panel C). 
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SUMMARY 
The enzyme endothelial nitric oxide synthase (eNOS) catalyzes the conversion of 
arginine, O2, and NADPH to NO and citrulline.  Previous results from our 
laboratory, and others, suggested an efficient, compartmentalized system for 
recycling of citrulline to arginine utilized for NO production.  In support of this 
hypothesis, we found that the recycling enzymes, argininosuccinate synthase 
(AS) and lyase (AL), colocalize with eNOS in caveolae, a subcompartment of the 
plasma membrane.  Under basal (unstimulated) conditions the degree of 
recycling was minimal.  Upon stimulation of NO production by bradykinin, 
however, recycling was co-stimulated to an extent that more than 80% of the 
citrulline produced was recycled to arginine. These results suggest an efficient 
caveolar recycling complex that supports the receptor-mediated stimulation of 
endothelial NO production.  To investigate the molecular basis for the unique 
location and function of endothelial AS and AL, we compared endothelial AS 
mRNA with liver AS mRNA.  No differences were found in the coding region of 
the mRNA species, but significant differences were found in the 5’-untranslated 
region (5’-UTR). The results of these studies suggested that sequence in the 
endothelial AS gene represented by position –92 to –43 nt from the translation 
start site in the extended AS mRNA 5’-UTRs plays an important role in 
differential and tissue-specific expression.  Overall, we have developed a strong 
evidential case supporting the proposal that arginine availability, governed by a 
caveolar-localized arginine-regeneration system, plays a key role in receptor-
mediated endothelial NO production.               
 
INTRODUCTION 
Endothelial nitric oxide synthase (eNOS), the enzyme that catalyzes the 
production of NO from the amino acid arginine in endothelial cells, plays a 
key role in vasoregulation as well as other important physiological 
processes such as angiogenesis. Impaired production of endothelial NO 
has been associated with hypertension, heart failure, 
hypercholesterolemia, atherosclerosis and diabetes (Govers and Rabelink, 
2001; Valence and Chan, 2001; Maxwell, 2002).  Circulating effectors, 
such as bradykinin (bk), bind to receptors on the lumenal surface of 
endothelial cells signaling the transient release of NO to the adjacent 
smooth muscle layer, resulting in relaxation of the vessel wall.   
 
The signal for eNOS activation is a transient increase in intracellular calcium, 
which activates the enzyme through binding of a calcium-calmodulin complex 
(Ca-Cam).  Endothelial NOS activation also occurs in response to shear stress 
(Govers and Rabelink, 2001; Maxwell, 2002).  Consistent with the important 
physiological roles of eNOS, the enzyme appears to be subject to multiple modes 
of regulation, in addition to primary regulation through reversible Ca-Cam binding 
and activation.  These include reversible phosphorylation and palmitoylation, 
substrate and cofactor availability, dimerization of enzyme subunits, intracellular 
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translocation, and protein-protein interactions (Govers and Rabelink, 2001).  
Several of these potential modes of regulation appear to be interrelated.  As a 
component of caveolae, which serve to sequester proteins involved in cell 
signaling, eNOS may transiently interact with several different caveolar 
components.  Previous work from several different laboratories, including our 
own, has suggested that a number of different proteins may be transiently and 
functionally associated with eNOS, including calmodulin, caveolin-1, bradykinin 
B2 receptor (Bk-B2), heat shock protein-90 (hsp90), argininosuccinate synthase 
(AS), argininosuccinate lyase (AL), Raf-1, Akt, ERK, and unidentified tyrosine-
phosphorylated proteins (Hellermann et al., 2000; Govers and Rabelink, 2001; 
Maxwell, 2002).  
 
A potential limiting factor for endothelial NO production is the availability of the 
substrate, arginine.  Intracellular levels of arginine have been estimated to range 
from 100 to 800 µM, which is well above the Km value of 5 µM for eNOS 
(Harrison, 1997).  Endothelial NO production can, nonetheless, be stimulated by 
exogenous arginine (Valence and Chan, 2001).  This phenomenon, termed the 
“arginine paradox”, suggests the existence of a separate pool of arginine directed 
to endothelial NO synthesis.   As illustrated in Fig. 1, arginine has a number of 
metabolic roles in addition to NO production, including production of major 
metabolites such as urea, polyamines, creatine, ornithine and methylarginine 
derivatives.  The segregation of the production of NO from these other metabolic 
processes would allow the controlled availability of arginine for NO production.  
 
One possible site of control is at the level of arginine uptake.  McDonald et al. 
(1997) showed that the CAT1 transporter, responsible for 60-80% of total carrier 
mediated arginine transport into endothelial cells, colocalizes with eNOS in 
caveolae, a subcompartment of the plasma membrane.  They proposed that the 
arginine utilized by eNOS, at least in part, might be maintained by the CAT1 
transporter.  Another important mechanism for controlling the availability of 
arginine directed to NO production may be the regeneration of arginine from the 
other product of the eNOS-catalyzed reaction, citrulline.  Hecker et al. (1990) 
initially demonstrated that citrulline, produced in the conversion of arginine to NO, 
can be recycled to arginine.  A possible linkage between NO production and 
arginine regeneration from citrulline was subsequently established for other cell 
types (Nussler et al., 1994; Shuttleworth et al., 1995).  This regeneration is 
catalyzed by the enzymes argininosuccinate synthase (AS) and 
argininosuccinate lyase (AL), both of which also play an essential role in the urea 
cycle in liver.  The potential importance of this regeneration system for 
endothelial NO production was supported by a report of two infants, with a 
deficiency of AL, who were shown to be hypertensive (Fakler et al., 1995).  Upon 
infusion of arginine, the blood pressure of these infants decreased to near normal 
levels, suggesting a critical role for arginine regeneration in the regulation of 
systemic blood pressure.  More recent evidence from DNA microarray analysis 
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suggests an important role for the arginine regeneration system by clearly 
demonstrating significant and coordinate upregulation of AS gene expression in 
response to shear stress stimulation of endothelial NO production (McCormick et 
al., 2001).  It was concluded that available arginine is a prerequisite for NO 
production and that in the absence of synthesis of additional eNOS, shear stress-
induced increases in NO synthesis depend on an increase in synthesis of 
arginine from citrulline through increased AS expression. 
 
Recent work from our laboratory, described herein, further supports the 
hypothesis that the arginine regeneration system, comprised of a caveolar 
complex that includes eNOS, AS, and AL, plays an important, and possibly 
essential, role in the receptor-mediated production of NO by vascular endothelial 
cells. 
 
Effects of Exogenous Arginine and Citrulline on Endothelial NO Production 
Endothelial NOS is localized in plasmalemmal caveolae.  The localization of 
eNOS in this signaling subcompartment of the plasma membrane may have 
important implications with regard to the regulation and catalytic efficiency of 
eNOS (Everson and Smart, 2001; Shaul, 2002).  We have recently found 
evidence for an efficient cycling of citrulline to arginine, raising the possibility of a 
channeling complex of eNOS and the enzymes of the citrulline-arginine cycle (AS 
and AL) localized in caveolae.  Our initial research effort that led to this finding 
was designed to test the hypothesis that an intracellular pathway exists for the 
generation of methylarginines to regulate NO production in nitric oxide producing 
tissues.  The goal of this initial work was to determine the physiological 
significance of intracellular methylarginines as regulators of NOS activity.  To 
examine the levels of endogenous methylarginines, we developed methods that 
allowed for the rapid and quantitative analysis (by HPLC) of arginine, citrulline 
and the methylarginines from endothelial cell extracts.  There was no apparent 
change in levels of methylarginines following stimulation of endothelial cells with 
either bradykinin or the calcium ionophore, A23187.  In an attempt to raise 
intracellular methylarginine levels, and further test our hypothesis, we added 
citrulline, which we expected to inhibit dimethylarginine dimethylaminohydrolase, 
the enzyme that converts NG-methylarginine or NG,NG-dimethylarginine to 
citrulline and monomethylamine or dimethylamine.  The objective was to 
determine whether inhibition of the degradation of methylarginines would 
increase their intracellular concentrations and thereby inhibit NO production.  To 
our surprise, stimulation of NO production by bradykinin was increased by the 
addition of 3 mM citrulline, rather than decreased, and there was no apparent 
change in methylarginine levels.   To further examine the molecular basis for the 
stimulation of NO production by citrulline, we compared the effect of exogenous 
citrulline with the effect of exogenous arginine on NO production and levels of 
intracellular arginine following bradykinin activation.  Surprisingly, added arginine 
did not cause as great an increase in endothelial NO production as added 
Appendix A (Continued) 
246 
citrulline.  In addition, there was a much larger increase in intracellular arginine in 
response to exogenous arginine compared with exogenous citrulline.  Added 
citrulline caused only a modest increase in intracellular arginine, while added 
arginine caused a substantial increase.  Thus, there appeared to be no 
correlation between total intracellular arginine levels and endothelial NO 
production.  To the best of our knowledge, this represents the first attempt to 
correlate NO production with the levels of intracellular arginine.  Furthermore, the 
effects of arginine and citrulline on NO production appeared to be synergistic 
since a combination of arginine and citrulline stimulated endothelial NO 
production more than either arginine or citrulline alone (Flam et al., 2001). Since 
arginine has a number of potential metabolic fates, while citrulline has only one 
known metabolic fate (Fig. 1), the efficiency of NO production could be enhanced 
if a separate pool of arginine is maintained by endothelial cells.  Recycling the 
product of the NOS-catalyzed reaction, citrulline, back to arginine via the 
enzymes of the arginine regeneration system, AS and AL would maintain this 
separate pool.  The pool of arginine used for NO synthesis would be essentially 
isolated from the bulk of intracellular arginine through the efficient operation of an 
arginine regeneration system.  The apparent efficiency of the process suggests a 
possible channeling of intermediates and a compartmentalized complex of eNOS 
and enzymes of the arginine regeneration system.  Our initial results supported a 
model in which eNOS is localized together with this arginine regenerating 
system, and regulatory components, to ensure optimal efficiency of NO 
production and regulation, without affecting other arginine-dependent cellular 
processes. 
 
Caveolar Localization of Arginine Regeneration Enzymes with eNOS 
Endothelial NOS is targeted by acylation to caveolae, where it interacts with 
caveolin-1 (Everson and Smart, 2001; Shaul, 2002).  In liver cells, the arginine 
generating enzymes, AS and AL, are associated with the outer mitochondrial 
membrane, reflecting the functional role of these enzymes in the production of 
urea (Cohen and Kuda, 1996).  To test our model for a colocalization of AS and 
AL with eNOS, we used two different fractionation protocols for the purification of 
caveolae (Smart et al., 1995; Song et al., 1996).  Both protocols generated a 
caveolar membrane fraction that was highly enriched in caveolin-1, eNOS, AS, 
and AL (Flam et al., 2001).  These results support the proposal that a separate 
pool of arginine, directed to NO synthesis, is effectively separated from the bulk 
of intracellular arginine through the functional localization of arginine 
regeneration enzymes and eNOS with plasmalemmal caveolae.  A possible 
consequence of this functional association would be the channeling of 
intermediates through AS, AL, and eNOS such that intermediates of the complex 
would not equilibrate with bulk intracellular arginine. 
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Degree of Recycling 
Cellular activity of eNOS has been estimated by measuring the rate of 
conversion of [3H]-arginine to [3H]-citrulline (Hardy and May, 2002).  Based on 
our results, we would predict that this measurement would underestimate the 
cellular activity of eNOS due to the efficient recycling of citrulline to arginine.  
Estimating cellular activity of eNOS by measuring rate of production of NO (as 
the degradation product nitrite), on the other hand, should give a better estimate 
of cellular activity of eNOS activity.  To test this hypothesis, and to estimate the 
degree of recycling of citrulline to arginine, we simultaneously measured the 
apparent rate of arginine to citrulline conversion and the rate of production of NO 
under basal (unstimulated) conditions and under stimulated (addition of 
bradykinin) conditions.   The ratio of these activities was close to one under basal 
conditions, but the apparent degree of recycling was costimulated with NO 
production as indicated by an increase in the ratio of NO produced to citrulline 
produced to approximately eight upon exposure of endothelial cells to agonist 
(Flam et al., unpublished).  These preliminary results suggest an efficient 
caveolar complex for the regeneration of arginine directed to receptor-mediated 
production of NO in endothelial cells.  Our initial results suggest an efficiency of 
greater than 80% for the recycling of citrulline to arginine. 
 
Molecular Basis for Functional Role and Location of Endothelial AS 
In liver tissue AS plays an essential role in urea synthesis and appears to be 
loosely associated with the outer mitochondrial membrane (Cohen and Kuda, 
1996).  In contrast, endothelial AS appears to be the rate limiting enzyme in the 
recycling of citrulline to arginine used for NO synthesis and is localized in 
caveolae.  Immunoblotting experiments suggested small differences in subunit 
molecular weights and isoelectric points of endothelial AS compared to liver AS 
(Flam et al., unpublished).  We speculated that these differences could be due to 
a splice variant, but analysis of the coding sequence of AS mRNA indicated no 
differences between the mRNA from endothelial cells and liver (Pendleton et al., 
2002).  Because upstream and downstream untranslated regions (UTRs) of 
mRNA can influence regulation of gene expression, we carried out both 5’-RACE 
(rapid amplification of cDNA ends) and 3’-RACE analysis to investigate possible 
differences in the UTRs.  We found three different 5’-UTR AS mRNA species in 
endothelial cells (shown below).  Only one of these products, the shortest 5'-UTR 
of 43 nucleotides (nt), was quantitatively expressed in liver.  No significant 
variation was found in the 3’-UTR.  The 5’-RACE analysis identified endothelial 
AS mRNA species with extended 5’-UTRs of 66 nt and 92 nt, in addition to a 
major 43 nt 5’-UTR AS mRNA.  Compositional analysis revealed that all three AS 
mRNA 5’-UTRs were enriched in G + C content (~76%), and were likely to form 
complex and stable secondary structures.  An upstream open reading frame 
(uORF) was detected in the 66 nt and 92 nt 5’-UTRs that was out-of-frame with 
the AS mRNA AUG start codon.  RNase protection analysis (RPA) and real-time 
reverse transcriptase-PCR verified and quantitated the differential expression of 
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the extended 5’-UTR species relative to the major 43 nt 5’-UTR AS mRNA.   
Estimates from RPA of the amount of the 92 nt and 66 nt species, relative to the 
43 nt species, were approximately 15% and 13%, respectively. 
 
Features of mRNA UTRs, specifically uORFs, are regarded as important 
determinants of translational efficiency and may have important biological 
implications on the regulation of translation.   We therefore designed experiments 
to determine to what extent the various 5’-UTRs of AS mRNA influenced 
translation.  Translational efficiencies for the 66nt and 92 nt AS 5’-UTR 
constructs were 70% and 25%, respectively of the translational efficiency for the 
43 nt 5’-UTR AS mRNA.  Sequential deletions, starting with the 5’-terminus of the 
92 nt 5’-UTR construct, resulted in a corresponding increase in translational 
efficiency, but the most pronounced effect resulted from mutation of the uORF, 
which restored translational efficiency to that observed with the 43 nt species.  
When the different AS mRNA 5’-UTRs, cloned in front of a luciferase reporter 
gene, were transfected into endothelial cells, the pattern of luciferase expression 
was nearly identical to that observed for the different 5’-UTR AS mRNAs in 
endothelial cells.  These results suggest that a complex 
transcriptional/translational infrastructure operates to coordinate AS and NO 
production that is reflected in AS mRNA structure and function (Pendleton et al., 
2002). 
 
Model for Coupling of Arginine Regeneration to Endothelial NO Production 
A model depicting our view of the coupling of arginine regeneration to endothelial 
NO production through the compartmentalized complex of AS, AL, and eNOS is 
shown in Fig. 2.  This coupling is apparently “disengaged” under basal 
(unstimulated) conditions and is “engaged” and tightly coupled in response to 
agonists such as bradykinin.  The molecular determinants and mechanisms 
involved in this coupling are not fully understood at this time.  Based on our 
studies, and evidence from other labs, we believe the coupling of arginine 
regeneration to endothelial NO production is important for the overall regulation 
of endothelial NO production and may be essential for agonist-stimulated 
endothelium-dependent vasorelaxation. 
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Fig. 1.  Metabolic roles and fates of arginine.  In addition to incorporation into 
protein, arginine serves as a metabolic precursor for several important 
metabolites as indicated by the arrows.  Also indicated is the two step conversion 
of citrulline to arginine. 
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Fig. 2. Novel 5' untranslated regions (UTRs) of endothelial argininosuccinate 
synthase mRNA.  
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Fig. 3.  Model for the coupling of endothelial NO production to the regeneration of 
the substrate arginine from the product citrulline.  Shown is the CAT1 transporter 
involved in arginine transport and complex of the coupling enzymes 
argininosuccinate synthase and argininosuccinate lyase with endothelial nitric 
oxide synthase. 
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